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ABSTRACT 
 
DOPAMINE TRANSPORTER (DAT) AND METABOTROPIC GLUTAMATE 
RECEPTOR 5 (MGLU5) IRREVERSIBLE PROBES FOR IDENTIFYING  
ANTI-PSYCHOSTIMULANT THERAPEUTICS 
 
By 
Ranganadh Velagaleti 
May 2014 
 
Dissertation supervised by Dr. David J. Lapinsky 
Numerous behavioral studies indicate that dopamine transporter (DAT) inhibitors 
and metabotropic glutamate receptor 5 (mGlu5) negative allosteric modulators (NAMs) 
possess promising anti-addiction therapeutic properties.  However, the lack of human 
DAT (hDAT) and mGlu5 X-ray crystal structures makes it difficult to understand how 
these promising anti-addiction compounds interact with their major drug targets at the 
molecular level.  This knowledge gap represents an important problem towards rationally 
designing new therapeutics for numerous addiction disorders.  The objective of this 
research was to develop irreversible chemical probes based on select DAT inhibitors and 
mGlu5 NAMs in order to map the corresponding binding sites and poses of these 
compounds within their major drug targets.  The central hypothesis was that these 
compounds could be derivatized, without significant loss in pharmacological activity, 
with a functional group capable of forming a covalent bond to their target protein and, if 
 v 
necessary, a tag functional group.  These probes would then allow proteomic experiments 
to be coupled with computational modeling in order to directly map the ligand-binding 
sites of these promising anti-addiction compounds within their target proteins.  The 
central hypothesis was tested by pursuing two specific aims: 1) identification of non-
tropane DAT inhibitor photoprobes suitable for DAT structure-function studies, and 2) 
identification of irreversible mGlu5 NAM ligands as chemical probes suitable for mGlu5 
structure-function studies.  Under the first aim, methylphenidate (MP) and GBR-12909 as 
non-tropane DAT inhibitors were structurally modified to contain a photoreactive group 
(e.g., aryl azide, benzophenone) and a tag (e.g., 125I, terminal alkyne, aliphatic azide).  
These compounds were then subjected to DAT pharmacological evaluation in order to 
identify suitable candidates for DAT structure-function studies.  Under the second aim, 
thiazole- and pyridine-based mGlu5 NAMs were structurally modified to contain either a 
photoreactive group (e.g., aryl azide, benzophenone) or an affinity labeling group (e.g., 
methanethiosulfonate, maleimide) and a tag (e.g., 125I, terminal alkyne, aliphatic azide).  
These compounds were then subjected to mGlu5 pharmacological evaluation in order to 
identify suitable chemical probe candidates for mGlu5 structure-function studies.  At 
present, several irreversible chemical probes from these specific aims have advanced to 
the proteomics stage of the experimental research strategy. 
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CHAPTER ONE 
1. Biological Literature Review 
1.1. The Problem of Cocaine Abuse 
Cocaine (1.1, Figure 1.1) abuse and addiction represent a major problem not only 
in the United States (U.S.), but worldwide (Degenhardt and Hall, 2012).  Cocaine abuse 
is not only a significant health problem, but this disease also imposes a huge economic 
burden to society (Corlett, 2013).  According to the 2011 National Survey on Drug Use 
and Health, 37.8 million Americans over the age of 11 have reported use of cocaine at 
least once in their lifetime (http://www.drugabuse.gov/drugs-abuse/cocaine).  
Additionally, the number of current cocaine users over the age of 11 is estimated to be 
1.4 million (http://www.drugabuse.gov/publications/drugfacts/nationwide-trends). 
 
Figure 1.1.  The chemical structure of cocaine, an abused psychostimulant. 
Historically, cocaine is a tropane alkaloid that was extracted from the leaves of 
the coca plant Erythroxylum coca in 1855 (Stolberg, 2011).  The compound was initially 
used for treatment of depression and morphine addiction, then later as a local anesthetic 
in ophthalmology during the 19th and early 20th centuries.  Cocaine can be used in its 
hydrochloride salt or free base form.  The hydrochloride salt is typically administered 
intravenously, whereas the free base, or a mixture of the free base with an ammonium salt 
impurity (so-called crack), is used for inhalation.  Since cocaine is the most potent 
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stimulant of natural origin (Avois et al., 2006), it is categorized as a Schedule II drug by 
the U.S. Drug Enforcement Administration 
(http://www.justice.gov/dea/druginfo/ds.shtml), and its medical use is strictly regulated 
by the U.S. federal government. 
Cocaine addiction causes severe medical, psychiatric, and psychosocial problems.  
Cocaine traditionally elicits euphoria, increased cardiovascular activity, hypothermia, and 
hypertension upon administration (Zimmerman, 2012).  Consequently, individuals who 
abuse cocaine are at high risk for stroke, heart, and pulmonary diseases.  In addition, 
cocaine addicts are much more susceptible to infectious diseases such as HIV/AIDS, 
Hepatitis B, and Hepatitis C (Parikh et al., 2012).  Furthermore, these individuals 
experience financial instability and ultimately destroy their wellbeing, eventually leading 
to social devastation and the alienation of loved ones (Vijayakumar et al., 2011).  
Cocaine withdrawal leads to many symptoms including decreased energy, limited 
ability to experience pleasure, depression, paranoia, hallucinations, and a strong desire to 
use cocaine again (Zimmerman, 2012).  As a result, overcoming cocaine dependence 
requires tremendous will power and a sincere desire to quit.  To date, no effective 
pharmacotherapy for cocaine addiction exists, and behavioral therapies often represent 
the only available method of treatment (Herdener et al., 2012).  It has been hypothesized 
that a correct combination of behavioral and pharmacological treatments may ultimately 
provide the most effective approach for treating cocaine abuse and addiction (Haile et al., 
2012). 
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1.2. Cocaine and the Dopaminergic System 
1.2.1. The Dopaminergic System 
The dopaminergic system refers to dopaminergic neurons that synthesize and 
release dopamine (1.2, Figure 1.2) as a chemical messenger.  Dopamine is a major 
catecholamine neurotransmitter that plays an important role in regulating brain processes 
associated with reward, attention, locomotor activity, and cognition (Tritsch and Sabatini, 
2012). 
 
Figure 1.2.  The chemical structure of dopamine as a neurotransmitter. 
Dopamine is produced in several areas of the brain, including the substantia nigra 
and the ventral tegmental area.  It is biosynthesized from tyrosine by tyrosine 
hydroxylase and stored in vesicles of presynaptic neurons.  In response to a presynaptic 
action potential, dopamine is released into the synaptic cleft via calcium-mediated 
exocytosis.  Dopamine can then interact with postsynaptic dopamine receptors to produce 
chemical impulses signaling satisfaction or reward (Arias-Carrion et al., 2010). 
The DAT is a neuronal membrane protein that functions to regulate extracellular 
dopamine levels by transporting dopamine back into presynaptic neurons, wherein 
dopamine can then be degraded by monoamine oxidase (MAO) (Figure 1.3).  As a result 
of its function, the DAT plays a critical role in regulating both the signal amplitude and 
duration of dopaminergic neurotransmission (Jaber et al., 1997).                                    
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Figure 1.3.  Dopaminergic neurotransmission (Reprinted with permission from 
http://www.cnsforum.com/imagebank/item/MAO_cocaine/default.aspx. Copyright 2014, accessed on 
02/26/2014) 
1.2.2. Effects of Cocaine on the Dopaminergic System 
The rewarding properties of cocaine and amphetamine have been explained via a 
dopamine hypothesis, and multiple studies have identified the DAT protein as the 
primary drug target associated with abuse and addiction of these psychostimulants 
(Woolverton and Johnson, 1992; Fleckenstein et al., 2007).  Cocaine has been shown to 
bind to the DAT within presynaptic neuronal membranes of the dopaminergic system and 
inhibit dopamine reuptake from the synaptic cleft.  This leads to increased extracellular 
dopamine levels that can continuously stimulate dopamine receptors on postsynaptic 
neurons (Woolverton and Johnson, 1992; Fleckenstein et al., 2007).  In turn, this 
phenomenon causes an increased activation of the dopaminergic reward pathways 
 5 
resulting in the euphoria and traditional ‘high’ associated with cocaine use (Figure 1.4) 
(Schmitt and Reith, 2010). 
Since cocaine bound to the DAT hinders the dopamine reuptake process, the 
concentration of dopamine can be reduced by either metabolic removal from the synaptic 
cleft or an increase in the number of DAT proteins.  As a result, dopamine levels in the 
synaptic cleft will eventually become reduced and lead to decreased euphoric or 
rewarding effects.  In turn this leads to craving, wherein cocaine users chronically self-
administer the drug in order to reactivate dopamine-mediated pathways that lead to the 
‘high’ associated with cocaine use (Schmitt and Reith, 2010).  
 
 
Figure 1.4.  Inhibition of dopamine reuptake upon binding of cocaine to the DAT (Reprinted with 
permission from http://www.cnsforum.com/imagebank/item/MAO_cocaine/ default.aspx. Copyright 
2014, accessed on 02/26/2014) 
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1.3. The DAT 
1.3.1. Chemical Composition and Structure of the DAT 
The hDAT is an 80 kDa integral membrane protein of 620 amino acids that 
belongs to the neurotransmitter/sodium symporter (NSS), or solute carrier 6  (SLC6), 
family of proteins (Pramod et al., 2013).  This protein features 12 transmembrane (TM) 
domains connected by both intracellular and extracellular loops, and the amino and 
carboxyl termini are located on the intracellular side of the protein (Figure 1.5).  The 
large extracellular loop linking TM 3-4 has several potential glycosylation sites that are 
important for the stability and plasma membrane trafficking of the DAT, while TMs 1 
and 6 are considered to be critical for both substrate and cocaine binding (Volz and 
Schenck, 2005; Wang and Lewis, 2010). 
 
Figure 1.5.  Diagram of the membrane topology of the hDAT  based upon bacterial leucine 
transporter (LeuT) crystal structures.  Full TM helices are numbered 1–12 and intra- and extracellular 
loops are numbered 1–5 with prefixes either ‘i’ or ‘e’ respectively (Schmitt et al., 2008. Reprinted 
with permission from J. Neurochem. 2008, 107, 928-940. Copyright 2008, International Society for 
Neurochemistry). 
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The precise tertiary structure of the hDAT remains unknown.  Nonetheless, 
crystal structures of homologues of the NSS/SLC6 family of transporters such as the 
bacterial (Aquifex aeolicus) LeuT (Yamashita et al., 2005; Zhou et al., 2007 and 2009; 
Singh et al., 2007 and 2008; Quick et al., 2009; Nyola et al., 2010; Wang et al., 2012; 
Krishnamurthy and Gouaux, 2012; Piscitelli and Gouaux, 2012; Wang and Gouaux, 
2012; Kantcheva et al., 2013) and the fly (Drosophila melanogaster) DAT (dDAT) 
(Penmatsa et al., 2013) have been recently solved.  These high-resolution structures of 
LeuT and dDAT have provided insight into the hDAT tertiary structure of this class of 
proteins, especially hDAT.  In turn, 3-D molecular models of hDAT have been generated 
via sequence homology with LeuT (Indarte et al., 2008; Manepalli et al., 2012), and 
several laboratories have performed site-directed mutagenesis experiments in order to try 
and predict the precise location of the cocaine-binding pocket relative to the substrate-
binding site (Beuming et al., 2008; Stockner et al., 2013).  Simultaneously, studies 
employing photoreactive analogs of cocaine have also suggested approximate ligand-
binding regions in the DAT (Vaughan et al., 2005 and 2007; Parnas et al., 2008).  
Despite decades of intense research, the molecular mechanism, and exact binding site(s) 
of cocaine and other DAT inhibitors remain unknown due to the lack of an accurate 
tertiary structure of the hDAT. 
1.3.2. Proposed Mechanism of Dopamine Reuptake by the DAT 
Dopamine reuptake is an energy-dependent process reliant on ion gradient created 
by Na+ K+-ATPase (Figure 1.6).  This process drives the opening of the DAT and co-
transport of dopamine, Na+, and Cl- from the synaptic cleft.  
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Figure 1.6.  Na+K+-ATPase induced concentration gradient in the DAT (Reprinted with permission 
from http://www.cnsforum.com/imagebank/item/rcpt_sys_DA_ reup/default.aspx. Copyright 2014, 
accessed on 02/26/2014). 
 
Figure 1.7.  Dopamine influx coupled with inward flow of Na+ and Cl- ions as part of  
the reuptake process (Reprinted with permission from 
http://www.cnsforum.com/imagebank/item/rcpt_sys_DA_ reup/default.aspx. Copyright 2014, 
accessed on 02/26/2014). 
. 
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Figure 1.8.  The DAT returns to an outward-facing conformation in  
order to facilitate another transport cycle (Reprinted with permission from 
http://www.cnsforum.com/imagebank/item/rcpt_sys_DA_ reup/default.aspx. Copyright 2014, 
accessed on 02/26/2014). 
 
Jardetzky has proposed an alternate accessing model in which dopamine, Na+, and 
Cl- first bind to the DAT in an outward-facing conformation (Figure 1.9) (Jardetzky, 
1966).  This binding is proposed to induce a conformational change in the transporter 
such that the dopamine-binding site becomes exposed to the intracellular side of the 
membrane (i.e., an inward-facing conformation), allowing dopamine, Na+, and Cl- to be 
released into the cell (Figure 1.7).  Subsequently, the DAT returns to an outward-facing 
conformation in order to facilitate another transport cycle (Figure 1.8). 
Jardetzky’s alternate access model, featuring transitions between outward- and 
inward-facing DAT conformations, was further corroborated by single-molecule 
dynamics studies, molecular simulations, and crystal structures of the LeuT (Yamashita 
et al., 2005).  In addition to the two low-energy conformations (i.e., the outward- and 
inward-facing conformations), these studies have also revealed a third-low energy state 
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termed the dually occluded, substrate-bound conformation (Figure 1.9) (Yamashita et al., 
2005; Schmitt et al., 2013). 
Most recently, three conformational states have been suggested to occur during 
dopamine (DA, Figure 1.9) transport: an outward-facing conformation for dopamine and 
ion pickup, an occluded conformation featuring dopamine and ion bound, and an inward-
facing conformation allowing dopamine and ion release (Figure 1.9) (Schmitt et al., 
2013).  First, Na+ and Cl- ions are proposed to bind to an ion/substrate-free (apo) 
outward-facing state of the DAT (Figure 1.9) and promote a more stabilized outward-
facing conformation featuring a fully open extracellular gate ready to bind substrate 
(Krishnamurthy and Gouaux, 2012).  Next, dopamine is proposed to bind at the primary 
substrate (S1) site (Figure 1.9) and close the extracellular gate via salt-bridge formation 
between extracellular gating residues Arg85 and Asp476 and aromatic bridge formation 
between Tyr156 and Phe320 to give rise to the occluded state.  Moreover, dopamine 
binding at the S1 site also induces conformational changes thereby shifting the DAT 
towards an inward-facing conformation.  Simultaneously, a second dopamine molecule 
has been proposed to bind to a secondary allosteric site (S2) in order to activate the 
conformational shift from the occluded to inward-facing state (Figure 1.9) (Shi et al., 
2008).  However, the nature of the S2 site and its relevance to DAT (NSS protein) 
function is highly controversial (Rudnick, 2007; Quick et al., 2012 and the rebuttal of 
Wang and Gouaux, 2012).  Finally, dopamine, Na+, and Cl- ions are released into the 
cytosol from the inward-facing state of the DAT due to hydration of its binding sites.  
Subsequent DAT changes from the inward- to outward-facing state allow another 
dopamine transport cycle to commence (Figure 1.9; Schmitt et al., 2013). 
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Figure 1.9.  Putative DAT conformational cycle (DA = dopamine) (Schmitt et al., 2013. Reprinted 
with permission from J. Pharmacol. Exp. Ther. 2013, 346, 2-10. Copyright 2013, JPET Online by 
American Society for Pharmacology and Experimental Therapeutics). 
1.4. DAT Ligands 
1.4.1. DAT Substrates 
Amphetamines (1.3-1.8; Figure 1.10) are a class of drugs notorious for high abuse 
and addiction potential.  Since these compounds are structurally similar to dopamine, 
amphetamines behave as DAT substrates and get transported into the presynaptic neuron, 
leading to an increased number of “inward-facing” transporter binding sites (Volz et al., 
2007).  Concomitantly, these drugs are also VMAT-2 substrates, releasing vesicular 
dopamine stores resulting in increased intracellular dopamine levels that enhance 
dopamine reverse transport into the synaptic cleft (Kahlig and Galli, 2003).   In addition, 
a channel-like mode of the DAT has been indicated with respect to amphetamine-
mediated dopamine efflux (Sonders et al., 1997; Kahlig et al., 2005).  The resulting 
excessive dopaminergic neurotransmission in the reward areas of the brain leads to 
amphetamine abuse and addiction (Fleckenstein et al., 2007). 
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Figure 1.10.  Chemical structures of amphetamines as DAT substrates. 
1.4.2. DAT Inhibitors  
A suggested treatment for cocaine addiction has been the pursuit of DAT 
inhibitors that act as cocaine antagonists without inhibiting dopamine uptake.  In 
particular, it has been suggested that the ideal DAT inhibitor for treatment of cocaine 
abuse should gradually eliminate craving for cocaine and help users maintain abstinence 
from cocaine (Rothman et al., 1989; Carroll et al., 1999).  However, the rational design 
of such compounds has been challenging due to limited 3-D structural information and 
poor understanding of dopamine- and inhibitor-binding sites within the DAT.  As a 
result, essentially all DAT inhibitors to date have been discovered either by serendipity or 
ligand-based drug design.  In particular, these compounds have been traditionally 
classified as either “cocaine-like” or “atypical” inhibitors due to their distinct behavioral 
effects.  In particular, given there are structural and behavioral differences between DAT 
inhibitors, it has been suggested this protein exhibits ligand-specific pleotropic functional 
qualities (Schmitt et al., 2013). 
1.4.2.1. “Cocaine-Like” DAT Inhibitors  
1.4.2.1.1. Tropanes 
Cocaine (1.1, Figure 1.1) is a pyschostimulant tropane analog that binds to the 
DAT and inhibits dopamine reuptake.  A large number of tropane analogs have been 
thoroughly investigated in the hope of finding a cocaine antagonist that does not inhibit 
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dopamine uptake to a significant extent (Carroll et al., 1999; Runyon and Carroll, 2006).  
However, the overwhelming majority of tropane analogs exhibit cocaine-like behavioral 
effects in vivo (Schmitt et al., 2013).  Nevertheless, studies of these compounds have led 
to the identification of several important tropane analogs including WIN-35,428 (1.9, 
Figure 1.11; IC50 = 18 nM; Ki = 6.5 nM), which functions as a competitive inhibitor of 
cocaine and displays 8-fold higher DAT binding affinity than cocaine (Clarke et al., 
1973; Madras et al., 1989).  WIN-35,428 is a stable, long-lasting cocaine analog because 
of the absence of the metabolically labile benzoate ester found within cocaine.  As a 
result, [3H]-WIN-35,428, a radiolabeled form of  WIN-35,428, is extensively used in 
determination of binding affinities of DAT ligands (Carroll et al., 1991).  
 
Figure 1.11.  Structural comparison between cocaine and WIN-35,428. 
 
1.4.2.1.2. Methylphenidate (MP) 
Methylphenidate (1.10, MP, Figure 1.12) is a highly potent DAT inhibitor 
approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention 
deficit hyperactivity disorder (ADHD) (Hodgkins et al., 2012).  MP displays 2-fold 
higher DAT binding affinity when compared to cocaine (Pan et al., 1994) and has similar 
pharmacophoric features (a basic nitrogen, methyl ester, and an aromatic ring).  
Predictably, MP has reinforcing effects similar to that of cocaine in animal models.  
However, these reinforcing effects in humans are substantially lower, and this drug has 
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been shown to reduce cocaine craving (Yano and Steiner, 2007).  In addition, MP has 
been used for decades and is considered relatively safe upon oral administration.  
Moreover, unlike cocaine, MP is not a sodium channel blocker at therapeutic levels and 
does not have harmful effects on nerve conductance when taken in excess.  As a result, 
MP and its analogs are currently being pursued as potential candidates for the treatment 
of cocaine dependence (Misra et al., 2010). 
 
Figure 1.12.  Structural comparison of cocaine versus MP.  
1.4.2.2. “Atypical” DAT Inhibitors  
1.4.2.2.1. Benztropines 
Benztropine (1.11, Figure 1.13) is a centrally acting 
anticholinergic/antihistamine agent whose anticholinergic effects have been established 
as therapeutically significant in the symptomatic management of Parkinsonism 
(Katzenschlager et al., 2003).  Benztropine antagonizes the effect of acetylcholine, 
decreasing the imbalance between the neurotransmitters acetylcholine and dopamine, 
which may improve symptoms of parkinsonian tremor.  Benztropine also functions as 
a DAT inhibitor, which makes it useful for people with extrapyramidal symptoms who 
take antipsychotics through a similar mechanism in the striatum (Soares and McGrath, 
2000).  Structurally, benztropine is a cocaine analog that lacks the methyl ester at the 2-
position of the tropane system, and contains a 3α-diphenylmethoxytropane in place of a 
3β-benzoyl ester.  Although benztropines have high affinity for the DAT, these 
 15 
compounds demonstrate unique behavioral profiles that are significantly different from 
that of cocaine.  For example, benztropines did not stimulate locomotor activity as 
effectively as cocaine, and did not fully substitute for cocaine in rats trained to 
discriminate cocaine from saline injections (Newman et al., 1995; Katz et al., 1999 and 
2004; Vela´zquez-Sa´nchez et al., 2010).  Moreover, benztropines were not self-
administered to the same degree as cocaine (Woolverton et al., 2000; Ferragud et al., 
2009; Hiranita et al., 2009) and have a relatively slow onset and reduced maximal effects 
compared to cocaine (Tanda et al., 2009).  As a result of these non-addictive behavioral 
properties, benztropine analogs have garnered significant attention as potential agents for 
the treatment of cocaine addiction (Rothman et al., 2008). 
 
Figure 1.13.  Structural comparison of cocaine versus benztropine as DAT inhibitors. 
1.4.2.2.2. GBR-12909 
Modified analogs of benztropine featuring a piperazine ring in place of the 
bicyclic tropane skeleton have been termed GBR analogs (Rothman et al., 2008).  GBR-
12909 (1.12, Figure 1.14) was initially envisioned as an antidepressant, but later was 
found to be a highly selective DAT inhibitor that is structurally distinct from cocaine 
(Esumi et al., 2013).  Similar to the benztropines, GBR-12909 and its analogs have also 
shown unique behavioral profiles that are significantly different from that of cocaine 
(Villemagne et al., 1999).  Pharmacological studies of GBR-12909 indicate this 
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compound has a higher affinity for, and slower dissociation rate from, the DAT in 
comparison to cocaine.  Moreover, GBR-12909 was shown to antagonize cocaine’s 
ability to increase extracellular dopamine levels (Rothman et al., 1991).  Additionally, 
GBR-12909 has a slower onset and longer duration of action than that of cocaine 
(Rothman et al., 1992).  As a result of its promising pharmacodynamic and 
pharmacokinetic profile, GBR-12909 was advanced into clinical trials for the treatment 
of cocaine abuse, but later was withdrawn due to long QT syndrome (Goldsmith et al., 
2007). 
 
Figure 1.14.  Structural comparison of GBR-12909 versus benztropine and cocaine  
as DAT inhibitors. 
1.4.3. Unique Behavioral Responses of DAT Inhibitors 
There is abundant evidence that different structural classes of DAT inhibitors 
preferentially bind to unique transporter conformational states, which are suggested to 
dictate the addictive liability of a particular DAT ligand (Loland et al., 2008).  This type 
of conformation-specific activity was first observed with differential effects for cocaine 
and benztropine with respect to an extracellular-facing DAT cysteine residue’s reactivity 
towards membrane-impermeable sulfhydryl reducing agents.  This experimental 
observation suggests that these particular DAT inhibitors stabilize different transporter 
conformations (Reith et al., 2001).  These observations have been further corroborated by 
several site-directed mutagenesis studies.  In particular, DAT mutations W84L and 
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D313N in the extracellular vestibule have been shown to stabilize an outward-facing 
DAT conformation (Chen et al., 2004).  Each of these mutations resulted in an increased 
DAT affinity for both cocaine and MP, whereas negligible or opposite effects on binding 
affinity of atypical inhibitors such as GBR-12909 and benztropine was observed.  
Additionally, these mutations did not affect the binding affinity of DAT substrates such 
as dopamine and amphetamine.  As a result, it has been suggested that preferential 
interaction of cocaine-like compounds with an outward-facing DAT conformational state 
may be responsible for the abusive or cocaine-like rewarding effects associated with 
these compounds (Schmitt et al., 2008).  
In contrast, Y335A mutation of the DAT has been shown to stabilize an inward-
facing DAT conformation (Kniazeff et al., 2008).  In the Y335A DAT mutant, binding of 
cocaine-like compounds was completely destroyed, whereas binding of atypical 
inhibitors such as GBR-12909 and benztropine was nominally impacted.  These 
observations give further credibility to the hypothesis that atypical DAT inhibitors 
display reduced, or even a complete lack of, cocaine-like rewarding effects due to their 
preferential interactions with the inward-facing DAT conformational state (Loland et al., 
2008; Kopajtic et al., 2010; Schmitt and Reith, 2011).  Moreover, it has been shown that 
the rate at which a particular DAT inhibitor enters the brain and interacts with the DAT 
significantly affects the addictive liability of the compound.  It has been observed that 
DAT inhibitors with a rapid onset of action tend to have greater addiction potential than 
those with a slower onset rate (Wee et al., 2006).  As a result, it is believed that the 
behavioral response to a specific DAT inhibitor is the result of a complex interplay 
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between the rate of delivery to the brain (pharmacokinetics) and the mode of interaction 
with the transporter (pharmacodynamics) (Schmitt et al., 2013). 
1.5. Cocaine and the Glutamatergic System 
1.5.1. The Glutamatergic System  
Glutamate (1.13, Figure 1.15) is a major excitatory neurotransmitter in the brain 
that regulates a variety of functions including cognition, memory, and learning 
(Meldrum, 2000).  Glutamate is known to exert its neuronal effects by principally 
interacting with two classes of receptors: ionotropic glutamate receptors (iGlus) and 
metabotropic glutamate receptors (mGlus) (Kew and Kemp, 2005). 
 
Figure 1.15.  Structural representation of glutamate as an excitatory neurotransmitter. 
iGlus are ligand-gated ion channels that are responsible for mediating fast 
excitatory neurotransmission.  This group of receptors consists of N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), and kainate 
receptors (Traynelis et al., 2010).  In contrast, mGlus are Family C G-protein-coupled 
receptors (GPCRs) that modulate the strength of synaptic transmission (Niswender and 
Conn, 2010).  Currently there are eight known members of the mGlu family that are 
classified into three groups (Group I, II, and III) according to their sequence homology, 
pharmacology, and signal transduction mechanism.  Group I mGlus (mGlu1 and mGlu5) 
are predominately located post-synaptically and enhance cell signaling by increasing 
intracellular calcium levels (Koulen et al., 1997).  In contrast, group II (mGlu2 and 
mGlu3) and group III (mGlu4, mGlu6, mGlu7, and mGlu8) mGlus are located pre-
 19 
synaptically and display inhibitory effects on neurotransmitter release by decreasing 
cyclic adenosine monophosphate (cAMP) levels (Muto et al., 2007).  
1.5.2. Effects of Cocaine on the Glutamatergic System 
Traditionally, scientific research on cocaine addiction has focused mainly on 
alterations in dopaminergic neurotransmission.  While dopamine is crucial for reward and 
initiation of addiction, end-stage addiction is primarily due to cellular adaptations in 
glutamatergic projections to the nucleus accumbens. In particular, repeated use of 
addictive drugs induces reorganization in neuronal circuit (Figure 1.16) of glutamatergic 
and dopaminergic interconnections among the basolateral amygdala, ventral tegmental 
area, nucleus accumbens, and prefrontal cortex, which ultimately leads to characteristic 
behaviors of addiction.   However, the mechanism by which the disruption of neuronal 
circuit of glutamate and dopamine (Figure 1.16) leads to addiction is less clear (Kalivas 
and Nora, 2005; Schmidt and Christopher, 2010). 
 
Figure 1.16. Neuronal circuit of glutamate and dopamine  
In addition to the disruption of neuronal circuit of glutamate and dopamine, there 
is significant evidence indicating a pivotal role for glutamatergic neurotransmission in 
mediating the addictive behaviors and long-term neuroplasticity associated with cocaine 
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abuse (Olive et al., 2012).  In rodent models of addiction, it has been shown that repeated 
exposure to cocaine increases the expression of mGlu5, which could play an important 
role in the behavioral effects of cocaine (Ghasemzadeh et al., 2009).  Additionally, 
mutant mGlu5-null mice have been shown to be insensitive to the locomotor-stimulating 
effects of cocaine and do not self-administer cocaine (Chiamulera et al., 2001).  
Analogously, a highly selective mGlu5 non-competitive antagonist/ (NAM), 2-methyl-6-
(phenylethynyl)-pyridine (MPEP, 1.14, Figure 1.17), has been shown to attenuate-
cocaine mediated behavioral effects including relapse to cocaine seeking (Chiamulera et 
al., 2001).  These particular studies have provided initial evidence that either 
pharmacological or genetic inhibition of mGlu5 can decrease the locomotor stimulant and 
reinforcing effects of cocaine.  In turn, several mGlu5 NAMs have been shown to reduce 
self-administration, conditioned reward, and reinstatement of drug seeking associated 
with cocaine (Cleva and Olive, 2012).  Despite a significant amount of promising 
behavioral evidence, the exact mechanism of mGlu5’s contribution to cocaine 
dependence remains unknown.  
 
Figure 1.17.  Structural representation of MPEP, a mGlu5 NAM.  
 
1.6. Structural and Functional Features of mGlu5  
mGlu5 is the most abundant mGlu in the brain and is expressed mainly 
throughout the striatum, cortex, hippocampus, caudate putamen, and nucleus accumbens 
(Matosin et al., 2013).  Structurally, mGlu5 contains three major domains: a large bi-
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lobal, venus flytrap extracellular N-terminal domain that hosts the orthosteric- / 
glutamate-binding site, a heptahelical domain containing seven TM regions linked by 
short loops, and an intracellular C-terminal domain (Figure 1.18, Wood et al., 2011).   
 
Figure 1.18.  Structural and functional representation of mGlu5 as a Family C GPCR (Wood et al., 
2011. Reprinted with permission from Biochemistry 2011, 50, 2403-2410. Copyright 2011, American 
Chemical Society). 
Binding of the orthosteric ligand, glutamate, to mGlu5 has been suggested to 
induce closure of the “Venus fly trap” domain.  Upon this binding, conformational 
changes of the TM domains are proposed to facilitate coupling of Gq proteins to mGlu5, 
which in turn leads to activation of protein kinase C (PKC) and phospholipase C (PLC), 
ultimately catalyzing the production of 1,4,5-inositol triphosphate and an increase in 
intracellular calcium levels (Pin and Acher, 2002).  
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1.7. mGlu5 Ligands 
1.7.1. Orthosteric- / Glutamate-Binding Site mGlu5 Ligands 
Development of ligands focused on the mGlu5 glutamate-binding site has yielded 
a variety of competitive agonists and antagonists.  However, the overwhelming majority 
of these compounds (e.g., 1.15 and 1.16, Figure 1.19) display poor selectivity for mGlu5 
due to the highly conserved nature of the glutamate-binding pocket found within all eight 
mGlu subtypes.  Furthermore, most of these orthosteric ligands are highly polar amino 
acid derivatives that could potentially lack favorable pharmacokinetic properties 
necessary for modulating CNS-based mGlu5s (Rocher et al., 2011).  
 
Figure 1.19.  Structural examples of compounds targeting the orthosteric- / glutamate-binding  
site of mGlu5. 
1.7.2. mGlu5 Allosteric Modulators 
Given selectivity and pharmacokinetic challenges associated with developing 
orthosteric ligands as viable CNS drug candidates, more recent mGlu5 research has 
shifted to the development of allosteric modulators (Figure 1.18) (Emmitte, 2013).  
Allosteric ligands are proposed to bind at distinct sites (e.g., within the TM domains) that 
are topologically distinct from the glutamate-binding site (N-terminal domain) (Sheffler 
et al., 2011).  Binding of these compounds in turn are proposed to induce conformational 
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changes that modulate the efficacy and binding affinity of glutamate, as well as coupling 
of the TM domains to the G-protein.  Allosteric ligands that enhance glutamate-induced 
activation or glutamate binding affinity, without triggering mGlu5 directly (i.e., mGlu5 
activation in the absence of glutamate), are termed positive allosteric modulators 
(PAMs).  Conversely, compounds that reduce glutamate-induced activation or glutamate 
binding affinity in a noncompetitive manner are termed NAMs.  In general, the pursuit of 
allosteric modulators has proven to be a justifiable approach for achieving greater mGlu5 
subtype selectivity due to the less conserved nature of allosteric binding sites versus the 
orthosteric-binding site (Conn et al., 2009).  Additionally, mGlu5 allosteric modulators 
are generally more hydrophobic than glutamate analogs targeting the orthosteric-binding 
site.  As a result, allosteric modulators are anticipated to have more appropriate 
physiochemical properties for CNS penetration.  Furthermore, mGlu5 allosteric 
modulators are less likely to contribute to receptor desensitization, internalization, and 
down regulation commonly associated with orthosteric ligands. 
Despite these advantages, numerous challenges are associated with the discovery 
and optimization of mGlu5 allosteric modulators as potential therapeutics (Conn et al., 
2009).  The significant lack of accurate and reliable mGlu5 3-D structural information 
makes structure-based design of allosteric modulators currently impossible.  Moreover, 
numerous mGlu5 allosteric modulators have been shown to exhibit unique 
pharmacological behavior including ligand-biased signaling and trafficking effects 
(Noetzel et al., 2013).  Additionally, structure-activity relationships (SAR) of mGlu5 
allosteric modulators are notoriously difficult or “flat”, wherein minimal changes to the 
structure can result in significant loss of activity (Zhao et al., 2007).  Furthermore, many 
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mGlu5 modulator chemotypes display a disturbing “molecular switch” phenomenon 
whereby a NAM can arise from a PAM scaffold (or vice versa) via minimal structural 
modification to the chemotype (Wood et al., 2011).  Additionally, mGlu receptor subtype 
selectivity may also potentially be changed upon minimal structural change to the ligand.  
As a result, the phenomenon of molecular switches raises concern over the pharmacology 
of putative metabolites, and represents a true nightmare for medicinal chemists trying to 
develop SAR for driving a program towards a clinical candidate with a single mode of 
pharmacology. 
1.7.2.1. mGlu5 NAMs 
The study of mGlu5 NAMs in cocaine abuse has been principally aided by the 
discovery of MPEP (1.14, Figure 1.20) (Gasparini et al., 1999) and 3-[(2-methyl-1,3-
thiazol-4-yl)ethynyl]-pyridine (1.17, MTEP, Figure 1.20) (Cosford et al., 2003), which 
have been shown to attenuate cocaine-mediated behavioral effects including relapse to 
cocaine seeking (Olive et al., 2012).  Although MTEP shows similar in vitro potency in a 
calcium influx assay (IC50 = 5 nM) versus MPEP (IC50 = 2 nM), MTEP displays less off-
target effects especially at the norepinephrine transporter (NET) and MAO-A.  Moreover, 
due to its higher oral bioavailability and brain penetration, MTEP has shown better in 
vivo efficacy in cocaine abuse animal models (Cleva and Olive, 2012).  Since the initial 
discovery of MPEP and MTEP, a plethora of alternative mGlu5 allosteric modulator 
chemotypes have been pursued not only as anti-addiction therapeutics, but as candidates 
for numerous other disorders associated with mGlu5 (e.g., anxiety, pain, 
gastroesophageal reflux disease, Parkinson’s disease, and fragile X syndrome) (Emmitte, 
2011 and 2013).  Most recently, a substituted 1-phenyl-3-(pyridin-2-yl) urea 
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(VU0463841, 1.18, Figure 1.20) was shown to attenuate drug seeking behaviors in 
relevant rat models of cocaine addiction (Amato et al., 2013).  In short, given 
encouraging results of MPEP-like compounds in behavioral models of drug addiction, 
small molecule negative allosteric modulation of mGlu5 represents an area of high 
interest towards the development of anti-addiction therapeutics. 
 
Figure 1.20.  Chemical structures of MPEP, MTEP, and VU0463841 as representative  
mGlu5 NAMs. 
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CHAPTER TWO 
2. Irreversible Chemical Labeling of Protein Drug Targets with Small 
Molecules: Literature Review 
2.1. Introduction 
Lack of accurate three-dimensional structural information with respect to the 
DAT and mGlu5 represents a critical barrier in the rational design of inhibitors and 
modulators for therapeutic use.  Although computer-generated homology models have 
given some insight into DAT (Indarte et al., 2008; Manepalli et al., 2012) and mGlu5 
(Pagano et al., 2000; Malherbe et al., 2003; Molck et al., 2012; Kaae et al., 2012) 
structure-function relationships, these powerful tools require further refinement and 
experimental validation in order to be confidently used in drug discovery and 
development programs.  Site-directed mutagenesis and chemical labeling with 
irreversible molecular probes represent traditional experimental approaches for validating 
homology models (Foucaud et al., 2001 and 2007) in order to refine computer-aided drug 
discovery methods such as virtual / in silico screening (Tanrikulu et al., 2013).  
Site-directed mutagenesis has been used as an experimental approach to indirectly 
determine ligand-target molecular interactions and validate DAT (Surratt et al., 2005; 
Volz and Schenk, 2005; Beuming et al., 2008; Stockner et al., 2013) and mGlu5 (Pagano 
et al., 2000; Malherbe et al., 2003; Molck et al., 2012; Kaae et al., 2012) homology 
models.  In this strategy, if an amino acid substitution results in a significant change of a 
ligand’s pharmacological effect, it indicates the residue’s importance within the ligand-
binding site.  However, the question of how these mutated amino acid residues directly 
affect the pharmacology of a ligand cannot be easily clarified, as mutations may have 
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long-range structural or functional effects that in turn may alter ligand pharmacology 
(Colquhoun, 1998; Cervantes et al., 2013).  Nevertheless, when a site-directed mutation 
does not significantly interfere with the pharmacological activity of the drug target, such 
an indirect effect cannot be suspected.  In particular, if the amino acid mutation is a 
cysteine, this residue can be chemically derivatized and the modified drug target can be 
subsequently assayed (Foucaud et al., 2001 and 2007). 
Alternatively, site-directed chemical labeling with irreversible molecular probes 
can provide unequivocal experimental results in determining direct ligand-target 
molecular interactions towards validating computationally-derived drug target homology 
models (Foucaud et al., 2001 and 2007).  This strategy employs affinity and photoaffinity 
labeling agents, which upon initial reversible binding to the requisite drug target can 
ultimately form an irreversible covalent bond to the drug target within the ligand-binding 
site, thus providing direct unambiguous structural information regarding ligand-target 
molecular interactions.  To date, employment of irreversible chemical probes has never 
been attempted with respect to mGlu5 structure-function studies.  However, this strategy 
has been extensively used with the DAT (Sallee et al., 1989; Grigoriadis et al., 1989; 
Carroll et al., 1992; Deutsch et al., 1992; Schweri et al., 1992; Agoston et al., 1997; 
Husbands et al., 1997; Dutta et al., 2001; Zou et al., 2001 and 2003; Cao et al., 2004; 
Lever et al., 2005; Newman et al., 2006; Murthy et al., 2007 and 2008; Lapinsky et al., 
2009, 2011, 2012a, and 2012b).  In this regard, it should be noted that multiple attempts 
to elucidate microlevel structural information regarding DAT ligand-binding sites by 
mass-spectrometry (MS) has not been successful, prinicipally due to limited resolution in 
proteolytic separation, labor intensive peptide mapping strategies, and low efficiency of 
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photolabel incorporation (Vaughan et al., 2005).  Nonetheless, site-directed chemical 
labeling techniques utilizing molecular probes have significantly evolved over the past 
decade in order to address the traditional shortcomings associated with this experimental 
approach (Foucaud et al., 2007; He et al., 2009).  These improvements and their 
applications to this research will be discussed in further detail in subsequent sections of 
this dissertation. 
2.2. Affinity Labeling  
Affinity labeling is a powerful biochemical technique to investigate the presence 
of nucleophilic amino acid residues within the binding sites of drug targets.  Affinity 
labeling agents are ligands decorated with an electrophilic functional group (EFG, 
Scheme 2.1), which upon close proximity to a nucleophile (Nu) within the drug target 
binding site can form a reversible binary complex whose lifespan is long enough to 
sustain a covalent bond-forming reaction.  In this complex, the probability of a reaction 
between the nucleophile within the ligand-binding site and the electrophile of the ligand 
does not depend on a collision, but rather upon the geometry of these functional groups 
and their intrinsic chemical reactivity.  Irreversible occupancy of the drug target can be 
then determined by a competitive radioligand binding assay, which subsequently 
confirms the presence of a nucleophilic amino acid within close proximity to the 
electrophilic functional group of the affinity labeling probe.  Next, the irreversible, 
covalent probe-target complex is then typically digested or fragmented via protease 
and/or chemical cleavage methods.  Subsequently, the resulting probe-labeled fragments 
can then be analyzed using epitope-specific immunoprecipitation, high performance 
liquid chromatography (HPLC), and mass spectrometry (MS) in order to identify the 
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amino acid composition / sequence peripheral to the covalent point of attachment of the 
probe to the drug target  (Chen et al., 2003; Foucaud et al., 2001 and 2007).  
 
Scheme 2.1.  Affinity labeling towards determining the binding site of a ligand within a drug target 
(Adapted with permission from Bioorg. Med. Chem. 2012, 20, 6237-6247.  
Copyright 2012, Elsevier). 
2.2.1. Thiol-Reactive Affinity Labeling Agents 
Thiol-reactive affinity labeling agents are ligands featuring electrophilic 
functional groups that have high or specific reactivity towards nucleophilic cysteine 
residues found within ligand-binding sites of a drug target.  Methanethiosulfonates (2.1) 
and maleimides (2.4) represent two of the most common electrophilic functional groups 
employed in the design of thiol-reactive affinity labeling agents (Scheme 2.2).  When a 
affinity labeling probe derivatized with a methanethiosulfonate (2.1) functional group 
initially binds to its drug target (2.2) reversibly, the methanethiosulfonate electrophile 
could potentially react with a close proximity cysteine residue to form an irreversible 
ligand-drug target complex (2.3) (Foucaud et al., 2007; Chalker et al., 2009).  Similarly, 
when an affinity labeling probe is derivatized with a maleimide (2.4) functional group 
and this probe binds with its drug target (2.2) reversibly, the maleimide electrophile could 
potentially react with a close proximity cysteine residue to form an irreversible ligand-
drug target complex (2.5) via conjugate addition (Foucaud et al., 2007; Chalker et al., 
2009). 
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Scheme 2.2.  Ligands derivatized with methanethiosulfonate and maleimide electrophilic functional 
groups reacting with cysteine residues of drug targets.  
In addition to methanethiosulfonate (2.1) and maleimide (2.4) functional groups 
(Scheme 2.2), isothiocyanates (2.6), alkyl and aryl halides (2.7), fluorosulfonates (2.8), 
aziridinium groups (2.9), and -halo carbonyl compounds (e.g., 2.10 and 2.11) represent 
widely used electrophiles employed in the design of thiol-reactive affinity labeling agents 
(Figure 2.1; Foucaud et al., 2007).  However, most of these electrophilic functional 
groups are not necessarily thiol specific.  For example, although maleimides (2.4) have 
higher specificity for thiols at normal physiological conditions, they tend to react with 
nucleophilic amines under slightly basic conditions (Narain, 2014).  In another instance, 
isothiocyanates (2.6; Sletten and Bertozzi, 2009) and iodoacetamides (2.11, X = -I; Boja 
and Fales, 2001; Nielsen et al., 2008) also react with nucleophilic amines, especially 
lysine residues.  Irrespective of these limitations, these common electrophilies have been 
extensively employed in the design of thiol-reactive affinity labeling agents (Narain, 
2014). 
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Figure 2.1.  Additional electrophilic functional groups commonly employed in the  
design of thiol-reactive affinity labeling agents. 
2.2.2. Engineered Affinity Labeling  
Engineered affinity labeling is a chemical biology strategy that combines thiol-
reactive affinity labeling agents with molecular modeling-guided site-directed 
mutagenesis of putative binding site residues into cysteines (Foucaud et al., 2001 and 
2007; Chalker et al., 2009).  For this research, this strategy is being pursued as an 
experimental approach to definitively validate mGlu5 homology models.  The strategy 
begins with an anti-addictive mGlu5 MPEP-binding site NAM derivatized with a thiol-
reactive functional group (TRFG) (Scheme 2.3).  These affinity labeling chemical probes 
can be subsequently docked into a mGlu5 homology model.  Next, a series of cysteine-
substituted mGlu5 mutants, rationally designed according to their position in the mGlu5 
homology model, will be prepared and pharmacologically tested for activity compared to 
wildtype mGlu5.  Upon incubation of an appropriate mGlu5 thiol-reactive affinity 
labeling probe with its cysteine-modified mGlu5 receptor partner, the rationally 
introduced cysteine is expected to covalently react with the thiol-reactive affinity labeling 
probe only if: 1.) the introduced cysteine belongs to the mGlu5 NAM binding site, and 2.) 
the introduced cysteine is in close proximity to the thiol-reactive electrophilic functional 
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group upon reversible binding of the affinity labeling probe.  Finally, irreversible 
occupancy of the MPEP-binding site within mGlu5 by a cysteine-reactive mGlu5 NAM 
can be confirmed by a competitive radioligand binding assay using [3H]-methoxyPEPy 
(Cosford et al., 2003a).  This research approach (Scheme 2.3) is expected to provide a 
mGlu5 homology model with experimental support and thereby enhance computer-aided 
drug discovery methods such as virtual / in silico screening.  Finally, this method can 
potentially investigate protein dynamics of mGlu5 as a full-length membrane-inserted 
protein, as well as modulator-induced conformational changes, in order to better 
understand the pharmacology of this therapeutically important drug target (Foucaud et 
al., 2007).  
 
Scheme 2.3.  Engineered affinity labeling approach for experimental validation of a mGlu5 homology 
model. 
2.3. Photoaffinity Labeling 
Photoaffinity labeling is a widely used technique for characterizing how a ligand 
interacts with its drug target at the molecular level (Dorman and Prestwich, 2000; 
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Geurink et al., 2012).  A photoaffinity probe is a ligand that contains a photoreactive 
functional group (PRG), which is essentially inert and chemically unreactive under 
normal conditions (Scheme 2.4).  Photoaffinity probes also generally contain a reporter 
group (RG), which is important for the identification of drug target fragments covalently 
modified by the photoaffinity probe.  Upon reversible binding of the photoaffinity probe 
to its drug target, UV irradiation at a defined wavelength is capable of converting the 
PRG into a more reactive chemical species, which then initiates covalent bond formation 
between the drug target and the photoaffinity probe.  Next, the irreversible, covalent 
probe-target complex is then typically digested or fragmented via protease and/or 
chemical cleavage methods.  Subsequently, the resulting probe-labeled fragments can 
then be analyzed using epitope-specific immunoprecipitation, HPLC, and  MS in order to 
identify the amino acid composition / sequence peripheral to the covalent point of 
attachment of the probe to the drug target (Dorman and Prestwich, 2000; Geurink et al., 
2012).  
 
 
Scheme 2.4.  Photoaffinity labeling towards determining the binding site of a ligand within a drug 
target (Adapted with permission from Bioorg. Med. Chem. 2012, 20, 6237-6247.  
Copyright 2012, Elsevier).  
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2.3.1. Select Photoreactive Groups Traditionally Employed in Photoaffinity 
Labeling 
2.3.1.1. Aryl Azides 
Aryl azides have been extensively used in photoaffinity probes because of 
their relatively small structural change (compared to their parent compound) and ease of 
chemical synthesis.  Photolysis of an aryl azide (2.12) at a wavelength of 254 nm 
traditionally forms a highly reactive singlet nitrene (2.13), which can directly react with 
the drug target by simultaneous hydrogen-abstraction and insertion reactions resulting in 
a stable nitrogen-carbon or labile nitrogen-heteroatom bond (2.16) (Scheme 2.5).  
Simultaneously, singlet nitrenes (2.13) can form triplet nitrenes (2.14) by intersystem 
crossing (ISC) to give the same product (2.16) via hydrogen abstraction (2.15) and 
radical-radical combination.  Additionally, singlet nitrenes can also rearrange to 
dehydroazepines (2.17) by ring expansion, which traditionally causes undesired 
nonspecific labeling (2.18) by reacting with proximal nucleophiles on other biological 
macromolecules (Dorman and Prestwich, 2000; Geurink et al., 2012).  
A major disadvantage of aryl azides in photoaffinity labeling is that their 
maximum absorption wavelength is <300 nm, which is a relatively high amount of 
energy that could potentially damage the biological system upon photoirradiation.  
Moreover, lack of reaction specificity and rearrangement of nitrenes (e.g., 2.13 to 2.17) 
traditionally results in low crosslinking yields (<30%) being observed.  In order to 
address these disadvantages and improve the efficiency of chemical cross-linking, 
(per)fluorinated and iodinated aryl azides have been used to decrease the rearrangement 
of nitrenes by their electron withdrawing nature.  Despite these disadvantages, aryl azides 
 35 
continue to remain important photoreactive groups in photoaffinity labeling for mapping 
drug-binding pockets at the molecular level (Dorman and Prestwich, 2000; Geurink et al., 
2012). 
 
Scheme 2.5.  Reaction pathways of aryl azides upon photoactivation.  
2.3.1.2. Benzophenones 
Analogous to aryl azides, benzophenones are widely used photoreactive 
groups in photoaffinity labeling, principally due to their commercial availability and high 
chemical cross-linking efficiency with drug targets.  Photolysis of a benzophenone (2.19) 
at 350 nm wavelength forms a diradical (2.20), which can directly crosslink to a drug 
target by hydrogen abstraction (2.21) and selective carbon-carbon bond formation by 
radical combination (2.22) (Scheme 2.6).  An important feature of this chemical 
mechanism is that diradical formation (2.20) is reversible.  Moreover, diradicals (2.20) 
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are highly stable in protic solvents.  As a result of these advantages, higher drug target 
cross-linking efficiency has been observed with benzophenones compared to other 
photoreactive functional groups traditionally employed in photoaffinity labeling (e.g., 
aryl azides and diazirines) (Dorman and Prestwich, 2000; Geurink et al., 2012).  
Additionally, although benzophenone diradicals can react with all types of amino acids, 
benzophenones tend to show higher selectivity towards methionine due to the chemical 
stability of the labeled product (Wittelsberger et al., 2006).  As a result of this unique 
methionine “magnet” effect (Wittelsberger et al., 2006), benzophenone groups have been 
routinely used in methionine proximity experiments (Fillion et al., 2013), wherein amino 
acids are systematically mutated into methionines, thus serving as “baits” with the goal of 
identifying drug target residues that are in close proximity to the ligand.   
 
Scheme 2.6.  Activation pathway of benzophenone photoreactive groups. 
Despite these numerous advantages, the bulky size of benzophenones can 
negatively impact the proper pharmacodynamic interactions between the photoprobe and 
its biological target.  Irrespective of this drawback, benzophenones remain one of the 
most preferred photoreactive groups in photoaffinity labeling, principally due to their 
higher chemical cross-linking efficiency and commercial availability (Dorman and 
Prestwich, 2000; Geurink et al., 2012) 
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2.3.2. Select Reporter Groups Traditionally Employed in Photoaffinity Probes 
2.3.2.1. Radioactive Isotopes 
Radioactive isotopes represent some the most popular reporter groups in 
photoaffinity labeling studies because they provide a highly sensitive signal, require 
minimal equipment for production, and are easy to detect using autoradiographic 
methods.  In particular, 125I is a widely used radioactive tag because of its relatively easy 
synthetic incorporation into a molecule of any complexity via numerous methods.  
Furthermore, the relatively small size of the iodine atom, when compared to other 
traditional reporter groups such as biotin or fluorophores, often results in minimum 
structural modification to the parent ligand.  Moreover, the ability of 125I-labeled 
molecules to be utilized in both in vitro and in vivo applications makes this reporter group 
particularly attractive with respect to the covalent labeling of biological macromolecules 
(Sadaghiani et al., 2007).  
However, the short half-life of 125I, t1/2 = ~60 days (Seevers and Counsell, 
1982), indicates that radio-iodinated molecules are not suitable for long storage times and 
can undergo relatively fast chemical degradation.  In addition, radiolabels are often 
harmful, thus requiring additional care in their handling and use in a laboratory setting 
(Sadaghiani et al., 2007; Lapinsky, 2012).  
2.3.2.2. ‘Clickable’ Handles as Chemical Reporters  
Towards addressing the disadvantages associated with radioactive isotopes as 
reporter groups in photoaffinity labeling, a relatively new strategy has emerged wherein 
either a terminal alkyne or aliphatic azide can be inserted into a photoprobe to serve as a 
‘clickable’ handle / chemical reporter.  These reporter groups are relatively small in size 
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and can be easily installed into a parent ligand.  Additionally, these functional groups are 
bioorthogonal and less likely to negatively influence biological activity when compared 
to the parent compound, principally by minimally disturbing key pharmacodynamic 
interactions.  As a result, these advantages make clickable handles the current reporter 
group of choice in terms of experiments associated with covalent labeling of biological 
macromolecules (Sadaghiani et al., 2007; Lapinsky, 2012).  
 
Scheme 2.7.  Tandem photoaffinity labeling-bioorthogonal conjugation (Lapinsky, 2012. Reprinted 
with permission from Bioorg. Med. Chem. 2012, 20, 6237-6247.  
Copyright 2012, Elsevier).  
Most recently, a routine chemical strategy has emerged wherein following 
covalent ligation of a photoprobe to a drug target by photoirradiation (Scheme 2.7), 
clickable handles are used for bioorthogonal conjugation / attachment of a wide variety of 
tags (e.g., biotin, fluorophores, FLAG peptide), thereby making this strategy particularly 
advantageous for the identification and isolation of probe-labeled biological targets.  In 
particular, bioorthogonal conjugation is traditionally performed using either a Staudinger-
Bertozzi ligation (Saxon and Bertozzi, 2000) or copper-catalyzed Huisgen 1,3-dipolar 
cycloaddition (so called ‘click’ reaction) (Rostovtsev et al., 2002) chemical reaction 
(Scheme 2.8).  This combined approach, termed tandem photoaffinity labeling-
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bioorthogonal conjugation (Lapinsky, 2012), also allows for high-throughput analysis 
and potential use in vivo (Sadaghiani et al., 2007). 
 
Scheme 2.8.  Bioorthogonal conjugation strategies traditionally employed after photoaffinity labeling.  
The only apparent drawback of this labeling strategy is that bioorthogonal 
chemical coupling yields can often vary in different systems.  In particular, low yields 
have been generally observed under Staudinger–Bertozzi ligation conditions when 
compared to copper-catalyzed Huisgen 1,3-dipolar cycloadditions (Speers et al., 2003).  
However, this variability in bioorthogonal conjugation yield is significantly trumped by 
the substantial advantages associated with the strategy (Lapinsky, 2012). 
2.3.2.3. Binding Ensemble Profiling with (f)Photoaffinity Labeling (BEProFL)   
Binding ensemble profiling with (f)photoaffinity labeling (BEProFL) (He et 
al., 2009) is a powerful strategy wherein photoaffinity labeling is coupled with traditional 
proteomic techniques and molecular modeling studies in order to accurately determine 
the three-dimensional structure of a ligand–target complex.  In particular, this strategy 
facilitates identification of key ligand–target molecular interactions (i.e., 
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pharmacodynamics) thereby unambiguously validating homology models via 
experimental support.  This strategy is being envisioned utilizing DAT and mGlu5 anti-
addiction photoprobes generated via this research, principally to experimentally validate 
and refine their respective homology models (Scheme 2.9).  In short, a DAT or mGlu5 
anti-addiction lead compound is derivatized with both a photoreactive group (PRG) and a 
reporter group (RG).  Upon reversible binding to their respective drug targets and 
subsequent photoaffinity labeling, an irreversible ligand-target complex is expected to be 
formed, which can then be subjected to traditional proteomic experiments and 
computational studies in order to map the ligand-binding poses and sites of DAT or 
mGlu5 anti-addiction compounds within their protein targets.  Utilization of the BEProFL 
approach is expected to further refine and/or validate DAT or mGlu5 homology models 
via experimental support, thereby enabling more confident computer-aided drug 
discovery efforts aimed at these targets (e.g., virtual / in silico screening, structure-based 
drug design) (Indarte et al., 2010; Mueller et al., 2010).   
 
Scheme 2.9.  Binding ensemble profiling with (f)photoaffinity labeling towards experimental 
validation and refinement of DAT and mGlu5 homology models.   
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CHAPTER THREE 
3. Chemical Literature Review 
3.1. Review of Synthetic Approaches Towards Racemic threo-MP as a Lead 
Compound 
A chemical synthesis of racemic threo-MP ((±)-1.10, Scheme 3.1) was first 
developed by Panizzon in 1944 (Panizzon, 1944) then later improved by Deutsch and 
colleagues in 1996 (Deutsch et al., 1996).  This scheme begins with treatment of 
phenylacetonitrile (3.1) with 2-bromopyridine (3.2) under basic conditions to provide 
nitrile 3.3, which was then subjected to acidic hydrolysis to provide amide 3.4 in 45% 
overall yield (Scheme 3.1).   
 
Scheme 3.1.  Synthesis of racemic threo-MP according to Deutsch et al., 1996. 
Hydrogenation of the pyridine ring of 3.4 and subsequent treatment with HCl 
provided a mixture of diastereomeric piperidine salts (3.5) in good yield (90%).  Acidic 
hydrolysis of the amide of 3.5, followed by epimerization under basic conditions and 
subsequent salt formation provided a diastereomeric mixture of racemic threo-ritilanic 
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acid derivatives (3.6) in moderate yield (64%).  Finally, esterification of 3.6 with 
methanolic HCl and subsequent recrystallization provided racemic threo-MP ((±)-1.10) 
in 84% yield (Deutsch et al., 1996).  This synthetic route by Deutsch and coworkers 
(Deutsch et al., 1996) was rather poor in terms of yield (9 steps, 18% overall yield) and 
often gave a mixture of products that required difficult chromatographic separations.  In 
turn, a relatively short and efficient synthesis of racemic threo-MP ((±)-1.10) was 
developed by Axten and colleagues in 1998 (Axten et al., 1998), which was then further 
improved by Gutman and colleagues in 2004 (5 steps, 56% overall yield) (Gutman et al., 
2004) (Scheme 3.2). 
 
Scheme 3.2.  Synthesis of racemic threo-MP according to Gutman et al., 2004. 
Synthesis of racemic threo-MP ((±)-1.10) according to Gutman et al. (Gutman et 
al., 2004) begins with treatment of α-keto ester 3.7 with piperidine (3.8) to provide α-keto 
amide 3.9 in nearly quantitative yield (Scheme 3.2).  Subsequent condensation of the 
ketone with tosylhydrazine under acidic conditions provided tosylhydrazone 3.10 in 85% 
yield.  Next, thermal cyclization of tosylhydrazone 3.10 under aqueous basic conditions 
using Aliquat 336 as a phase transfer catalyst, followed by column chromatography and 
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recrystallization from diethyl ether, gives diastereomerically pure racemic threo-β-lactam 
(±)-3.11 as the major product in moderate yield (68%).  Finally, threo-β-lactam (±)-3.11 
was converted to racemic threo-MP ((±)-1.10) in quantitative yield by ring opening with 
MeOH under acidic conditions (Scheme 3.2).  
Simultaneously, Dias and De Piloto Fernandes (Dias and De Piloto Fernandes, 
2000) reported their improved synthesis (7 steps, 35% overall yield) of racemic threo-MP 
((±)-1.10) from known precursors α-ethoxy carbamate 3.15 (Nagasaka et al., 1986) and 
silyl ketene acetal 3.17 (Tanaka and Fuji, 1992) (Scheme 3.4).  Their synthetic approach 
features protection of lactam nitrogen 3.12 as its carbamate 3.14, which upon treatment 
with NaBH4 and EtOH in HCl provided α-ethoxy carbamate 3.15 in 63% overall yield 
(Scheme 3.3; Nagasaka et al., 1986).  Simultaneously, treatment of benzylic ester 3.16 
with LDA and TMSCl provided silyl ketene acetal 3.17 in 90% yield (Scheme 3.3; 
Tanaka and Fuji, 1992). 
 
Scheme 3.3.  Synthesis of α-ethoxy carbamate (3.15, Nagasaka et al., 1986) and silyl ketene acetal 
(3.17, Tanaka and Fuji, 1992) precursors. 
  Next, condensation between α-ethoxy carbamate 3.15 and silyl ketene acetal 
3.17 in the presence of TESOTf gave an inseparable diastereomeric mixture of N-
protected racemic threo-MP derivatives (3.18) in 90% yield (Scheme 3.4).  
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Hydrogenolysis of the carbamate within 3.18 afforded a mixture of racemic threo- and 
erythro-MP free bases, which were separated by column chromatography.  Finally, 
racemic threo-MP free base was treated with methanolic HCl to produce the 
hydrochloride salt ((±)-1.10) in 69% yield. 
 
Scheme 3.4.  Synthesis of racemic threo-MP according to  
Dias and De Piloto Fernandes, 2000. 
 
Concomitantly, Deutsch and coworkers (Deutsch et al., 2001) reported a new 
synthetic route for racemic threo-MP ((±)-1.10) (8 steps, 7% overall yield) based on a 
Blaise reaction (Scheme 3.5).  This synthetic route begins with conversion of 4-chloro-1-
butanol (3.19) to 4-cyano-1-butanol, whose alcohol was converted to the corresponding 
mesylate (3.20) in 25% yield.  Mesylate 3.20 was then subjected to a Blaise reaction with 
methyl 2-bromo-2-phenylacetate (3.21) in presence of zinc to provide imine 3.22, which 
rearranges to form Z-enamine 3.23 in 63% yield. Reduction of enamine 3.23 was readily 
accomplished with sodium cyanoborohydride at pH 6, wherein piperidine formation 
occurred spontaneously during the work-up under basic conditions to provide a 
diastereomeric mixture of racemic threo- and erythro-MPs (3.25) in 78% yield.  Finally, 
epimerization of the diastereomeric mixture of racemic threo- and erythro-MPs (3.25) 
under basic conditions and subsequent treatment with methanolic HCl followed by 
recrystallization provided racemic threo-MP ((±)-1.10) in 55 % yield (Scheme 3.5).  
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Scheme 3.5.  Synthesis of racemic threo-MP according to Deutsch et al., 2001. 
3.2. Known Synthesis of Racemic threo-4-Iodo-MP as a Lead Compound 
A synthesis of racemic threo-4-iodo-MP ((±)-3.31, Scheme 3.6) developed from 
racemic threo-MP ((±)-1.10) has been described by Pan and coworkers (Pan et al., 1996).  
This scheme begins with N-benzoylation of racemic threo-MP to provide amide (±)-3.26 
in near quantitative yield.  The amide was subsequently nitrated with nitric acid to give 
predominantly the p-nitro isomer ((±)-3.27) in moderate yield (85%).  The nitro 
functional group was then reduced with iron under acidic conditions to provide aniline 
(±)-3.28 in 85% yield, followed by subsequent diazotization and displacement with 
potassium iodide to produce p-iodo compound (±)-3.29 in 60% yield.  In turn, global 
hydrolysis of benzamide (±)-3.29 under strong acidic conditions provides racemic threo-
4-iodo-ritalinic acid ((±)-3.30) in 40% yield, which upon esterification with methanolic 
HCl quantitatively leads to racemic threo-4-iodo-MP ((±)-3.31) (Scheme 3.6). 
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Scheme 3.6.  Synthesis of racemic threo-4-iodo-MP according to Pan et al., 1996. 
3.3. Review of Synthetic Approaches Towards Enantiopure (R,R)-MP as a Lead 
Compound  
The shortest and most efficient synthetic route for preparing the more 
pharmacologically active enantiomer of threo-MP (Ding et al., 1997; Williard et al., 
2007), that is (R,R)-MP ((+)-1.10), has been developed via direct resolution of 
commercially available racemic threo-MP ((±)-1.10) (Scheme 3.7) (Prashad et al., 1999a 
and 2000).  This approach features treatment of racemic threo-MP ((±)-1.10) with 
dibenzoyl-D-(-)-tartaric acid (3.32) in the presence of 4-methylmorpholine in a mixture of 
MeOH and water (2:1 v/v).  Such conditions provided the dibenzoyl-D-(-)-tartaric acid 
salt of (R,R)-MP ((+)-3.33) in 44% yield with excellent enantiomeric purity (R,R : S,S = 
99.54 : 0.46).  Subsequent basification of diastereomeric salt (+)-3.33 with sodium 
hydroxide, followed by HCl salt formation and water-HCl recrystallization gives (R,R)-
MP ((+)-1.10) in 91% yield with excellent enantiomeric purity (R,R : S,S = >99.9 : <0.1) 
(Scheme 3.7).   
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Scheme 3.7.  Preparation of (R,R)-MP via diastereomeric salt formation  
(Prashad et al., 1999a).  
 
A highly efficient enantioselective synthesis reported by Axten and coworkers 
(Axten et al., 1999) features concomitant stereocontrol of two chiral centers directly from 
commercially available starting materials (Scheme 3.8).  This strategy begins with 
rhodium-catalyzed asymmetric C-H insertion of methyl phenyldiazoacetate (3.35) with 
N-Boc-piperidine (3.34) leading to enantioselective formation of N-Boc-MP (+)-3.37 in 
65% yield with 94% de and 69% ee.  Removal of the Boc group of (+)-3.37 with HCl gas 
in MeOH gave crude (R,R)-MP in 68% yield with 94% de and 69% ee.  Next, crude 
(R,R)-MP was recrystallized twice from ethanol-diethyl ether (1:1 v/v) to provide 
optically pure (R,R)-MP ((+)-1.10) in 24% yield with 95% de and >95% ee (Scheme 3.8).  
 
Scheme 3.8.  Preparation of (R,R)-MP via rhodium-catalyzed C-H insertion  
(Axten et al., 1999). 
 
Other synthetic approaches towards enantiopure (R,R)-MP have been published a 
comprehensive review (Prashad, 2001).  The most recently developed enantiopure 
synthesis of (R,R)-MP, by Krishna and coworkers (Krishna et al., 2007), features a ring-
closing metathesis protocol to construct the piperidine ring and Sharpless asymmetric 
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epoxidation to efficiently generate two contiguous stereocentres (Scheme 3.9). This 
approach begins with coupling of propargyl alcohol (3.38) with allyl bromide in the 
presence of copper iodide, tetrabutyl ammonium iodide, and potassium carbonate to give 
hex-5-en-2-yn-1-ol, whose triple bond was partially reduced in the presence of nickel 
acetate and sodium borohydride to afford Z-alkene 3.39 in 77% yield.  Sharpless 
asymmetric epoxidation of alkene 3.39 with cumene hydroperoxide in the presence of (–
)-diisopropyl D-tartrate and titanium(IV) isopropoxide afforded epoxide 3.40 (92% ee), 
which was then subjected to chelation-assisted regioselective nucleophilic ring-opening 
with phenyl lithium in the presence of  copper iodide to provide 1,3-diol 3.41 in 60% 
overall yield.  Then primary alcohol of alkene 3.41 was then selectively protected with 
TBDPS chloride, while the secondary alcohol was mesylated and subsequently displaced 
with azide to provide intermediate 3.42 in 60% yield.  Next, the azide of intermediate 
3.42 was reduced to the primary amine under Staudinger reaction conditions followed by 
acryloylation to afford bis-olefin 3.43 in 75% yield.  Subsequent ring-closing reaction of 
diene 3.43 using Grubbs’ first-generation catalyst 3.44 provided α,β-unsaturated lactam 
3.45, which was then converted to piperidine 3.46 in 55% yield by first reducing the 
olefin via hydrogenation and then the amide with BH3•DMS.  Next, the secondary amine 
within piperidine 3.46 was protected as its carbamate and the silyl group was removed to 
produce the primary alcohol, which was subsequently oxidized to aldehyde 3.47 in 51% 
yield via Dess–Martin periodinane.  The final steps of this elaborate synthesis feature 
oxidation of aldehyde 3.47 to the corresponding carboxylic acid, followed by treatment 
with methanolic HCl to provide (R,R)-MP ((+)-1.10) in 61% yield with high optical 
purity (Scheme 3.9).   
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Scheme 3.9.  Preparation of (R,R)-MP via ring-closing metathesis (Krishna et al., 2007). 
 
 
3.4. Known Synthesis of Racemic threo-3,4-Dichloro-MP as a Lead Compound 
Racemic threo-3,4-dichloro-MP ((±)-3.53, Scheme 3.10) represented a lead 
compound for photoprobe design because it displays a number of interesting DAT 
pharmacological properties when compared to racemic threo-MP.  For example, racemic 
threo-3,4-dichloro-MP is equipotent as an inhibitor of [3H]-WIN 35,428 (1.9) binding 
and [3H]-dopamine (1.2) uptake, whereas racemic threo-MP is threefold less potent as 
inhibitor of [3H]-dopamine (1.2) uptake. 
A synthesis of racemic threo-3,4-dichloro-MP has been reported by Deutsch and 
coworkers (Deutsch et al., 1996).  This synthesis is analogous to the chemistry depicted 
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in Scheme 3.1 and begins by reacting 3,4-dichlorophenylacetonitrile (3.48) with 2-
bromopyridine (3.2) to provide nitrile 3.49 (Scheme 3.10).  Subsequent acidic hydrolysis 
provided amide 3.50 in 40% overall yield.  Hydrogenation of the pyridine ring of amide 
3.50 followed by treatment with HCl provided a mixture of diastereomeric piperidine 
salts (3.51) in 80% yield.  Acidic hydrolysis of the amide of 3.51, epimerization under 
basic conditions, then subsequent salt formation provided a diastereomeric mixture of 
racemic threo-3,4-dichloro-ritilanic acid derivatives (3.52) in 54% yield.  Finally, 
esterification of carboxylic acids 3.52 with methanolic HCl followed by recrystallization 
provided racemic threo-3,4-dichloro-MP ((±)-3.53) in 80% yield (Deutsch et al., 1996).  
 
Scheme 3.10.  Synthesis of racemic threo-3,4-dichloro-MP  
according to Deutsch et al., 1996. 
 
3.5. Review of Synthetic Approaches Towards GBR-12909 as a Lead Compound 
GBR-12909 (1.12, Scheme 3.11) represents one of the most studied DAT 
inhibitors to date as a potential cocaine abuse therapeutic.  The original synthesis of this 
compound was disclosed by Van der zee and coworkers in 1980 (Van der zee et al., 
1980).  Their approach featured initial treatment of 4,4’-difluorobenzhydrol (3.54) with 
2-chloroethanol (3.55) under acidic conditions to provide chloride 3.56 in moderate yield 
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(85%) (Scheme 3.11).  Next, displacement of the chloride within 3.56 with excess 
piperazine (3.57) provided mono-substituted piperazine derivative 3.58 in 55% yield, 
which upon alkylation with 1-phenyl-3-bromopropane (3.59) provided GBR-12909 
(1.12) in 80% yield.  Finally, treatment of GBR-12909 (1.12) with maleic acid followed 
by MeOH-DMF recrystallization provided GBR-12909 dimaleate (3.60) in 45% yield. 
 
Scheme 3.11.  Synthesis of GBR-12909 according to Van der zee et al., 1980. 
Given its tremendous therapeutic promise, GBR-12909 (1.12) was needed in 
large-scale (kilogram) quantities for clinical trials.  For this purpose, a synthetic route 
developed by the National Institute on Drug Abuse (NIDA) (Scheme 3.12) was evaluated 
for scale-up by Ironside and coworkers (Ironside et al., 2002).  Analogous to that 
previously described, this effort began with initial treatment of 4,4’-difluorobenzhydrol 
(3.54) with 2-chloroethanol (3.55) under acidic conditions to provide chloride 3.56 in 
moderate yield (65%) after column chromatography (Scheme 3.12).  In parallel, 
treatment of 1-phenyl-3-bromopropane (3.59) with excess piperazine (3.57) in refluxing 
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acetonitrile provided 1-(3-phenylpropyl)piperazine, which upon treatment with dioxane-
HCl and subsequent MeOH-acetone recrystallization afforded 1-(3-
phenylpropyl)piperazine dihydrochloride (3.61) in moderate yield (45%).  Next, a 
coupling reaction between chloride 3.56 and mono-substituted piperazine derivative 3.61 
was performed in refluxing acetonitrile to provide GBR-12909 (1.12), which was then 
converted to dihydrochloride salt 3.62 in 30% yield by treatment with dioxane-HCl and 
subsequent water-ethanol recrystallization. 
 
Scheme 3.12.  Attempted scale-up synthesis of GBR-12909 by Ironside et al., 2002. 
A major obstacle in the scale-up of GBR-12909 via NIDA’s synthetic route 
(Scheme 3.12) was chloride 3.56 formation, wherein extraction with EtOAc formed 
emulsions and required tedious column chromatographic purification.  Moreover, the 
synthesis of dihydrochloride salts 3.61 and 3.62 employed 1,4-dioxane-HCl as an adverse 
reagent and produced difficult to filter solids, which typically needed vacuum-drying 
prior to proceeding to the next step.  In addition, the coupling of intermediates 3.56 and 
3.61 was low yielding and not reproducible.  As a result, Ironside and coworkers 
(Ironside et al., 2002) pursued improvements to the synthetic route previously developed 
by NIDA (Scheme 3.13).   
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Scheme 3.13.  Successful scale-up synthesis of GBR-12909 by Ironside et al., 2002. 
In the optimized synthetic route, replacement of p-TsOH with catalytic H2SO4 
during chloride 3.56 synthesis, and introduction of heptane as the extraction solvent, 
eliminated the emulsion and tedious chromatographic purification problems, thus 
resulting in an improved yield from 65% to 98% (Scheme 3.12 versus Scheme 3.13).  
Moreover, undesirable 1,4-dioxane-HCl was replaced with ethanol and HCl during salt 
formation reactions to provide piperazines 3.61 and 3.62 with improved filtration 
properties, higher purity, and increased yield (from 45% to 62%; Scheme 3.12 versus 
Scheme 3.13).  Furthermore, utilization of a preformed iodoether (3.63), replacement of 
acetonitrile (CH3CN) with methyl ethyl ketone (MEK), and use of an aqueous base in the 
last coupling step was relatively high yielding and reproducible (Scheme 3.12 versus 
Scheme 3.13).  As a result of these improved scale-up conditions depicted in Scheme 
3.13, GBR-12909 (1.12) was successfully synthesized in kilogram quantities for clinical 
trials. 
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3.6. Review of Synthetic Approaches Towards MPEP as a Lead Compound  
MPEP (1.14, Scheme 3.14) represents a prototype NAM of mGlu5.  This 
compound was originally synthesized by Tsuchiya and coworkers (Tsuchiya et al., 1984) 
by Sonogashira coupling 2-bromo-6-methylpyridine (3.64) with ethynyl benzene (3.65) 
(Scheme 3.14).  However, practical experimental conditions and the yield of MPEP 
(1.14) were not reported as a result of this work. 
 
Scheme 3.14.  Synthesis of MPEP by Tsuchiya et al., 1984. 
Given the importance of MPEP (1.14) as a lead compound with respect to mGlu5, 
several alternative synthetic strategies have been subsequently reported to that of 
Tsuchiya et al. 1984.  One strategy developed by Sorensen and Pombo-Villar (Sorensen 
and Pombo-Villar, 2005) features microwave-mediated one-pot desilylation of 
trimethyl(phenylethynyl) silane (3.66) with tetrabutylammonium chloride (TBACl), 
followed by copper-free palladium-mediated Sonogashira coupling with 2-bromo-6-
methylpyridine (3.64) to give MPEP (1.14) in 50% yield (Scheme 3.15). 
 
Scheme 3.15.  Synthesis of MPEP by  
Sorensen and Pombo-Villar, 2005. 
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Another strategy towards the synthesis of MPEP (1.14) begins with Sonogashira 
coupling of 2-bromo-6-methylpyridine (3.64) with trimethylsilyl acetylene (3.67) to 
provide alkyne-protected pyridine derivative 3.68 in 70% yield (Alagille et al., 2005) 
(Scheme 3.16).  Subsequent one-pot desilylation of protected alkyne 3.68 with 
tetrabutylammonium fluoride (TBAF) and palladium-mediated Sonogashira coupling 
with iodobenzene (3.69) provided MPEP (1.14) in 78% yield (Jaeschke et al., 2007).  
 
Scheme 3.16.  Synthesis of MPEP by Jaeschke et al., 2007. 
A different strategy developed by Saleh and coworkers (Saleh et al., 2011), 
features Heck alkynylation of 2-bromo-6-methylpyridine (3.64) with ethynylbenzene 
(3.65) to provide MPEP (1.14) in 90% yield (Scheme 3.17).  It is noteworthy to mention 
that 1-n-butyl-3-methylimidazolium tetrafluoroborate ([BMIM][BF4]) was chosen as the 
reaction solvent due to its high compatibility with transition metals, low vapor pressure, 
ease of handling, and potential for recycling, which are favorable for industrial-scale 
synthesis. 
 
Scheme 3.17.  Synthesis of MPEP by Saleh et al., 2011. 
Another strategy developed by Reddy and coworkers (Reddy et al., 2013) features 
palladium-catalyzed decarboxylative coupling of 3-phenylpropiolic acid (3.70) with 2-
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bromo-6-methylpyridine (3.64) to give MPEP (1.14) in 70% yield (Scheme 3.18).  This 
synthetic route employing 3-phenylpropiolic acid (3.70) is valuable because homo-
coupled side products traditionally associated with using terminal alkynes (e.g., 3.65, 
Scheme 3.14) are not observed during industrial-scale synthesis. 
 
Scheme 3.18.  Synthesis of MPEP by Reddy et al., 2013. 
3.7. Review of Synthetic Approaches Towards MTEP as a Lead Compound 
MTEP (1.17, Scheme 3.19) represents another prototype NAM for mGlu5.  This 
compound was originally synthesized by Cosford and coworkers in 2003 (Cosford et al., 
2003).  Their strategy began with condensation of acid chloride 3.72 with 
bis(trimethylsilyl)acetylene (3.73) to provide -chloro ketone derivative 3.74 in 70% 
yield (Scheme 3.19).  Subsequent cyclization with thioacetamide (3.75) provided alkyne-
protected methylthiazole derivative 3.76 in 60% yield.  Finally, subjection of alkyne 3.76 
to one-pot desilylation with tetrabutylammonium fluoride (TBAF) and Sonogashira 
coupling with 3-bromopyridine (3.77) afforded MTEP (1.17) in 50% yield (Cosford et 
al., 2003). 
 
Scheme 3.19.  Synthesis of MTEP by Cosford et al., 2003. 
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Roppe and coworkers (Roppe et al., 2004) synthesized MTEP (1.17) analogous to 
Cosford et al., 2003 with a minor modification in Sonogashira coupling between alkyne-
protected methylthiazole derivative 3.76 and 3-bromopyridine (3.77) (Scheme 3.20).  
Usage of Pd(PPh3)4 in place of PdCl2(PPh3)2 led to an increased yield of MTEP (1.17) 
from 50% to 87% (Scheme 3.19 versus Scheme 3.20). 
 
Scheme 3.20.  Synthesis of MTEP by Roppe et al., 2004. 
Iso and coworkers (Iso et al., 2006) synthesized MTEP (1.17) analogous to 
Cosford et al., 2003 with the exception of using 3-iodopyridine (3.78) as the electrophile 
and Pd(PPh3)4 as the catalyst during Sonogashira coupling of alkyne-protected 
methylthiazole derivative 3.76 (Scheme 3.21).  Although the reaction time significantly 
decreased from 4 hours to 30 minutes, no significant improvement in yield was observed 
as a result of these particular changes (Scheme 3.19 versus Scheme 3.21).  
 
Scheme 3.21.  Synthesis of MTEP by Iso et al., 2006. 
Finally, McIldowie and coworkers (McIldowie et al., 2009) reported a medium-
scale (5 grams) synthesis of MTEP (1.17, Scheme 3.22) with minor modifications to the 
Sonogashira coupling between alkyne-protected methylthiazole derivative 3.76 and 3-
bromopyridine (3.77) versus the original route developed by Cosford et al., 2003.  Usage 
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of Pd(PPh3)4, diisopropyl amine, and slower generation of the terminal alkyne by 
extended syringe-pump addition of tetrabutylammonium fluoride (TBAF) provided 
MTEP (1.17) in 78% yield (Scheme 3.22). 
 
 
Scheme 3.22.  Synthesis of MTEP by McIldowie et al., 2009. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
CHAPTER FOUR 
4. Statement of Research Problems 
4.1. Current Knowledge Gaps 
4.1.1. DAT Structure-Function Knowledge Gap 
The discrete molecular / pharmacodynamic interactions between cocaine-like or 
atypical DAT inhibitors with the DAT remain unknown.  In particular, it is not clear how 
structurally distinct DAT inhibitor classes (e.g., tropane versus non-tropane DAT 
inhibitors) specifically interact with the DAT to generate specific behavioral and/or 
phenomenological effects (e.g., addictive versus non-addictive behavioral responses). 
4.1.2. mGlu5 Structure-Function Knowledge Gap 
Notable advances have been made in characterizing the MPEP-binding site within 
the TM domain of mGlu5 (Pagano et al., 2000; Malherbe et al., 2003; Molck et al., 2012; 
Kaae et al., 2012).  However, it is unclear how subtle changes to the chemical structure of 
a mGlu5 MPEP-binding site allosteric modulator can lead to either an opposite mode of 
mechanism of action (i.e., a “molecular switch” from a mGu5 NAM to a mGlu5 PAM, or 
vice versa) or a change in the ligand’s mGlu receptor subtype selectivity profile. 
4.2. Long-Term Goal of This Research 
The long-term goal of this research is to understand how promising anti-addiction 
compounds interact with their major drug targets at the molecular level, and use that 
information in rational drug discovery and drug development efforts. 
4.3. Overall Objective of This Research  
The overall objective of this research was to develop irreversible chemical probes 
based on promising DAT and mGlu5 anti-addiction compounds in order to map their 
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corresponding binding sites and poses within their major drug targets.  
4.4. Central Hypothesis of This Research  
The central hypothesis of this research (Scheme 4.1) was that promising DAT and 
mGlu5 anti-addiction compounds could be derivatized, without significant loss in 
pharmacological activity, with a functional group (FG) capable of forming a covalent 
bond to its target protein and, if necessary, a reporter group (RG).  These probes are 
expected to allow DAT and mGlu5 proteomic experiments to be coupled with DAT and 
mGlu5 computational modeling (i.e., engineered affinity labeling previously described in 
Section 2.2.2 and BEProFL previously described in Section 2.3.2.3) in order to directly 
map the ligand-binding poses and sites of these anti-addiction compounds within their 
target proteins. 
 
 
Scheme 4.1.  Central hypothesis of this research. 
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4.5. Rationale of This Research 
The rationale of this research is that once it is known how promising DAT and 
mGlu5 anti-addiction compounds specifically interact within their major drug targets at 
the molecular level, lead compounds can then be logically manipulated into novel drug 
candidates that bind and modulate the function of these anti-addiction drug targets.  
Furthermore, this research is expected to predict the pharmacological profile of existing 
and novel DAT and mGlu5 anti-addiction compounds and their major metabolites, 
ultimately allowing rational structure-based drug design and confident virtual / in silico 
screening in order to identify novel chemotypes targeting the DAT or mGlu5 as anti-
addiction drug target proteins. 
4.6. Rational Design of MP-Based Photoprobes Suitable for DAT Structure-
Function Studies 
MP ((±)-1.10, Figure 4.2) is a highly potent DAT inhibitor clinically approved by 
the U.S. FDA for the treatment of ADHD (Hodgkins et al., 2012).  MP displays 2-fold 
higher DAT binding affinity when compared to cocaine (Pan et al., 1994) and has similar 
pharmacophoric features (a basic nitrogen, methyl ester, and an aromatic ring).  
Predictably, MP has reinforcing effects similar to that of cocaine in animal models; 
however, these reinforcing effects in humans are substantially lower, and MP has been 
shown to reduce cocaine craving (Yano and Steiner, 2007).  Additionally, MP has been 
used for decades and is considered relatively safe upon oral administration.  Moreover, 
unlike cocaine, MP is not a sodium channel blocker and does not have harmful effects on 
nerve conductance when taken in excess (Schwartz et al., 2010).  As a result, MP and its 
analogs are currently being pursued as potential candidates for the treatment of cocaine 
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dependence (Misra et al., 2010).  Despite MP’s clinical significance, its specific 
molecular contacts with the DAT remain unknown.  In order to address this knowledge 
gap, several MP-based DAT inhibitor photoprobes were designed for potential use in 
DAT structure-function studies. 
4.6.1. Rational Design of Racemic threo-N-Azidobenzyl-4-Iodo/3-Iodo-MP 
Photoaffinity Ligands for DAT Structure-Function Studies 
With respect to DAT inhibitor photoaffinity probe design, an overwhelming 
number of known compounds contain an aromatic 3-iodo-4-azido substituted ring motif 
(Figure 4.1; Sallee et al., 1989; Grigoriadis et al., 1989; Carroll et al., 1992; Agoston et 
al., 1997; Dutta et al., 2001; Zou et al., 2001 and 2003; Cao et al., 2004; Lever et al., 
2005; Newman et al., 2006; Chen et al., 2007; Lapinsky et al., 2009, 2012a, and 2012b).  
In particular, the 3-iodine of this common photoaffinity labeling structural motif not only 
represents a position for a radioisotope tag as I125, but also an electron-withdrawing group 
that is proposed to stabilize the singlet nitrene (2.13, Scheme 2.5) of the aryl azide upon 
photoreaction (Soundararajan and Platz, 1990).  However, this aromatic 3-iodo-4-azido-
substituted ring motif has been proposed to inherently lead to low labeling efficiency 
(e.g., <1%) of the aryl azide into the DAT protein due to its juxtaposition ortho to the 
sterically bulky iodine atom (Vaughan et al., 2005).  Towards addressing this potential 
disadvantage, novel probes were designed in which the photoreactive aryl azide group 
and the 125I radiotracer tag were placed on different parts of the MP ((±)-1.10, Figure 4.2) 
scaffold (Lapinsky et al., 2011). 
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Figure 4.1.  Photoaffinity probes containing an aromatic 3-iodo-4-azido-substituted ring motif. 
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Figure 4.2.  Rational design of racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP compounds as DAT 
photoaffinity ligands. 
4-Iodo-MP ((±)-3.31, Figure 4.2) and 3-iodo-MP ((±)-4.18, Figure 4.2) were 
chosen as lead compounds for MP photoprobe design since it is known these analogs 
display 6-fold (Deutsch et al., 1996) and 18-fold higher DAT binding affinity, 
respectively, versus MP ((±)-1.10).  As a result, the 3- and 4-positions of MP’s aromatic 
ring were envisioned as logical places to anchor the bulky iodine atom as a future 
radiotracer tag (i.e., I125) within rationally designed DAT photoaffinity probes.  
Additionally, known N-benzyl-MP analogs ((±)-4.19 to (±)-4.23, Figure 4.2) were 
considered as lead compounds for photoprobe design since these compounds are known 
to display either improved or retained DAT binding affinity versus MP ((±)-1.10) (Misra 
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et al., 2010). Based on these established structure–activity relationships for (±)-threo-MP 
analogs, a series of DAT photoaffinity ligands ((±)-4.24 to (±)-4.29, Figure 4.2) was 
rationally designed via molecular hybridization of known iodo-MP analogs ((±)-3.31 and 
(±)-4.18) with known N-benzyl-MP analogs ((±)-4.19 to (±)-4.23).  These target 
photoprobes featured systematic placement of a photoreactive aryl azide on the aromatic 
ring of the N-benzyl substituent and anchoring of an iodine atom at either the 3- or 4-
position of MP’s aromatic ring. 
4.6.1.1. Results of Racemic threo-N-Azidobenzyl-4-Iodo/3-Iodo-MP Photoaffinity 
Ligands for DAT Structure-Function Studies 
Target compounds ((±)-4.24 to (±)-4.29, Figure 4.2) were synthesized (see 
Chapter 5) and submitted to Dr. Christopher K. Surratt’s pharmacology lab at Duquesne 
University for determination of their DAT binding affinity in comparison to the known 
MP analogs previously described.  Dr. Surratt’s laboratory determined that lead 
compounds 4-iodo-MP ((±)-3.31) and 3-iodo-MP ((±)-4.18) displayed 2-fold and 5-fold 
higher DAT binding affinity, respectively, versus MP ((±)-1.10) (Table 4.1).  However, it 
was observed that substituting the piperidine nitrogen of these iodo-MPs with a N-benzyl 
group bearing a photoreactive aromatic azide resulted in a significant decrease in DAT 
binding affinity (15-fold to 110-fold lower DAT binding affinity than (±)-MP; see Table 
4.1).  From this series of hybrid compounds, p-azido-N-benzyl-4-iodo-MP ((±)-4.26) 
displayed the highest DAT binding affinity (Ki = 363 ± 28 nM).  This compound was 
subsequently synthesized in its I125 form in the laboratory of Dr. John Lever (University 
of Missouri – Columbia) and advanced to DAT photoaffinity labeling studies in the 
laboratory of Dr. Roxanne Vaughan (University of North Dakota).  (±)-[I125]-4.26 was 
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shown to bind covalently to rat striatal DAT and hDAT expressed in cultured cells 
(Lapinsky et al., 2011).  Co-incubation of (±)-4.26 with nonradioactive D-(+)-MP or (-)-
2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane (β-CFT, WIN-35,428, a cocaine analog) 
blocked DAT labeling (see Appendix).  Compound (±)-4.26 represents the first 
successful example of a DAT photoaffinity ligand based on the MP scaffold. Such 
ligands are expected to assist in mapping non-tropane ligand-binding pockets within 
plasma membrane monoamine transporters. 
Table 4.1.  DAT binding affinity for racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP photoaffinity 
ligands.  Inhibition of [3H]-WIN-35,428 binding by compounds at hDAT N2A neuroblastoma cells. 
No. Compound 
[3H]-WIN binding inhibition, 
hDAT Ki (nM)* 
(±)-1.10 MP                      25 ± 1 
(±)-3.31 4-Iodo-MP                      14 ± 3 
(±)-4.24 o-Azido-N-benzyl-4-iodo-MP                    517 ± 65 
(±)-4.25 m-Azido-N-benzyl-4-iodo-MP                  2754 ± 169 
(±)-4.26 p-Azido-N-benzyl-4-iodo-MP                    363 ± 28 
(±)-4.18 3-Iodo-MP                     4.5 ± 1 
(±)-4.27 o-Azido-N-benzyl-3-iodo-MP                  1112 ± 163 
(±)-4.28 m-Azido-N-benzyl-3-iodo-MP                  2056 ± 73 
(±)-4.29 p-Azido-N-benzyl-3-iodo-MP                    658 ± 70 
* Each Ki value represents data from at least three independent experiments with each data point on 
the curve performed in duplicate.  P < 0.05 versus Ki of (±)-threo-MP. 
With respect to DAT binding affinity and the position of the photoreactive azide 
functional group on the N-benzyl aromatic ring (Table 4.1), the para position appears to 
be about the same (15- and 26-fold lower binding affinity than (±)-MP) as compared to 
the ortho position (21- and 44-fold lower binding affinity than (±)-MP).  Substitution of 
the photoreactive azide at the meta position resulted in a much greater decrease in DAT 
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binding affinity (110- and 82-fold lower binding affinity than (±)-MP).  There was no 
obvious advantage in terms of DAT binding affinity associated with the position of the 
iodine in these hybrid analogs (average Ki: 3-iodo compounds = 1280 nM; 4-iodo 
compounds = 1210 nM).  As a result, these rationally designed azido-N-benzyl-iodo-MPs 
(Lapinsky et al., 2011) behaved unlike previously reported MPs in which N-benzyl 
substitution either increased or retained DAT affinity (Misra et al., 2010). 
4.6.2. Rational Design of Racemic threo-p-Azido-N-Benzyl-4-Iodo-Ritalinol as a 
Potential Photoaffinity Ligand for DAT Structure-Function Studies 
From the previous series of compounds, it was observed that N-benzylation of 
iodo-MPs (±)-3.31 and (±)-4.18 (Figure 4.2) led to a significant decrease in DAT binding 
affinity.  Out of this series of hybrid compounds, p-azido-N-benzyl-4-iodo-MP ((±)-4.26, 
Figures 4.2 and 4.3) displayed the highest DAT binding affinity (Ki = 363 ± 28 nM).  In 
order to improve DAT binding affinity for MP-based photoprobes (i.e., target goal of Ki < 
100 nM), p-azido-N-benzyl-4-iodo-ritalinol ((±)-4.33, Figure 4.3) was rationally designed 
as a potential DAT photoaffinity ligand.  Support for the design of this particular 
photoprobe stemmed from the observation that N-benzyl-ritalinols (i.e., wherein MP’s 
methyl ester is reduced to its corresponding 1˚ alcohol) display higher binding affinity 
than their respective N-benzyl-MP analogs (Misra et al., 2010).  When there is no 
substituent (R1 = H) on the aromatic ring of the MP / ritalinol scaffold, there is moderate 
(2-fold) improvement in DAT binding affinity for N-benzyl-ritalinol (±)-4.31 when 
compared to N-benzyl- MP (±)-4.19.  However, when there are halogen substituents (R1 
= 3,4-diCl) on the aromatic ring of the MP / ritalinol scaffold, there is significant (28-
fold) improvement in DAT binding affinity for the N-benzyl-ritalinol scaffold (i.e., (±)-
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4.32) versus the N-benzyl-MP scaffold (i.e., (±)-4.30).  As a result of this known SAR, it 
was envisioned that methyl ester reduction of photoprobe (±)-4.26, which carries an 
iodine atom at the 4-position of MP’s aromatic ring and a p-azido-N-benzyl substituent, 
to the corresponding ritalinol analog (i.e., p-azido-N-benzyl-4-iodo-ritalinol (±)-4.33, 
Figure 4.3) would significantly improve DAT binding affinity versus that obtained for 
previously successful methyl ester photoprobe (±)-4.26. 
 
Figure 4.3.  Rational design of racemic threo-p-azido-N-benzyl-4-iodo-ritalinol as a MP-based DAT 
photoaffinity ligand. 
4.6.2.1. Results of Racemic threo-p-Azido-N-Benzyl-4-Iodo-Ritalinol as a 
Potential Photoaffinity Ligand for DAT Structure-Function Studies 
Target photoprobe (±)-4.33 (Figure 4.3) was synthesized (see Chapter 5); 
however, no improvement in DAT binding affinity for this compound ((±)-4.33; Ki = 379 
± 73 nM) was observed when compared to parent methyl ester compound (±)-4.26 (Ki = 
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363 ± 28 nM) (Figure 4.3).  Due to this discouraging DAT binding affinity result, no 
other DAT photoprobes were pursued based on either 3- or 4-iodo-MP. 
4.6.3. Rational Design of Racemic threo- and (R,R)-MP-Based Photoaffinity 
Ligands Containing the Traditional 3-Iodo-4-Azido Labeling Motif  
 
Figure 4.4.  Rational design of racemic threo- and (R,R)-MP-based DAT photoaffinity ligands with 
the traditional 3-iodo-4-azido labeling motif. 
Due to discouraging DAT binding affinity results (Ki >100 nM) associated with 
photoaffinity ligands based on 3- or 4-iodo-MP (Figures 4.2 and 4.3), MP DAT 
photoaffinity ligands possessing the traditional 3-iodo-4-azido labeling motif (i.e., (±)-
4.35 and (±)-4.36, Figure 4.4) were pursued.  Support for the rational design of these 
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potential DAT photoprobes stemmed from the observation that N-benzyl-MP analogs 
((±)-4.19 to (±)-4.23) display either improved or retained DAT affinity versus MP ((±)-
1.10) (Misra et al., 2010). Moreover, N-benzyl-ritalinol analogs (e.g., (±)-4.31 and (±)-
4.34) are known to display enhanced DAT affinity versus MP ((±)-1.10) and N-benzyl-
MP analogs ((±)-4.19 to (±)-4.23) (Misra et al., 2010).  Furthermore, the traditional 3-
iodo-4-azido labeling motif (e.g., found in 4.7, MFZ-2-24, Figure 4.4) has been used in a 
number of successful tropane-based DAT photoprobes (see Figure 4.1) (Vaughan et al., 
2005).  Simultaneously, it is well known that (R,R)-MP ((+)-1.10, Figure 4.4) represents 
the active enantiomer of racemic threo-MP ((±)-1.10) (Ding et al., 1997; Williard et al., 
2007).  Therefore, (R,R)-MP DAT photoaffinity ligands bearing the traditional 3-iodo-4-
azido labeling motif were also rationally designed (i.e., (-)-4.35 and (-)-4.36, Figure 4.4) 
4.6.3.1. Results of Racemic threo- and (R,R)-MP-Based Photoaffinity Ligands 
Containing the Traditional 3-Iodo-4-Azido Labeling Motif  
Target photoprobes ((±)-4.35, (-)-4.35, (±)-4.36 and (-)-4.36, Figure 4.4) were 
synthesized (see Chapter 5) and submitted to the Surratt lab for pharmacological 
determination of their DAT binding affinities.  Probes (±)-4.35 (Ki = 3243 ± 803 nM) and 
(-)-4.35 (Ki = 1911 ± 272 nM) displayed a significant loss in DAT binding affinity when 
compared to lead compounds (±)-1.10 and (+)-1.10 (Figure 4.4).  However, photoprobes 
(±)-4.36 (Ki = 233 ± 91 nM) and (-)-4.36 (Ki = 218 ± 29 nM) proved superior and 
displayed only a 3- to 4-fold loss in DAT binding affinity when compared to lead 
compounds (±)-1.10 and (+)-1.10.  As a result of its improved DAT binding affinity and 
enantiomeric purity relative to previously successful MP-based photoprobe (±)-4.26 
developed during this work (Lapinsky et al., 2011), photoprobe (-)-4.36 was advanced to 
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radiosynthesis and preliminary photoaffinity labeling studies wherein this compound has 
been shown to successfully covalently label the hDAT expressed in cultured cells (see 
Appendix; Lapinsky et al., unpublished results). 
4.6.4. Rational Design of Racemic threo-3,4-Dichloro-MP-Based Photoaffinity 
Ligands Containing the Traditional 3-Iodo-4-Azido Labeling Motif 
 
Figure 4.5.  Rational design of racemic threo-3,4-dichloro-MP-based DAT photoaffinity ligands 
containing the traditional 3-iodo-4-azido labeling motif. 
It is known that 3,4-dichloro-MP ((±)-3.53, Figure 4.5) displays 16-fold higher 
DAT binding affinity than MP ((±)-1.10) (Misra et al., 2010).  Therefore, 3,4-dichloro-
MP photoaffinity ligands containing the traditional 3-iodo-4-azido labeling motif were 
rationally designed ((±)-4.37 and (±)-4.38, Figure 4.5) in an attempt to obtain MP-based 
irreversible molecular probes with high DAT binding affinity.  The rational design of 
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these compounds stemmed from the observation that N-benzyl-3,4-dichloro-MP ((±)-
4.30) retained appreciable DAT binding affinity relative to that of N-benzyl-MP ((±)-
4.19).  Furthermore, it is known that N-benzyl-3,4-dichloro-ritalinol ((±)-4.32) displays 
significantly higher DAT binding affinity versus N-benzyl-ritalinol ((±)-4.31), N-benzyl-
MP ((±)-4.19), and lead MP analogs (±)-1.10 and (±)-3.53 (Misra et al., 2010).   
4.6.4.1. Results of Racemic threo-3,4-Dichloro-MP-Based Photoaffinity Ligands 
Containing the Traditional 3-Iodo-4-Azido Labeling Motif 
Upon synthesis of these target compounds (see Chapter 5) and determination 
of their DAT binding affinities by the Surratt laboratory, methyl ester (±)-4.37 (Ki = 3446 
± 469 nM) and primary alcohol (±)-4.38 (Ki = 1248 ± 746 nM) displayed a significant 
loss in DAT binding affinity when compared to lead molecules (±)-1.10 and (±)-3.53 
(Figure 4.5).  As a result of their very poor DAT binding affinities (i.e., unable to achieve 
a goal DAT Ki < 100 nM), methyl ester (±)-4.37 and primary alcohol (±)-4.38 were not 
considered justifiable candidates for further development into radioiodo photoprobes for 
DAT structure-function studies. 
4.7. Rational Design of GBR-12909-Based Photoprobes Suitable for DAT 
Structure-Function Studies 
GBR-12909 (1.12, Figure 4.6) was initially envisioned as an antidepressant, but 
later was found to be a highly selective DAT inhibitor that is structurally distinct from 
cocaine (Esumi et al., 2013).  Similar to the benztropines, GBR-12909 and its analogs 
display unique behavioral profiles that are significantly different from that of cocaine 
(Villemagne et al., 1999).  Pharmacological studies of GBR-12909 indicate that this 
compound has a higher affinity for, and slower dissociation rate from, the DAT in 
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comparison to cocaine.  Moreover, GBR-12909 was shown to antagonize cocaine’s 
ability to increase extracellular dopamine levels (Rothman et al., 1991).  Additionally, 
GBR-12909 has a slower onset and longer duration of action than that of cocaine 
(Rothman et al., 1992).  As a result of its promising pharmacodynamic and 
pharmacokinetic profile, GBR-12909 was advanced into clinical trials for the treatment 
of cocaine abuse, but later was withdrawn due to long QT syndrome (Goldsmith et al., 
2007).  Despite its clinical significance and development as a potential cocaine abuse 
therapeutic, the specific drug-DAT contacts responsible for eliciting GBR-12909’s 
unique behavioral profile remain unknown.  In order to address this knowledge gap, 
several GBR-12909-based DAT inhibitor photoprobes were designed to be utilized in 
future DAT structure-function studies. 
4.7.1. Rational Design of a Clickable Benzophenone-Alkyne-Based GBR-12909 
Photoprobe for DAT Structure-Function Studies 
One of the most common ways to create a clickable photoaffinity ligand is to 
utilize a benzophenone as a photoreactive group and a terminal alkyne as a click 
chemistry handle (e.g., 4.39, Figure 4.6) (Van Scherpenzeel et al., 2009 and 2010; Chen 
et al., 2010; Ban et al., 2010; Eirich et al., 2011 and 2012; Park et al., 2012; Cisar and 
Cravatt, 2012; Saario et al., 2012).  With this observation in mind, benzophenone-alkyne-
based GBR-12909 DAT photoprobe 4.40 (Figure 4.6) was rationally designed given the 
SAR that bulky substituents at the para position of the N-phenylpropyl moiety of GBR-
12909 (1.12) are tolerated without a large reduction in DAT pharmacological activity 
(Matecka et al., 1997).   
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Figure 4.6.  Rational design of a clickable benzophenone-alkyne-based  
GBR-12909 DAT photoprobe. 
 
4.7.1.1. Results of a Clickable Benzophenone-Alkyne-Based GBR-12909 
Photoprobe for DAT Structure-Function Studies 
As of the writing of this dissertation, target photoprobe 4.40 (Figure 4.6) was 
successfully synthesized (see Chapter 5), and this compound is currently being evaluated 
in DAT pharmacology experiments by the Surratt laboratory. 
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4.7.2. Rational Design of a Diazido-Based GBR-12909 Photoprobe for DAT 
Structure-Function Studies 
 
Figure 4.7.  Rational design of a diazido-based GBR-12909 DAT photoprobe.   
Another common approach to turn lead compounds into clickable photoaffinity 
ligands is to utilize a 1,3,5-trisubstituted phenyl moiety bearing an aryl azide as a 
photoreactive group and a methylene aliphatic azide as a click chemistry handle (e.g., 
4.42, Figure 4.7) (Hosoya et al., 2004, 2005, and 2009; Sun et al., 2006; He et al., 2009; 
Gandy et al., 2011; Neelarapu et al., 2011; Vaidya et al., 2012).  Based on this 
information, target photoprobe 4.43 (Figure 4.7) was rationally designed by incorporating 
the common 1,3,5-trisubstituted-phenyl diazide moiety into the terminal phenyl ring of 
GBR-12909’s N-propylphenyl substituent.  The design of this clickable DAT photoprobe 
stems from previous success of radioactive 3-azido-[3H]-GBR-12935 (4.41), which after 
UV photolysis of crude synaptosomal membranes led to a single radiolabeled polypeptide 
suggested to be glycosylated DAT with an apparent molecular mass of 80 kDa (Berger et 
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al., 1991).  Compared to known radioactive DAT photoprobe 4.41, target nonradioactive, 
clickable photoprobe 4.43 features incorporation of two para fluorine substituents on the 
diphenoxy ether moiety analogous to that of GBR-12909 (1.12), and an azidomethylene 
click chemistry handle meta to the photoreactive aryl azide.   
4.7.2.1. Results of a Diazido-Based GBR-12909 Photoprobe for DAT Structure-
Function Studies 
As of the writing of this dissertation, target photoprobe 4.43 (Figure 4.7) was 
successfully synthesized (see Chapter 5), and this compound is currently being evaluated 
in DAT pharmacology experiments by the Surratt laboratory. 
4.8. Rational Design of Irreversible mGlu5 NAMs as Chemical Probes Suitable 
for mGlu5 Structure-Function Studies 
Despite noteworthy advances in characterizing the MPEP-binding site within the 
TM domain of mGlu5 (Pagano et al., 2000; Malherbe et al., 2003; Molck et al., 2012; 
Kaae et al., 2012), a mechanistic and/or conformational rationale is unknown for how 
subtle variations to a mGlu5 allosteric modulator can engender either the opposite mode 
of pharmacology or a change in the mGlu receptor subtype selectivity profile.  In order to 
address this research question, irreversible mGlu5 NAMs are envisioned as valuable 
compounds to be utilized in mGlu5 structure-function studies. 
4.8.1. Rational Design of a Clickable Benzophenone Propargyl Ether mGlu5 NAM 
Photoprobe for mGlu5 Structure-Function Studies 
It is known that MPEP-binding site mGlu5 NAM 4.44 (Figure 4.8) displays very 
high mGlu5 binding affinity (Ki = 6 nM) (Iso et al., 2006).  Furthermore, derivitization of 
the 3-position of the phenyl ring within 4.44 to either a phenol (4.45) or a benzylic ether 
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(4.46) results in a 8- to 10-fold loss in mGlu5 binding affinity; however, these 
compounds still retain their mGlu5 NAM functional activity.   
 
Figure 4.8.  Rational design of a MPEP-binding site clickable thiazole benzophenone propargyl ether 
mGlu5 NAM photoprobe. 
In addition, a mGlu5 responsive imaging probe (4.47, Figure 4.8) was recently 
reported featuring a large gadolinium-DOTA moiety conjugated to the 3-position of 
phenyl ring of 4.44 (Mishra et al., 2012).  Although mGlu5 binding affinity was not 
reported for this imaging probe, the observation that this conjugate retained pronounced 
mGlu5 antagonistic activity suggested that the gadolinium-DOTA moiety within 4.47 
could potentially be replaced with other chemical entities (e.g., an “all-in-one” 
photoreactive click chemistry moiety) and still retain desired mGlu5 NAM 
pharmacology.  With these thoughts in mind, target clickable mGlu5 NAM photoprobe 
4.49 (Figure 4.8) was rationally designed by replacing the gadolinium-DOTA moiety of 
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conjugate 4.47 with a known (Van Scherpenzeel et al., 2010) “all-in-one” chemical 
moiety featuring a benzophenone photoreactive functional group and a propargyl ether 
clickable handle (i.e., see representative example probe 4.48, Figure 4.8) attached to the 
3’-OH of MPEP-binding site NAM 4.45 via an ethyl diether linkage.  
4.8.1.1. Results of a Clickable Benzophenone Propargyl Ether mGlu5 NAM 
Photoprobe for mGlu5 Structure-Function Studies 
Target photoprobe 4.49 (Figure 4.8) was successfully synthesized (see 
Chapter 5) and submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for 
mGlu5 pharmacological evaluation.  Target probe 4.49 displays improved mGlu5 binding 
affinity (Ki = 11 ± 0.8 nM; HEK293A cells; [
3H]-methoxyPEPy) versus lead compounds 
4.45 (Ki = 59 ± 0.9 nM) and 4.46 (Ki = 48 ± 0.8 nM), and retained mGlu5 NAM 
functional potency (IC50 = 1 µM).  As of the writing of this dissertation, clickable 
photoprobe 4.49 is being subjected to mGlu5 tandem photoaffinity labeling-
bioorthogonal conjugation experiments in Dr. Gregory’s laboratory at Monash University 
(see Appendix). 
4.8.2. Rational Design of a Clickable MPEP-Binding Site Diazido mGlu5 NAM 
Photoprobe for mGlu5 Structure-Function Studies 
Using the same SAR as that for the design of conjugate photoprobe 4.49 via lead 
compounds 4.44 – 4.47, target clickable mGlu5 photoprobe 4.50 (Figure 4.9) was 
rationally designed by replacement of the benzyl ether of 4.46 with the common “all-in-
one” diazido benzylic ether moiety (e.g., see representative example probe 4.42, Figure 
4.9, He et al., 2009), wherein the aryl azide represents a photoreactive functional group 
and the aliphatic azide represents a click chemistry handle.   
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Figure 4.9.  Rational design of a thiazole MPEP-binding site diazido mGlu5 negative  
allosteric modulator clickable photoprobe.  
 
4.8.2.1. Results of a Clickable MPEP-Binding Site Diazido mGlu5 NAM 
Photoprobe for mGlu5 Structure-Function Studies 
Target photoprobe 4.50 (Figure 4.9) was synthesized (see Chapter 5) and 
submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5 
pharmacological evaluation.  Target photoprobe 4.50 displayed 1.5-fold less mGlu5 
binding affinity (Ki = 72 ± 15 nM; HEK293A cells; [
3H]-methoxyPEPy) in comparison to 
lead compound 4.46 and retained mGlu5 NAM function.  Given target photoprobe 4.50 
meets desired pharmacological criteria for identifying suitable probes for mGlu5 
structure-function studies (i.e., Ki < 100 nM, no more than 10-fold lower mGlu5 binding 
affinity compared to an appropriate lead compound, and retention of mGlu5 NAM 
functional activity), this compound is currently being subjected to mGlu5 tandem 
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photoaffinity labeling-bioorthogonal conjugation experiments in Dr. Gregory’s laboratory 
at Monash University. 
4.8.3. Rational Design of an Azido-Iodo Thiazole mGlu5 MPEP-Binding Site NAM 
Photoprobe for mGlu5 Structure-Function Studies 
In terms of optimum photoprobe design, compact photoprobes featuring 
placement of a photoreactive group directly on the parent lead compound are most 
desirable (Lapinsky et al., 2012a).  In particular, upon photoaffinity labeling, the covalent 
point of photoprobe attachment to a drug target, which is directly dictated by the location 
of the photoreactive functional group within the photoprobe, can be somewhat removed 
from the lead compound chemical scaffold when a chemical linker is used (e.g., often a 
conformationally flexible, variable-length methylene linker).  For photoprobes that 
feature utilization of a chemical linker between the photoreactive functional group and 
the lead compound chemical scaffold, covalent photoprobe adduction to the drug target 
may occur at a residue near, but not at, a direct ligand-drug target contact point, thus 
representing a significant limitation when trying to delineate the discrete molecular 
interactions between the photoprobe and the drug target.  Furthermore, compact 
photoprobes bearing a photoreactive functional group directly on the lead compound 
chemical scaffold are expected to result in a more conformationally restricted 
photoprobe-drug target complex in 3-D drug target molecular modeling studies. 
 81 
 
Figure 4.10.  Rational design of an azido-iodo mGlu5 negative allosteric  
modulator thiazole photoprobe. 
In an attempt to create compact photoprobes that avoid chemical linkers and 
feature placement of a photoreactive group directly on a mGlu5 NAM scaffold, high 
affinity cyano thiazole 4.51 (Simeon et al., 2011) (Figure 4.10) was selected as a lead 
compound.  Target photoprobe 4.52 was rationally designed by replacing the nitrile of 
MPEP-binding site mGlu5 NAM 4.51 with a photoreactive aryl azide and retention of the 
heteroaromatic iodide as a potential future radiotracer tag (i.e., I125).  Moreover, the 
fluorine atom on the phenyl ring meta to photoreactive aryl azide is envisioned to help 
stabilize the desired singlet nitrene during mGlu5 photoaffinity labeling experiments 
(Schnapp et al., 1993).  As a result, target photoprobe 4.52 is significantly more compact 
than conjugate mGlu5 NAM photoprobes 4.49 and 4.50.  As a result, photoprobe 4.52 is 
expected to covalently attach to amino acid residue(s) directly within the MPEP-binding 
site of mGlu5 and result in a more conformationally restricted photoprobe-mGlu5 
complex in 3-D mGlu5 molecular modeling studies.   
4.8.3.1. Results of an Azido-Iodo Thiazole mGlu5 MPEP-Binding Site NAM 
Photoprobe for mGlu5 Structure-Function Studies 
Target photoprobe 4.52 (Figure 4.10) was synthesized (see Chapter 5) and 
submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5 
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pharmacological evaluation.  Target photoprobe 4.52 retained mGlu5 NAM functional 
activity, but this compound displayed a 27-fold loss in mGlu5 binding affinity (Ki = 35 ± 
0.7 nM; HEK293A cells; [3H]-methoxyPEPy) when compared to lead nitrile compound 
4.51.  Despite the fact that target photoprobe 4.52 meets some of the desired 
pharmacological criteria for identifying suitable probes for mGlu5 structure-function 
studies (i.e., Ki < 100 nM and retention of mGlu5 NAM functional activity), its chemical 
synthesis proved very challenging with respect to retaining the highly activated iodine 
atom on the thiazole ring.  As a result of the relatively easy loss of the iodine atom on the 
thiazole ring during chemical synthesis, radiosynthesis of photoprobe 4.52 in its I125 form 
towards eventual utilization in mGlu5 photoaffinity labeling experiments was not 
pursued. 
4.8.4. Rational Design of an Azido-Propargyl mGlu5 MPEP-Binding Site NAM 
Clickable Photoprobe for mGlu5 Structure-Function Studies 
Given the relative instability and synthetic challenges associated with azido-iodo 
mGlu5 NAM thiazole photoprobe 4.52 (Figure 4.10), a high affinity cyano MPEP methyl 
ether derivative (4.53, Figure 4.11) (Keck et al., 2012) was selected as a lead compound 
in order to pursue a photoprobe that avoided chemical linkers and featured placement of a 
photoreactive group directly on an mGlu5 NAM scaffold.  Clickable photoprobe 4.54 
(Figure 4.11) was rationally designed by isosterically replacing the nitrile of mGlu5 
MPEP-binding site NAM 4.53 with a photoreactive aryl azide and slightly extending the 
methyl ether into a clickable propargyl ether.  Once again, compared to conjugate 
photoprobes 4.49 and 4.50, target photoprobe 4.54 is more compact and expected to 
covalently attach to amino acid residue(s) directly within the mGlu5 MPEP-binding 
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pocket and result in a more conformationally restricted photoprobe-mGlu5 complex in 3-
D mGlu5 molecular modeling studies.   
 
Figure 4.11.  Rational design of an azido-propargyl mGlu5 negative allosteric  
modulator MPEP-binding site clickable photoprobe. 
4.8.4.1. Results of an Azido-Propargyl mGlu5 MPEP-Binding Site NAM 
Clickable Photoprobe for mGlu5 Structure-Function Studies 
Target clickable photoprobe 4.54 (Figure 4.11) was synthesized (see Chapter 
5) and submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5 
pharmacological evaluation.  Target photoprobe 4.54 displays the highest mGlu5 binding 
affinity the Lapinsky group has ever synthesized and pharmacologically evaluated to date 
(Ki of 0.5 nM; 2.6-fold higher than lead compound 4.53).  Given target photoprobe 4.54 
meets all of the desired pharmacological criteria for identifying suitable probes for 
mGlu5 structure-function studies (i.e., Ki < 100 nM, no more than 10-fold lower mGlu5 
binding affinity compared to an appropriate lead compound, and retention of mGlu5 
NAM functional activity), this compound is currently being subjected to preliminary 
mGlu5 tandem photoaffinity labeling-bioorthogonal conjugation experiments in Dr. 
Gregory’s laboratory at Monash University. 
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4.8.5. Rational Design of a Methanethiosulfonate mGlu5 MPEP-Binding Site NAM 
Thiol-Reactive Chemical Probe for mGlu5 Engineered Affinity Labeling 
Experiments 
As an alternative to photoaffinity labeling and previously described in Section 
2.2.2, coupling drug target molecular modeling studies with cysteine-substituted drug 
target mutants and thiol-reactive affinity labeling probes represents a powerful 
experimental approach towards ultimately validating and refining 3-D homology models 
of a drug target (Foucaud et al., 2007).  In this regard, a potential thiol-reactive, MPEP-
binding site affinity labeling probe (4.55, Figure 4.12) for mGlu5 cysteine-substituted 
engineered affinity labeling was rationally designed analogous to that described for 
conjugate clickable photoprobe 4.49 (Section 4.8.1).  In particular, target affinity labeling 
probe 4.55 was envisioned and accessed by functionalizing the 3’-OH position of known 
MPEP-binding site mGlu5 NAM 4.45 (Figure 4.12) with an ethyl linker and a thiol-
specific and reactive methanethiosulfonate electrophilic functional group (Foucad et al., 
2007).   
 
Figure 4.12.  Rational design of a thiazole methanethiosulfonate mGlu5 MPEP-binding site  
NAM thiol-reactive affinity labeling probe. 
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4.8.5.1. Results of a Methanethiosulfonate mGlu5 MPEP-Binding Site NAM 
Thiol-Reactive Chemical Probe for mGlu5 Engineered Affinity Labeling 
Experiments 
Target affinity labeling probe 4.55 (Figure 4.12) was synthesized (see Chapter 
5) and submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5 
pharmacological evaluation.  Encouragingly, this potential thiol-reactive mGlu5 affinity 
labeling probe retained appropriate mGlu5 binding affinity (Ki = 13 ± 0.8 nM, ~2-fold 
lower than parent compound 4.44).  Given target probe 4.55 meets all of the desired 
pharmacological criteria for identifying suitable probes for mGlu5 structure-function 
studies (i.e., Ki < 100 nM, no more than 10-fold lower mGlu5 binding affinity compared 
to an appropriate lead compound, and retention of mGlu5 NAM functional activity), this 
compound is currently being subjected to preliminary mGlu5 cysteine-substituted 
engineered affinity labeling studies in Dr. Gregory’s laboratory at Monash University. 
4.8.6. Rational Design of a Maleimide-Based mGlu5 MPEP-Binding Site NAM 
Thiol-Reactive Chemical Probe for mGlu5 Engineered Affinity Labeling 
Experiments 
Analogous to the rational design of probe 4.55, another potential thiol-reactive 
NAM probe (4.56) for mGlu5 cysteine-substituted engineered affinity labeling was 
envisioned by functionalizing the 3-position of MPEP-binding site NAM 4.44 (Figure 
4.13) with a maleimide electrophilic moiety (Foucad et al., 2007).  It is well known that 
maleimide-based electrophiles tend to undergo conjugate addition reactions preferentially 
with thiol-based nucleophiles (e.g., cysteine) during affinity labeling versus other types of 
nucleophiles (e.g., tyrosine) (Chalker et al., 2009).   
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Figure 4.13.  Rational design of a maleimide-based thiazole mGlu5 MPEP-binding site  
NAM thiol-reactive affinity labeling probe. 
4.8.6.1. Results of a Maleimide-Based mGlu5 MPEP-Binding Site NAM Thiol-
Reactive Chemical Probe for mGlu5 Engineered Affinity Labeling 
Experiments 
Target affinity labeling probe 4.56 (Figure 4.13) was synthesized (see Chapter 
5) and submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5 
pharmacological evaluation.  Unfortunately, Dr. Gregory experienced a number of 
solubility issues while attempting to determine the mGlu5 binding affinity for this 
compound.  As a result, currently no future experiments are envisioned with this 
particular probe. 
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CHAPTER FIVE 
5. Chemical Discussion  
5.1. Synthesis of MP-Based Photoprobes Suitable for DAT Structure-Function 
Studies 
5.1.1. Synthesis of Racemic threo-N-Azidobenzyl-4-Iodo/3-Iodo-MP Photoaffinity 
Ligands for DAT Structure-Function Studies 
As previously described in Section 4.6.1, in order to overcome the labeling 
efficiency drawback associated with photoprobes containing the traditional 3-iodo-4-
azido labeling motif, we desired racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP analogs 
as potential photoaffinity ligands for DAT structure-function studies.  We envisioned the 
synthesis of a series of racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP (MP) analogs 
((±)-4.24-4.29) as photoaffinity ligands for DAT structure-function studies via N-
alkylation of either 4-iodo-MP ((±)-3.31) or 3-iodo-MP ((±)-4.18) with a known series of 
azido benzyl bromides (5.1-5.3; Mornet et al., 1984) (Scheme 5.1).  With this synthetic 
strategy in mind, an efficient, relatively large-scale synthesis of 4-iodo-MP ((±)-3.31) and 
3-iodo-MP ((±)-4.18) was initially desired and pursued. 
 
 
Scheme 5.1.  Proposed retrosynthesis of a series of racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP 
analogs as photoaffinity ligands for DAT structure-function studies. 
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5.1.1.1. Problems With the Known Synthetic Route for Preparing Racemic threo-
4-Iodo-MP  
A synthetic route for preparing 4-iodo-MP ((±)-3.31, Scheme 5.3) is known in 
the chemical literature (Pan et al., 1996).  However, this synthetic route is not necessarily 
desirable for generating 4-iodo-MP in relatively large quantities, principally because this 
scheme is rather poor yielding (6 steps, 9% overall yield) and utilizes MP ((±)-1.10, 
Scheme 5.2) as a relatively expensive substance controlled by the FDA. 
 
Scheme 5.2.  Synthesis of racemic threo-MP performed according to  
Axten et al., 1998 and Gutman et al., 2004. 
Racemic threo-MP ((±)-1.10) was first synthesized on a multi-gram scale 
according to Axten et al. and Gutman et al. (Axten et al., 1998; Gutman et al., 2004) 
(Scheme 5.2).  Briefly, commercially available α-keto ester 3.7 was treated with 
piperidine (3.8) to provide α-keto amide 3.9 in nearly quantitative yield.  Subsequent 
condensation of ketone 3.9 with tosylhydrazine under acidic conditions provided 
tosylhydrazone 3.10 in 85% yield.  Next, thermal cyclization of tosylhydrazone 3.10 
under aqueous basic conditions using Aliquat 336 as a phase transfer catalyst, followed 
by column chromatography and recrystallization from diethyl ether, gave 
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diastereomerically pure racemic threo-β-lactam (±)-3.11 as the major product in 
moderate yield (68%).  Finally, threo-β-lactam (±)-3.11 was converted to racemic threo-
MP ((±)-1.10) in quantitative yield by ring opening with MeOH under acidic conditions. 
 
Scheme 5.3.  Synthesis of racemic threo-4-iodo-MP performed  
according to Pan et al., 1996. 
Next, racemic threo-MP ((±)-1.10) was then converted to 4-iodo-MP ((±)-
3.31) according to Pan et al. (Pan et al., 1996) (Scheme 5.3).  This synthesis began with 
N-benzoylation of racemic threo-MP to provide amide (±)-3.26 in near quantitative yield.  
The amide was then subsequently nitrated with nitric acid to give predominantly the p-
nitro isomer (±)-3.27 as the major product in moderate yield (85%).  The nitro functional 
group was then reduced with iron under acidic conditions to provide aniline (±)-3.28, 
which was then diazotized and displaced with iodide to produce p-iodo compound (±)-
3.29 in 60% yield.  In turn, global hydrolysis of benzamide (±)-3.29 under strong acidic 
conditions then provided racemic threo-4-iodo-ritalinic acid ((±)-3.30) in 40% yield, 
which upon esterification with methanolic HCl quantitatively provided racemic threo-4-
iodo-MP ((±)-3.31).  The 4-iodo-MP product synthesized by this route was determined to 
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be ≥95% diastereomerically pure by 1H NMR upon comparison to the known data for 
enantiomerically pure threo- and erythro-MP and its para-substituted derivatives (Thai et 
al., 1998). 
The synthetic route performed for 4-iodo-MP ((±)-3.31) via Schemes 5.2 and 
5.3 was lengthy (10 steps) and very low yielding (9%).  Furthermore, this route was 
rather cumbersome on a large scale due to significant formation of the undesirable ortho- 
and meta-nitro isomers of compound (±)-3.27 (detected via 1H NMR), which were 
difficult to separate by column chromatography.  In addition, benzamide deprotection / 
global hydrolysis from (±)-3.29 to (±)-3.30 was rather harsh and time consuming, 
typically taking several days for reaction completion on a large scale.  As a result, a 
shorter, more efficient large scale synthesis of 4-iodo-MP ((±)-3.31) was desired 
involving cheap, readily available, non-controlled starting materials in order to synthesize 
a variety of MP-based DAT photoprobes.  The following strategies were attempted in 
order to develop an improved synthetic route for 4-iodo-MP ((±)-3.31). 
5.1.1.2. Strategies Towards an Improved Large Scale Synthesis of Racemic threo-
4-Iodo-MP 
5.1.1.2.1. Electrophilic Aromatic Iodination of a Racemic threo-β-Lactam Building 
Block 
Electrophilic aromatic iodination of known β-lactam (±)-3.11 (Axten et al., 
1998; Gutman et al., 2004) with N-iodosuccinimide (NIS) in H2SO4 (conditions adapted 
from Chaikov et al., 2007) followed by lactam methanolysis under acidic conditions was 
envisioned as a particularly short and attractive route to racemic threo-4-iodo-MP 
(Scheme 5.4), particularly since β-lactam (±)-3.11 was synthetically accessible in large 
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quantities in the lab via Scheme 5.2.  Attempted electrophilic aromatic iodination of β-
lactam (±)-3.11 was complete in four hours based on the formation of a single non-polar 
spot on TLC.  However, 1H NMR revealed the presence of the ortho- and meta-iodo 
isomers of (±)-5.4.  Additionally, the presence of the erythro diastereomer of β-lactam 
(±)-5.4 was also observed by 1H NMR.  Given that it was extremely challenging to obtain 
pure desired (±)-5.4 via silica gel chromatography after this chemical reaction (Scheme 
5.4), this strategy was abandoned in favor of more practical routes (vide infra). 
 
Scheme 5.4.  Attempted electrophilic aromatic iodination of a racemic threo-β-lactam  
building block towards 4-iodo-MP. 
5.1.1.2.2. Application of Axten’s Racemic threo-MP Synthetic Methodology 
Towards the Synthesis of Racemic threo-4-Iodo-MP   
A synthesis of racemic threo-4-iodo-MP ((±)-3.31) was then investigated 
(Scheme 5.5) via appropriate application of synthetic methodology previously described 
to synthesize racemic threo-MP ((±)-1.10) (Axten et al., 1998; Gutman et al., 2004).  
This strategy began with Friedel-Craft’s acylation of commercially available iodobenzene 
(3.69) with commercially available ethyl chlorooxoacetate (5.5) to give known α-keto 
ester 5.6 (Kiesewetter, 1993), which upon condensation with piperidine (3.8) provided 
novel α-keto amide 5.7 in 63% yield.  Subsequent reaction of ketone 5.7 with 
tosylhydrazine under acidic conditions then provided tosylhydrazone 5.8 in moderate 
yield (85%).  Thermal cyclization of tosylhydrazone 5.8 (i.e., the para-iodo derivative of 
 92 
known tosylhydrazone 3.10) under aqueous basic conditions using Aliquat 336 as a phase 
transfer catalyst, column chromatography, then subsequent recrystallization from diethyl 
ether provided diastereomerically pure racemic threo-β-lactam (±)-5.4 as the major 
product in moderate yield (60%).  In turn, diastereomerically pure racemic threo-β-
lactam (±)-5.4 was converted to 4-iodo-MP ((±)-3.31) in quantitative yield by ring 
opening with MeOH under acidic conditions (Lapinsky et al., 2011).  Racemic threo-4-
iodo-MP ((±)-3.31) synthesized by this chemistry was determined to be ≥95% 
diastereomerically pure by 1H NMR upon comparison to the known data for 
enantiomerically pure threo- and erythro-MP and its para-substituted derivatives (Thai et 
al., 1998). 
 
 
Scheme 5.5.  Novel synthesis of racemic threo-4-iodo-MP by application of methodology previously 
described for the synthesis of racemic  
threo-MP by Axten et al., 1998. 
The chemistry described in Scheme 5.5 worked fairly well in the lab yielding 
4-iodo-MP ((±)-3.31) in 5 steps and 5% overall yield.  Although this represents a 
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significant improvement when compared to the known synthetic route (Schemes 5.2 and 
5.3, 10 steps, 9% overall yield), synthesis of iodo keto ester 5.6 by Friedel-Craft’s 
acylation (Kiesewetter, 1993) proved low yielding on a large scale (Table 5.1). 
Table 5.1.  Different reaction scales for the production of iodo keto ester 5.6. 
Attempt Scale 
(mmol) 
Solvent Yield of 5.6 
1  5 CS2 15 % 
2 10 CS2 13 % 
3 30  CS2 8 % 
4 150  CS2 3 % 
5 5  DCM 18 % 
 
The reaction workup for formation of iodo keto ester 5.6 was rather 
challenging due to formation of a sticky gum that was principally responsible for low 
yields (Table 5.1, attempts 1 and 2).  This problem became more significant on a larger 
scale and led to a further decrease in product yield (Table 5.1, attempts 3 and 4).  
Changing the reaction solvent from carbon disulfide (CS2) to dichloromethane (DCM) 
(Table 5.1, attempts 1 versus 5) made reaction monitoring by TLC and the workup 
process relatively easier.  However, the product yield was comparable to that when CS2 
was used as the reaction solvent (Table 5.1, attempts 1 versus 5).  As a result of these 
practical challenges, an alternative route was envisioned and pursued utilizing 
commercially available nitro α-keto ester 5.9 in order to access the previously described 
iodo keto amide 5.7 directly via an aniline precursor (Scheme 5.6). 
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Scheme 5.6.  An alternative, efficient synthesis of iodo keto amide 5.7 via diazotization  
of an aniline precursor. 
Treatment of commercially available nitro α-keto ester 5.9 with piperidine 
(3.8) provided α-keto amide 5.10 in 95% yield and involved no column chromatography 
purification (Scheme 5.6) (Lapinsky et al., 2012a).  The nitro group of 5.10 was 
subsequently reduced with tin (II) chloride under acidic conditions to provide aniline 
precursor 5.11 in 70% yield.  The aniline was then subjected to diazotization and iodide 
displacement to provide the previously described iodo keto amide 5.7 in good yield 
(78%).  This synthetic route proved very practical even on a large scale.  Furthermore, a 
significant improvement in product yield for iodo keto amide 5.7 was observed using this 
strategy (Scheme 5.6, 3 steps, 52% overall yield versus Scheme 5.5, 2 steps, 10% overall 
yield on a 10 mmol scale), which ultimately significantly improved the synthesis of 4-
iodo-MP ((±)-3.31). The optimized synthesis of 4-iodo-MP ((±)-3.31) (Scheme 5.7) 
utilizes 6 steps and produces the target compound in 26 % overall yield.  This represents 
a significant improvement in terms of the number of synthetic steps and overall product 
yield when compared to the known synthetic route for 4-iodo-MP (Pan et al., 1996; 10 
steps, 9% overall yield, Schemes 5.2 and 5.3). 
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Scheme 5.7.  Optimized chemical synthesis of racemic threo-4-iodo-MP  
developed as part of this dissertation work. 
Simultaneous to this work on developing an enhanced route to 4-iodo-MP, an 
efficient synthesis of 3-iodo-MP ((±)-4.18) (Scheme 5.8) was developed by Nageswari 
Yarravarapu in the Lapinsky laboratory at Duquesne University (Lapinsky et al., 2011).  
This material could then be utilized to subsequently produce desired MP-based DAT 
photoprobes upon N-alkylation with a series of known azido benzyl bromides (5.1-5.3; 
Mornet et al., 1984) (Scheme 5.10).  The synthesis of 3-iodo-MP ((±)-4.18) begins with 
regioselective meta-iodination of α-keto amide 3.9 to provide iodo α-keto amide 5.12 in 
77% yield.  Subsequent condensation of the ketone within 5.12 with tosylhydrazine under 
acidic conditions provided tosylhydrazone 5.13 in moderate yield (72%).  Next, thermal 
cyclization of tosylhydrazone 5.13 (i.e., the meta-iodo derivative of known tosyl 
hydrazine 3.10) under aqueous basic conditions using Aliquat 336 as a phase transfer 
catalyst, followed by column chromatography and recrystallization from diethyl ether, 
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provided diastereomerically pure racemic threo-β-lactam (±)-5.14 as the major product in 
moderate yield (55%).  Finally, diastereomerically pure racemic threo-β-lactam (±)-5.14 
was converted to 3-iodo-MP ((±)-4.18) in quantitative yield by ring opening with MeOH 
under acidic conditions.  Racemic threo-3-iodo-MP ((±)-4.18) synthesized by this route 
was determined to be ≥95% diastereomerically pure by 1H NMR upon comparison to the 
known data for enantiomerically pure threo- and erythro-MP and its para-substituted 
derivatives (Thai et al., 1998). 
 
 
 
Scheme 5.8.  Synthesis of racemic threo-3-iodo-MP performed  
according to Lapinsky et al., 2011. 
5.1.1.3.  Synthesis of Requisite Azido Benzyl Bromides Needed to Produce a 
Series of Racemic threo-N-Azidobenzyl-4-Iodo/3-Iodo-MP Photoaffinity 
Ligands for DAT Structure-Function Studies 
In order to produce desired series of racemic threo-N-azidobenzyl-4-iodo/3-
iodo-MP photoaffinity ligands (Scheme 5.10) for DAT structure-function studies, a series 
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of requisite azido benzyl bromides (5.1-5.3) were needed for N-alkylation of either 3- or 
4-iodo-MP.  Two of these azido benzyl bromides, 5.1 and 5.3, were accessed by their 
known chemical literature procedures (Mornet et al., 1984).  Specifically, commercially 
available anilines 5.15 and 5.17 were subjected to diazotization and azide displacement to 
provide known azido toluene derivatives 5.16 and 5.18 (Mornet et al., 1984), which were 
subsequently converted to their azido benzyl bromide derivatives 5.3 and 5.1 by free 
radical bromination (Scheme 5.9). 
 
 
 
Scheme 5.9.  Synthesis of requisite azido benzyl bromides needed to produce a series of racemic 
threo-N-azidobenzyl-4-iodo/3-iodo-MP photoaffinity ligands. 
Simultaneously, meta-azido toluene derivative 5.20 was successfully made 
analogous to its ortho and para derivatives utilizing commercially available aniline 5.19 
by employing diazotization followed by azide displacement conditions.  However, 
synthesis of meta-azido benzyl bromide 5.2 by free radical bromination was not 
reproducible according to the literature (Mornet et al., 1984), as this reaction appeared to 
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not proceed to completion and formed only the undesired dibrominated derivative 5.21 
(Scheme 5.9). 
5.1.1.4.  N-Alkylation of Racemic threo-4-Iodo/3-Iodo-MP with a Series of Azido 
Benzyl Bromides Towards a Series of Racemic threo-N-Azidobenzyl-4-
Iodo/3-Iodo-MP Photoaffinity Ligands for DAT Structure-Function 
Studies 
 
Scheme 5.10.  Synthesis of a target series of racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP 
derivatives as potential DAT photoaffinity ligands. 
Ortho- ((±)-4.24 and (±)-4.27) and para-azido-substituted ((±)-4.26 and (±)-
4.29) target MP-based photoaffinity probes were synthesized in moderate yield (50% to 
67%) by N-alkylation of either 3- or 4-iodo-MP with the corresponding ortho- (5.1) or 
para-substituted (5.3) azido benzyl bromide (Scheme 5.10).  Simultaneously, meta-
substituted azido photoaffinity probes (±)-4.25 and (±)-4.28 were synthesized in 48% and 
53% yield using 3- or 4-iodo-MP and a sequence of N-alkylation with commercially 
available meta-nitro benzyl bromide (5.22), nitro reduction, and diazotization followed 
by azide displacement (Lapinsky et al., 2011). 
 99 
5.1.1.5.  Stannylation of Racemic threo-p-Azido-N-Benzyl-4-Iodo-MP Towards 
Radioiodination and DAT Covalent Ligation Via Photoaffinity Labeling 
With respect to identifying candidate probes for photoaffinity labeling 
experiments, ideal compounds are those that are bioactive in the same range as the parent 
compound.  However, compounds with as much as 1000-fold lower activity can still be 
useful (Dorman and Prestwich, 2000).  Given racemic threo-p-azido-N-benzyl-4-iodo-
MP ((±)-4.26) displayed modest DAT binding affinity, and the highest DAT binding 
affinity (Ki = 363 ± 28 nM) in the series of racemic threo-N-azidobenzyl-4-iodo/3-iodo-
MP compounds (4.24-4.29), further development of this compound into a potential DAT 
photoprobe was pursued.  Given that wash-resistant binding experiments involving 
nonradioactive azido compounds frequently give false positives in the assessment of 
covalent attachment (Agoston et al., 1997), synthesis of a radioiodinated (i.e., [125I]) 
version of racemic threo-p-azido-N-benzyl-4-iodo-MP ((±)-4.26) was pursued to 
determine if photoactivation could produce covalent ligation to the DAT.  In this regard, 
racemic p-azido-N-benzyl-4-iodo-MP ((±)-4.26) was subjected to Stille coupling 
(conditions adapted from Shu et al., 1996) with bis(tributyltin) to provide stannyl 
derivative (±)-5.23 in 40% yield (Scheme 5.11).  This compound was then converted to 
radioactive iodide derivative [125I]-(±)-4.26 by Dr. John Lever at the University of 
Missouri-Columbia (see Section A.1 in Appendix). Subsequently, the DAT was 
irreversibly labeled ((±)-5.24, Scheme 5.11) succesfully with [125I]-(±)-4.26 by Dr. 
Roxanne Vaughan’s group at the University of North Dakota (see Section A.1 in 
Appendix).  In summary, [125I]-(±)-4.26 represents the first successful example of a DAT 
photoaffinity ligand based on a MP scaffold, thus representing an important contribution 
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to the arsenal of probes for characterizing DAT function and 3-D structure (Lapinsky et 
al., 2011).   
 
Scheme 5.11.  Stannylation of (±)-4.26 towards radioiodination by Dr. John Lever and DAT covalent 
ligation by Dr. Roxanne Vaughan. 
5.1.2. Synthesis of Racemic threo-p-Azido-N-Benzyl-4-Iodo-Ritalinol as a Potential 
Photoaffinity Ligand for DAT Structure-Function Studies 
 As previously described in Section 4.6.2, since N-benzylation of iodo-MPs (±)-
3.31 and (±)-4.18 led to a significant decrease in DAT binding affinity, we desired 
racemic threo-p-azido-N-benzyl-4-iodo-ritalinol ((±)-4.33) in order to potentially obtain a 
MP-based photoprobe with improved DAT binding affinity (i.e., target goal of DAT Ki < 
100 nM) relative to previously successful probe [125I]-(±)-4.26 (Lapinsky et al., 2011).  
We envisioned the synthesis of racemic threo-p-azido-N-benzyl-4-iodo-ritalinol ((±)-
4.33) as a potential photoaffinity ligand for DAT structure-function studies via N-
alkylation of 4-iodo-ritalinol ((±)-5.25) with known p-azido benzyl bromide (5.3; Mornet 
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et al., 1984) (Scheme 5.12).  With this strategy in mind, an efficient synthesis of 4-iodo-
ritalinol ((±)-5.25) was desired and pursued.  
 
Scheme 5.12.  Retrosynthetic strategy towards racemic threo-p-azido-N-benzyl-4-iodo-ritalinol as a 
potential photoaffinity ligand for DAT structure-function studies. 
5.1.2.1. Attempted Methyl Ester Reduction of Racemic threo-4-Iodo-MP with 
LiAlH4 to Access Racemic threo-4-Iodo-Ritalinol 
Methyl ester reduction of 4-iodo-MP ((±)-3.31) with LiAlH4 (conditions 
adopted from Kim et al., 2007) was envisioned as the shortest route to 4-iodo-ritalinol 
(Scheme 5.13) due to the availability of 4-iodo-MP previously described (Scheme 5.3).  
This strategy began with basification of 4-iodo-methyphenidate ((±)-3.31) with 1M 
aqueous NaOH to provide the free base (±)-5.26 in 72% yield.  Subsequently, methyl 
ester reduction was then attempted with 0.6 equivalents of LiAlH4 at 0 ˚C (Table 5.2, 
attempt 1).  Although TLC of this reaction indicated a complete reaction in 30 minutes 
and generation of a single, more polar spot, 1H NMR indicated a minor amount of desired 
4-iodo-ritalinol ((±)-5.25) alongside deiodinated side product (±)-5.27 as the major 
product.  Furthermore, it proved very challenging to separate these ritalinols by silica gel 
chromatography due to their rather high polarity.  
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Table 5.2.  LiAlH4 reaction conditions employed for methyl ester  
reduction of racemic threo-4-iodo-MP. 
Attempt LiAlH4  
Equivalents 
Reaction 
Conditions 
Result  
1 0.6 0 ˚C, 30 min Concomitant  
deiodination 
2 0.3 -10 ˚C, 15 min 
 
 
Scheme 5.13.  Methyl ester reduction of racemic threo-4-iodo-MP to access  
racemic threo-4-iodo-ritalinol. 
Attempts to eliminate the undesirable deiodinated side product ritalinol ((±)-
5.27) by decreasing the number of equivalents of LiAlH4 to 0.3 equivalents, alongside 
lower reaction temperature (-10 ˚C) (Table 5.2, attempt 2) and time (15 min) yielded 
similar results.  At this stage, the crude mixture of 4-iodo-ritalinol ((±)-5.25) and ritalinol 
((±)-5.27) was N-benzylated to determine whether the expected mixture of N-benzyl-4-
iodo-ritalinol ((±)-5.28) and N-benzyl-ritalinol ((±)-4.31) could be separated by silica gel 
chromatography (Scheme 5.13).  However, once again silica gel chromatography proved 
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difficult in terms of separating these N-benzyl-ritalinols.  As a result, methyl ester 
reduction using a strong reducing agent such as LiAlH4 was abandoned in favor of milder 
reducing agents in order to avoid undesirable deiodination to produce side product 
ritalinol ((±)-5.27). 
It should be noted that at the time of this project, 4-iodo-MP (via Scheme 5.3) 
was considered very valuable material by the Lapinsky lab since its synthetic route had 
yet to be optimized.  However, as previously delineated, Nageswari Yarravarapu from the 
Lapinsky lab at Duquesne University had already developed an efficient large scale 
synthetic route for 3-iodo-MP (Scheme 5.8).  As a result, the following model reduction 
reactions were performed using 3-iodo-MP and its readily available precursors. 
5.1.2.2.  Attempted Methyl Ester Reduction of Racemic threo-3-Iodo-MP with 
LiBH4 to Access Racemic threo-3-Iodo-Ritalinol: a Model Reaction for 
Reduction of Racemic threo-4-Iodo-MP to Racemic threo-4-Iodo-Ritalinol 
At this time, methyl ester reduction conditions reported by Lapinsky and 
Bergmeier (Lapinsky and Bergmeier, 2001) using LiBH4 as a milder reducing agent was 
attempted in order to address the previously observed undesirable deiodination using 
LiAlH4.   In this regard, 3-iodo-MP ((±)-4.18) was first treated with 1M aqueous NaOH 
in order to provide the free base (±)-5.29 in 85% yield, then methyl ester reduction with 
LiBH4 was attempted (Scheme 5.14).  TLC of this reaction indicated a complete reaction 
after 24 hours with formation an unexpected nonpolar spot.  Although 1H NMR of this 
isolated material did not indicate the desired 3-iodo-ritalinol ((±)-5.30), the methyl ester 
of (±)-5.29 was observed with impurities, thus indicating a potentially stable borane 
complex where the piperidine nitrogen may have prevented desired reduction of the 
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methyl ester under these reaction conditions.  All attempts to force this reduction reaction 
to completion using excess LiBH4 (10 equivalents) and heating (60 ˚C) proved 
unsuccessful, and as a result this strategy was no longer pursued. 
 
Scheme 5.14.  Attempted methyl ester reduction of racemic threo-3-iodo-MP with LiBH4 as model 
reaction to access racemic threo-4-iodo-ritalinol. 
5.1.2.3.  Attempted Reductive Ring Opening of a Racemic threo-3-Iodo-β-Lactam 
Building Block with LiAlH4 to Access Racemic threo-3-Iodo-Ritalinol: a 
Model Reaction for the Synthesis of Racemic threo-4-Iodo-Ritalinol as a 
Desired Compound 
At this stage of the project, an optimized small scale synthesis of 4-iodo-MP 
((±)-3.31 via Scheme 5.5) via methanolysis of racemic threo-4-iodo-β-lactam (±)-5.4 was 
developed.  In this regard, reductive lactam ring opening (conditions adapted from 
D’hooghe et al., 2009) using 3-iodo-β-lactam (±)-5.14 with LiAlH4 was envisioned as an 
appropriate model system to circumvent the previously described deiodination problem 
(Scheme 5.15).  Attempted reductive ring opening of 3-iodo-β-lactam (±)-5.14 with solid 
LiAlH4 (2 equivalents) in diethyl ether under reflux conditions resulted in the recovery of 
starting material.  However, repeating this reaction with one equivalent of a 1.0 M 
solution of LiAlH4 in THF gave a mixture of deiodinated β-lactam ((±)-3.11) alongside 
starting material (±)-5.14.  Given this unsuccessful reaction, this synthetic strategy was 
abandoned in favor of using milder reducing agents.  
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Scheme 5.15.  Attempted reductive ring opening of a racemic threo-3-iodo-β-lactam building block 
with LiAlH4 as a model reaction to access racemic threo-4-iodo-ritalinol. 
5.1.2.4.  Borane Reduction of Racemic threo-3-Iodo-Ritalinic Acid as a Model 
Reaction to Access Racemic threo-4-Iodo-Ritalinol  
Given the failed attempts of reducing the methyl ester of 3-iodo-MP ((±)-4.18) 
and reductive ring opening of 3-iodo-β-lactam (±)-5.14, borane reduction of 3-iodo-
ritalinic acid ((±)-5.31) was attempted next as a model reaction to potentially access 
racemic threo-4-iodo-ritalinol.  This strategy began with acidic hydrolysis of 3-iodo-β-
lactam (±)-5.14 to provide 3-iodo-ritalinic acid ((±)-5.31) in 80% yield (Scheme 5.16).  
The carboxylic acid of (±)-5.31 was then successfully reduced with 5 equivalents of 
BH3•THF (conditions adapted from Bosch et al., 2004) to access crude 3-iodo-ritalinol 
((±)-5.30) in low yield (20%).  Irrespective of the low yield, lack of deiodinated side 
product ritalinol (±)-5.27 was very encouraging and made this synthetic strategy 
appropriate for accessing 4-iodo-ritalinol ((±)-5.25). 
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Scheme 5.16.  Borane reduction of racemic threo-3-iodo-ritalinic acid as a model reaction  
to access racemic threo-4-iodo-ritalinol. 
5.1.2.5. Borane Reduction of Racemic threo-4-Iodo-Ritalinic Acid Towards the 
Synthesis of Racemic threo-p-Azido-N-Benzyl-4-Iodo-Ritalinol 
 
Scheme 5.17.  Synthesis of racemic threo-p-azido-N-benzyl-4-iodo-ritalinol via  
borane reduction of racemic threo-4-iodo-ritalinic acid.   
Given the successful borane reduction of 3-iodo-ritalinic acid ((±)-5.31) to 3-
iodo-ritalinol ((±)-5.30), this prompted me to hydrolyze 4-iodo-β-lactam (±)-5.4 (from 
Scheme 5.7) to produce 4-iodo-ritalinic acid ((±)-3.30) in 99% yield (Scheme 5.17).  
Subsequent reduction of the carboxylic acid to the primary alcohol with borane 
(conditions from Scheme 5.16) provided 4-iodo-ritalinol ((±)-5.25) in 43% yield.  The 
crude ritalinol (±)-5.25 was then taken forward and N-alkylated with para-azido benzyl 
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bromide (5.3 from Scheme 5.9) to provide racemic threo-p-azido-N-benzyl-4-iodo-
ritalinol ((±)-4.33) in 50% yield as a potential photoaffinity ligand for DAT structure-
function studies. 
5.1.3. Synthesis of Racemic threo-MP-Based Analogs Containing the Traditional 3-
Iodo-4-Azido Labeling Motif as Potential Photoaffinity Ligands for DAT 
Structure-Function Studies 
 As previously described in Section 4.6.3, since photoaffinity ligands based on 3-
iodo-MP ((±)-4.18) and 4-iodo-MP ((±)-3.31) had poor DAT binding affinity, we desired 
racemic threo-MP-based analogs containing the traditional 3-iodo-4-azido labeling motif 
as potential photoaffinity ligands with improved DAT binding affinity relative to 
previously described successful DAT probe [125I]-(±)-4.26 (Lapinsky et al., 2011).  In 
particular, we envisioned the synthesis of these photoprobes via N-alkylation of either 
racemic threo-MP ((±)-1.10; Axten et al., 1998; Gutman et al., 2004) or ritalinol ((±)-
5.27; Kim et al., 2007) with 3-iodo-4-azido benzyl chloride (5.32; Murray et al., 2005) 
(Scheme 5.18).  As a result, syntheses of racemic threo-MP ((±)-1.10), ritalinol ((±)-
5.27), and 3-iodo-4-azido benzyl chloride (5.32) were pursued in parallel. 
 
Scheme 5.18.  Proposed retrosynthesis of racemic threo-MP analogs containing the traditional 3-iodo-
4-azido labeling motif as potential photoaffinity ligands for DAT structure-function studies. 
5.1.3.1.  Synthesis of 3-Iodo-4-Azido Benzyl Chloride in Order to Access Racemic 
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threo-MP Analogs Containing the Traditional 3-Iodo-4-Azido Labeling 
Motif 
In order to produce desired target racemic threo-MP-based photoaffinity 
ligands containing the traditional 3-iodo-4-azido labeling motif (Scheme 5.18), 3-iodo-4-
azido benzyl chloride (5.32) was needed for N-alkylation of racemic threo-MP and 
ritalinol.  3-Iodo-4-azido benzyl chloride (5.32) was synthesized according to the known 
chemical literature (Murray et al., 2005).   
 
Scheme 5.19.  Synthesis of 3-iodo-4-azido benzyl chloride needed to produce racemic threo-MP-
based analogs containing the traditional 3-iodo-4-azido labeling motif as potential photoaffinity 
ligands for DAT structure-function studies. 
Briefly, commercially available aniline 5.33 was subjected to electrophilic 
iodination to provide iodide 5.34 in 67% yield (Scheme 5.19).  Next, the amino group of 
5.34 was diazotized and displaced with azide to provide methyl ester 5.35 in 99% yield.  
Subsequent hydrolysis of ester 5.35 under basic conditions provided the carboxylic acid 
5.36 in 97% yield, which in turn was reduced to the primary alcohol (5.37) in 70% yield 
via a mixed anhydride intermediate (Shu et al., 1996).  Finally, alcohol 5.37 was 
 109 
converted to 3-iodo-4-azido benzyl chloride (5.32) upon treatment with mesyl chloride 
wherein the benzylic mesylate is displaced by chloride anion. 
5.1.3.2.  N-Alkylation of Racemic threo-MP with 3-Iodo-4-Azido Benzyl Chloride 
To Produce a MP-Based Photoaffinity Ligand Containing the Traditional 
3-Iodo-4-Azido Labeling Motif 
Target racemic threo-MP-based photoaffinity probe (±)-4.35 was synthesized 
in 28% yield by reacting the secondary amine of racemic threo-MP ((±)-1.10 from 
Scheme 5.2) with 3-iodo-4-azido benzyl chloride (5.32 from Scheme 5.19) (Scheme 
5.20).   
 
Scheme 5.20.  Synthesis of a racemic threo-MP-based photoaffinity ligand containing the traditional 
3-iodo-4-azido labeling motif. 
5.1.3.3.  N-Alkylation of Racemic threo-Ritalinol with 3-Iodo-4-Azido Benzyl 
Chloride To Produce a Racemic threo-MP-Based Photoaffinity Ligand 
Containing the Traditional 3-Iodo-4-Azido Labeling Motif 
In order to access an additional racemic threo-MP-based photoaffinity ligand 
containing the traditional 3-iodo-4-azido labeling motif, racemic threo-MP ((±)-1.10 
from Scheme 5.2) was first treated with 1M aqueous NaOH to provide the free base 
compound (±)-5.38 in 70% yield (Scheme 5.21).  Subsequent reduction of the methyl 
ester with LiAlH4 then provided racemic threo-ritalinol ((±)-5.27) in 90% yield (Kim et 
al., 2007).  Finally, the piperidine of (±)-5.27 was N-alkylated with 3-iodo-4-azido benzyl 
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chloride (5.32 from Scheme 5.19) to provide target ritalinol-based photoaffinity probe 
(±)-4.36 in 19% yield. 
 
Scheme 5.21.  Synthesis of a racemic threo-ritalinol-based photoaffinity ligand  
containing the traditional 3-iodo-4-azido labeling motif. 
5.1.4. Synthesis of (R,R)-MP-Based Photoaffinity Ligands Containing the 
Traditional 3-Iodo-4-Azido Labeling Motif for DAT Structure-Function 
Studies 
In order to avoid photoprobes as racemic mixtures as previously described in 
Section 4.6.3, we desired enantiomerically pure (R,R)-MP-based analogs containing the 
traditional 3-iodo-4-azido labeling motif as potential photoaffinity ligands for DAT 
structure-function studies.  In particular, we envisioned the synthesis of these 
enantiomerically pure photoprobe compounds via N-alkylation of (R,R)-MP ((+)-1.10; 
Prashad et al., 1999a) and (R,R)-ritalinol (5.27; Prashad et al., 1999b) with 3-iodo-4-
azido benzyl chloride (5.32; Murray et al., 2005) (Scheme 5.22).  With this synthetic 
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strategy in mind, parallel syntheses of target photoaffinity ligands (-)-4.35 and (-)-4.36 
were pursued. 
 
Scheme 5.22.  Proposed retrosynthesis for enantiomerically pure (R,R)-MP-based photoaffinity 
ligands containing the traditional 3-iodo-4-azido labeling motif. 
5.1.4.1. N-Alkylation of (R,R)-MP with 3-Iodo-4-Azido Benzyl Chloride Towards 
an Enantiomerically Pure MP-Based Photoaffinity Ligand Containing the 
Traditional 3-Iodo-4-Azido Labeling Motif 
Target enantiomerically pure (R,R)-MP-based photoaffinity probe (-)-4.35 
was synthesized in 19% yield by N-alkylation of (R,R)-MP ((+)-1.10; provided by retired 
Professor Howard M. Deutsch (Georgia Tech University)) with 3-iodo-4-azido benzyl 
chloride (5.32 from Scheme 5.19) (Scheme 5.23).   
 
Scheme 5.23.  Synthesis of an enantiomerically pure (R,R)-MP-based photoaffinity ligand containing 
the traditional 3-iodo-4-azido labeling motif. 
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5.1.4.2. N-Alkylation of (R,R)-Ritalinol with 3-Iodo-4-Azido Benzyl Chloride To 
Access an Additional (R,R)-MP-Based Photoaffinity Ligand Containing 
the Traditional 3-Iodo-4-Azido Labeling Motif 
 
Scheme 5.24.  Synthesis of a (R,R)-ritalinol-based photoaffinity ligand for DAT structure-function 
studies containing the traditional 3-iodo-4-azido labeling motif. 
In order to access an additional enantiomerically pure (R,R)-MP-based 
photoaffinity ligand for potential DAT structure-function studies, (R,R)-MP ((+)-1.10; 
provided by retired Professor Howard M. Deutsch (Georgia Tech University) was first 
treated with aqueous 1M NaOH in order to provide the free base compound 5.38 in 72% 
yield (Scheme 5.24).  The methyl ester of this enantiomerically pure compound was then 
reduced with LiAlH4 (using conditions adapted from Kim et al., 2007) to provide 
enantiomerically pure (R,R)-ritalinol (5.27) in 93% yield.  Finally, the piperidine nitrogen 
of enantiomerically pure 5.27 was alkylated under basic conditions with 3-iodo-4-azido 
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benzyl chloride (5.32 from Scheme 5.19) to provide access target ritalinol-based 
photoaffinity probe (-)-4.36 in 46% yield.  This potential DAT photoprobe was 
subsequently converted to its oxalate salt (5.39) in 34% yield for pharmacological 
evaluation. 
5.1.4.3.  Stannylation of (-)-3-Iodo-4-Azido-N-Benzyl-Ritalinol Towards 
Radioiodination and DAT Covalent Ligation Via Photoaffinity Labeling 
Given (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) displayed the highest 
DAT binding affinity (Ki = 218 ± 29 nM) of the enantiopure MP-based photoaffinity 
ligands synthesized during this work, further development of this compound into a 
potential DAT photoprobe was pursued.  Once again, given that wash-resistant binding 
experiments involving nonradioactive azido compounds frequently give false positives in 
the assessment of covalent attachment (Agoston et al., 1997), synthesis of a 
radioiodinated (i.e., [125I]) version of enantiopure (-)-3-iodo-4-azido-N-benzyl-ritalinol  
((-)-4.36) was pursued to determine if photoactivation could produce covalent ligation to 
the DAT.  In this regard, enantiopure (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) was 
subjected to Stille coupling (conditions adapted from Shu et al., 1996) with 
bis(tributyltin) to provide stannyl derivative (-)-5.40 in 40% yield (Scheme 5.25).  This 
compound was then converted to radioactive iodide derivative [125I]-4.36 by Dr. John 
Lever at the University of Missouri-Columbia (see Section A.2 in Appendix). 
Subsequently, the DAT was irreversibly labeled (5.41, Scheme 5.25) succesfully with 
[125I]-4.36 by Dr. Roxanne Vaughan’s group at the University of North Dakota (see 
Section A.2 in Appendix). In summary, [125I]-4.36 represents the first successful example 
of an enantiopure DAT photoaffinity ligand based on a MP scaffold, thus representing an 
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important contribution to the arsenal of chemical probes useful for characterizing DAT 
function and 3-D structure. 
 
Scheme 5.25.  Stannylation of an enantiomerically pure ritalinol-based probe towards radioiodination 
by Dr. John Lever and DAT covalent ligation by Dr. Roxanne Vaughan. 
5.1.5. Synthesis of Racemic threo-3,4-Dichloro-MP-Based Photoaffinity Ligands 
Containing the Traditional 3-Iodo-4-Azido Labeling Motif for DAT 
Structure-Function Studies 
As previously described in Section 4.6.4, racemic threo-3,4-dichloro-MP analogs 
containing the traditional 3-iodo-4-azido labeling motif ((±)-4.37 and (±)-4.38) were 
desired as potential photoaffinity ligands for DAT structure-function studies.  As a result 
and analogous to the synthesis of MP-based photoprobes previously described in this 
dissertation, N-alkylation of racemic threo-3,4-dichloro-MP ((±)-3.53; Deutsch et al., 
 115 
1996) or 3,4-dichloro-ritalinol ((±)-5.42; Kim et al., 2007) with 3-iodo-4-azido benzyl 
chloride (5.32; Murray et al., 2005) was envisioned as a synthetic strategy (Scheme 5.26) 
to access potential DAT photoprobes with higher binding affinity versus that of probes 
previously described.  With this strategy in mind, parallel syntheses of target 
photoaffinity ligands (±)-4.37 and (±)-4.38 were pursued. 
 
Scheme 5.26.  Proposed retrosynthesis of racemic threo-3,4-dichloro-MP-based analogs as potential 
photoaffinity ligands containing the traditional 3-iodo-4-azido labeling motif. 
5.1.5.1. N-Alkylation of Racemic threo-3,4-Dichloro-MP with 3-Iodo-4-Azido 
Benzyl Chloride Towards Photoaffinity Ligands Containing the 
Traditional 3-Iodo-4-Azido Labeling Motif 
 
Scheme 5.27.  Synthesis of a racemic threo-3,4-dichloro-MP-based photoaffinity  
ligand containing the traditional 3-iodo-4-azido labeling motif. 
Analogous to that previously described, target racemic threo-3,4-dichloro-
MP-based photoaffinity probe (±)-4.37 was synthesized in 24% yield by reacting racemic 
threo-3,4-dichloro-MP ((±)-3.53; provided by retired Professor Howard M. Deutsch 
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(Georgia Tech University)) with 3-iodo-4-azido benzyl chloride (5.32 from Scheme 5.19) 
under basic conditions (Scheme 5.27). 
5.1.5.2. N-Alkylation of Racemic threo-3,4-Dichloro-Ritalinol with 3-Iodo-4-Azido 
Benzyl Chloride Towards an Additional MP-Based DAT Photoaffinity 
Ligand Containing the Traditional 3-Iodo-4-Azido Labeling Motif 
 
Scheme 5.28.  Synthesis of a racemic threo-3,4-dichloro-ritalinol-based photoaffinity ligand 
containing the traditional 3-iodo-4-azido labeling motif. 
Given that N-benzyl-ritalinol derivatives tend to possess higher DAT binding affinity 
than their methyl ester counterparts (previously described in Section 4.6.4), a synthesis of 
a racemic threo-3,4-dichloro-ritalinol analog containing the traditional 3-iodo-4-azido 
labeling motif was pursued.  In particular, racemic threo-3,4-dichloro-MP ((±)-3.53; 
provided by retired Professor Howard M. Deutsch (Georgia Tech University)) was first 
converted to its free base form by treatment with 1M aqueous NaOH (Scheme 5.28).  The 
methyl ester of compound (±)-5.43 was then reduced with LiAlH4 to provide racemic 
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threo-3,4-dichloro-ritalinol ((±)-5.42; Kim et al., 2007) in 80% yield.  Finally, the 
piperidine nitrogen of (±)-5.42 was selectively alkylated under basic conditions via 
reaction with 3-iodo-4-azido benzyl chloride (5.32 from Scheme 5.19) in order to provide 
target 3,4-dichloro-ritalinol-based photoaffinity probe (±)-4.38 in 23% yield. 
5.2. Synthesis of GBR-12909-Based Photoprobes Suitable for DAT Structure-
Function Studies 
5.2.1. Synthesis of a Clickable Benzophenone-Alkyne-Based GBR-12909 Analog as 
a Potential Photoprobe for DAT Structure-Function Studies 
In an effort to transition away from radioiodinated-based compounds, several 
DAT photoprobes were envisioned employing terminal alkynes or aliphatic azides as 
click chemistry handles for application of a tandem photoaffinity labeling-bioorthogonal 
conjugation strategy (Lapinsky, 2012; see Section 4.7).  In particular, we envisioned 
synthesis of a clickable benzophenone-alkyne-based GBR-12909 photoprobe (4.40) for 
DAT structure-function studies via Sonogashira coupling of iodobenzophenone 5.44 with 
trimethylsilyl acetylene (3.67) followed by silyl group deprotection (Scheme 5.29).  This 
synthetic strategy appeared to be particularly attractive since iodobenzophenone 5.44 
could also represent a potential radioactive GBR-12909-based DAT photoaffinity probe 
via pursuit of its 125I form.  In particular, we envisioned iodobenzophenone 5.44 could be 
obtained via N-alkylation of known mono-substituted piperazine derivative 3.58 (Van der 
zee et al., 1980) with alkyl bromide 5.45.  In turn, the synthesis of alkyl bromide 5.45 
was envisioned via Friedel-Craft’s acylation of commercially available 1-phenyl-3-
bromopropane (3.59) with 4-iodobenzoyl chloride (5.46). 
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Scheme 5.29.  Proposed retrosynthesis of a clickable benzophenone-alkyne-based GBR-12909  
analog as a potential photoprobe for DAT structure-function studies. 
 
With this retrosynthetic strategy in mind, 4,4’-difluorobenzhydrol (3.54) was first 
treated with 2-chloroethanol (3.55) under acidic conditions to provide known chloride 
3.56 (Ironside et al., 2002) in moderate yield (85%) (Scheme 5.30).  Next, displacement 
of the primary chloride within 3.56 by reacting with excess piperazine (3.57) provided 
the known mono-substituted piperazine derivative 3.58 (Van der zee et al., 1980) in 55% 
yield.  Subsequent alkylation of piperazine 3.58 with alkyl bromide 5.45, obtained via 
Friedel-Craft’s acylation (conditions adapted from Tanaka et al., 1992) of 1-phenyl-3-
bromopropane (3.59) with 4-iodobenzoyl chloride (5.46), provided GBR-12909 analog 
5.44 in 62% yield.  In order to access the photoprobe containing the terminal alkyne click 
chemistry handle, Sonogashira coupling (conditions adapted from Gangjee et al., 2000) 
conditions were employed by reacting iodo benzophenone 5.44 with trimethylsilyl 
acetylene (3.67) under palladium-catalyzed reaction conditions.  Subsequent silyl group 
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deprotection using tert-butyl ammonium fluoride (TBAF) provided target benzophenone-
alkyne-based GBR-12909 analog 4.40 in 37% yield. 
 
 
Scheme 5.30.  Synthesis of a clickable benzophenone-alkyne-based GBR-12909 analog as  
a potential photoprobe for DAT structure-function studies. 
5.2.2. Synthesis of a Diazido-Based GBR-12909 Analog as a Potential Photoprobe 
for DAT Structure-Function Studies 
5.2.2.1. An Attempted β-Alkyl Suzuki-Miyaura Coupling Strategy Towards the 
Synthesis of a Diazido-Based GBR-12909 Analog for DAT Structure-
Function Studies 
As previously described in Section 4.7.2, an alternative GBR-12909 DAT 
photoprobe was desired containing the 1,3,5-disubstitued diazido phenyl motif commonly 
used in tandem photoaffinity labeling-bioorthogonal conjugation (Lapinsky, 2012).  In 
this regard, we envisioned the synthesis of probe 4.43 for DAT structure-function studies 
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via β-alkyl Suzuki-Miyaura coupling between known N-allyl alkene 5.47 (Hsin et al., 
2003) and known iodo diazide 5.48 (Hosoya et al., 2009)  (Scheme 5.31).  In particular, 
this synthetic strategy was initially pursued given there are numerous examples of sp2-sp2 
carbon-carbon bond forming reactions involving 5.48 under Suzuki-Miyaura coupling 
conditions (Hosoya et al., 2009), thus indicating both the aryl and aliphatic azide 
functional groups survive this palladium-catalyzed reaction. Furthermore, this synthetic 
strategy was selected with an objective to potentially develop a method for readily 
arming any compound of interest with this common diazide motif upon attachment of 
iodo diazide 5.48 to a terminal alkene. 
 
 
Scheme 5.31.  Envisioned β-alkyl Suzuki-Miyaura coupling strategy towards the synthesis of a 
clickable diazido-based GBR-12909 DAT photoprobe. 
 
With this strategy in mind, synthesis of GBR-12909 (1.12) itself via β-alkyl 
Suzuki-Miyaura coupling of known alkene 5.47 (Hsin et al., 2003) with commercially 
available iodobenzene (3.69) was initially pursued as a model reaction to see if this 
chemistry would prove successful (Scheme 5.32). 
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Scheme 5.32.  Envisioned β-alkyl Suzuki-Miyaura coupling towards the synthesis of  
GBR-12909 as a model reaction. 
5.2.2.1.1. Synthesis of GBR-12909 via β-Alkyl Suzuki-Miyaura Coupling: a Model 
Reaction 
Before proceeding with the synthesis of target diazido-based GBR-12909 
analog 4.43 via β-alkyl Suzuki-Miyaura coupling, a model reaction was performed using 
commercially available iodobenzene (3.69) and readily accessible known alkene 5.47 
(Hsin et al., 2003) in an attempt to synthesize GBR-12909 (1.12) by β-alkyl Suzuki-
Miyaura coupling (Scheme 5.33).  This work began by reacting chloride 3.56 (from 
Scheme 5.30) with allyl piperazine (5.49) to provide known terminal alkene 5.47 (Hsin et 
al., 2003) in 55% yield.  Next, β-alkyl Suzuki-Miyaura coupling (conditions adapted 
from Lapinsky and Bergmeier, 2001) involving alkene 5.47, 9-BBN, 
PdCl2(dppf)•CH2Cl2, and iodobenzene (3.69) provided impure GBR-12909 (1.12) in 20% 
yield (Scheme 5.33).  Irrespective of the low yield of this reaction, successful formation 
of GBR-12909 (1.12) by this chemistry prompted pursuit of known iodo diazide 5.48 
(Hosoya et al., 2009), which would be required for application of this chemical strategy 
to synthesize target diazido GBR-12909 analog 4.43. 
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Scheme 5.33.  Synthesis of GBR-12909 via β-alkyl Suzuki-Miyaura coupling: a model reaction. 
5.2.2.1.2. Synthesis of a Known Aryl-Iodo Diazide Towards Generation of a 
Clickable GBR-12909-Based DAT Photoprobe  
In order to access diazido GBR-12909-based photoprobe 4.43 for DAT 
structure-function studies, known iodo diazide 5.48 was synthesized according to the 
chemical literature (Hosoya et al., 2009) (Scheme 5.34).  Commercially available aniline 
5.50 was first diazotized and reacted with potassium iodide to provide the known aryl 
iodide 5.51 (Vaidyanathan et al., 2001) in 95% yield.  The carboxylic acid of iodide 5.51 
was then reduced with sodium borohydride in the presence of boron trifluoride diethyl 
ether (conditions adapted from Cho et al., 2004) to provide the primary alcohol 5.52 in 
71% yield.  Next, the aromatic nitro group of 5.52 was reduced with tin (II) chloride 
under acidic conditions to provide aniline 5.53 in 90% yield.  Diazotization of the aniline 
followed by displacement with sodium azide then provided aryl azide 5.54 (Hosoya et al., 
2002) in 93% yield.  Finally, the primary alcohol of 5.54 was converted into a mesylate 
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leaving group and displaced with sodium azide to provide the aliphatic azide 5.48 
(Hosoya et al., 2009) in 80% yield. 
 
Scheme 5.34.  Synthesis of a known aryl-iodo diazide building block towards a clickable GBR-
12909-based DAT photoprobe. 
5.2.2.1.3. Attempted Synthesis of a Diazido-Based GBR-12909 Photoprobe for DAT 
Structure-Function Studies Via β-Alkyl Suzuki-Miyaura Coupling  
Based on successful β-alkyl Suzuki-Miyaura reaction conditions used to 
synthesize GBR-12909 (1.12; Scheme 5.33), synthesis of target diazido-based GBR-
12909 photoprobe 4.43 was attempted by trying to couple terminal alkene 5.47 with iodo-
diazide 5.48 (Scheme 5.35).  This attempted coupling reaction resulted in multiple spots 
on TLC.  In particular, 1H NMR of an isolated proposed target spot indicated 
decomposition of one or more of the organic azides.  As a result of this experiment, β-
alkyl Suzuki-Miyaura coupling between terminal alkene 5.47 and relatively stable aryl 
iodide 5.55 (Giblin et al., 2005a; obtained via esterification of carboxylic acid 5.51 from 
Scheme 5.34) was envisioned as a key reaction to access GBR-12909 analog 5.56 as an 
 124 
important synthetic intermediate.  Sequential nitro and ester reductions of intermediate 
5.56 followed by incorporation of both the aryl and aliphatic azides as previously 
described was then envisioned to provide the target diazido-based GBR-12909 analog 
4.43 (Scheme 5.35).  However, attempted β-alkyl Suzuki-Miyaura coupling between 
terminal alkene 5.47 and aryl iodide 5.55 produced multiple spots on TLC, none 
indicative of target 5.56 upon chromatography and 1H NMR.  Given the relative lack of 
success of these two attempted β-alkyl Suzuki-Miyaura coupling reactions, this chemical 
strategy towards target diazido-based GBR-12909 photoprobe 4.43 was dropped in favor 
of pursuit of alternative synthetic routes (vide infra). 
 
Scheme 5.35.  Attempted synthesis of a diazido-based GBR-12909 photoprobe via  
β-alkyl Suzuki-Miyaura coupling. 
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5.2.2.2. Reductive Amination Strategy Towards the Synthesis of a Diazido-Based 
GBR-12909 Photoprobe for DAT Structure-Function Studies 
Given the relative lack of success via a proposed β-alkyl Suzuki-Miyaura 
coupling strategy, alternative synthetic strategies toward target diazido-based GBR-
12909 photoprobe 4.43 were pursued (Scheme 5.36).  In particular, access to this target 
photoprobe was envisioned via GBR-12909 analog 5.56 as a key synthetic intermediate, 
wherein this compound could potentially be accessed through reductive amination of 
novel aldehyde 5.57 with known piperazine 3.58 (Van der zee et al., 1980).  In turn, the 
requisite aldehyde 5.57 could potentially be obtained by via known alkene 5.58 (Ek et al., 
2002) by sequential hydroboration-oxidation followed by alcohol oxidation.  With these 
synthetic thoughts in mind, pursuit towards target diazido-based GBR-12909 photoprobe 
4.43 was re-initiated. 
 
Scheme 5.36.  Proposed reductive amination strategy towards the synthesis of a  
diazido-based GBR-12909 photoprobe. 
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With Scheme 5.36 in mind, synthesis of GBR-12909 (1.12) by reductive 
amination of piperazine 3.58 (from Scheme 5.30) with commercially available 3-
phenylpropanal (5.59) was first envisioned as a model reaction to determine whether this 
chemistry could proceed successfully (Scheme 5.37).  
 
Scheme 5.37.  Envisioned reductive amination strategy towards the synthesis of GBR-12909 as a 
model reaction towards a target diazido-based GBR-12909 photoprobe. 
5.2.2.2.1. Synthesis of GBR-12909 by Reductive Amination as a Model Reaction 
Towards a Target Diazido-Based GBR-12909 Photoprobe 
 
Scheme 5.38.  Synthesis of GBR-12909 by reductive amination. 
Before pursuit of novel aldehyde 5.57 for the envisioned reductive amination 
strategy towards target diazido-based GBR-12909 photoprobe 4.43 (Scheme 5.36), a 
reductive amination reaction was attempted involving known piperazine 3.58 (from 
Scheme 5.30) and commercially available 3-phenylpropanal (5.59) using conditions from 
Abdel-Magid et al., 1996 (Scheme 5.38).  This model reaction proved successful 
providing GBR-12909 (1.12) in 70% yield.  Given the success of this particular model 
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reaction, pursuit of novel aldehyde 5.57 for reductive amination to access key 
intermediate 5.56 required for the synthesis of target diazido-based GBR-12909 analog 
4.43 was initiated.  
5.2.2.2.2. Synthesis of a Novel Aldehyde in Order To Access a Key Synthetic 
Intermediate for the Synthesis of a Diazido-Based GBR-12909 DAT 
Photoprobe 
Novel aldehyde 5.57 was required in relatively large amounts in order to 
access key intermediate 5.56 for the synthesis of target diazido-based GBR-12909 
photoprobe 4.43.  Initial strategy for synthesis of aldehyde 5.57 began with conversion of 
aniline 5.60 to terminal alkene 5.58 (Scheme 5.39; Ek et al., 2002, red color) via 
diazotization and free radical allylation.  Next, terminal alkene 5.58 was subjected to 
hydroboration-oxidation (conditions adapted from Kim et al., 2008) to provide primary 
alcohol 5.62 in 40% yield.  Subsequently, primary alcohol 5.62 was oxidized to its 
corresponding aldehyde (5.57) using pyridinium chlorochromate (PCC), followed by 
reductive amination with piperazine 3.58 (Van der zee et al., 1980) to provide GBR-
12909 analog 5.56 in good yield (70%).  However, synthesis of aldehyde 5.57 by this 
hydroboration-oxidation route was rather low yielding (Scheme 5.39, red color, 3 steps, 
7% overall yield, 0.4 mmol scale).  In particular, this chemistry was much lower yielding 
on a larger scale (1 mmol) and attempts utilizing BH3•Me2S as a hydroboration reagent 
did not result in a significant improvement.  As a result, a more practical, alternative 
route was pursued in order to generate aldehyde 5.57 on a larger scale (Scheme 5.39, blue 
color).   
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This alternative strategy to aldehyde 5.57 began with subjection of aniline 
5.60 to diazotization and iodide displacement conditions to provide aryl iodide 5.55 in 
70% yield (Scheme 5.39, blue color, Giblin et al., 2005b).  Subsequent Heck-coupling 
(conditions adapted from Deng et al., 2009) of this aryl iodide with allyl alcohol (5.63) 
then provided direct access to target aldehyde 5.57 in 57% yield (Scheme 5.39, blue 
color).  This chemistry proved very practical even on a relatively large scale (7 mmol).  
Additionally, a significant improvement in the yield of aldehyde 5.57 was observed using 
this strategy and also involved fewer synthetic steps (Scheme 5.39, blue color, 2 steps, 
40% overall yield versus Scheme 5.39, red color, 3 steps, 7% overall yield). 
 
Scheme 5.39.  Synthesis of a novel aldehyde and a key GBR-12909 analog as an intermediate  
needed for the synthesis of a diazido-based GBR-12909 dopamine photoprobe. 
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5.2.2.2.3. Further Modifications of a GBR-12909 Analog Towards the Synthesis of 
a Diazido-Based GBR-12909 Photoprobe for DAT Structure-Function 
Studies 
 
Scheme 5.40.  Further successful modifications of a GBR-12909 analog to produce a diazido-based 
GBR-12909 photoprobe for DAT structure-function studies. 
With large quantities of GBR-12909 analog 5.56 as a synthetic intermediate in 
hand, the nitro group of this compound was reduced with tin (II) chloride dihydrate to 
provide aniline 5.64 in 74% yield (Scheme 5.40).  The ethyl ester of 5.64 was then 
reduced with LiAlH4 to provide the corresponding primary alcohol (5.65) in 81% yield. 
Next, the aniline of intermediate 5.65 was subjected to diazotization and azide 
displacement to provide access to aryl azide 5.66 in 70% yield.  Finally, the primary 
alcohol of intermediate 5.66 was converted into a mesylate leaving group to provide 5.67 
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in 40% yield, then subsequently displaced with sodium azide to produce diazido-based 
GBR-12909 target photoprobe 4.43 in 40% yield. 
5.3. Synthesis of Irreversible mGlu5 NAMs as Chemical Probes Suitable for 
mGlu5 Structure-Function Studies 
5.3.1. Synthesis of Lead mGlu5 NAMs as Controls for mGlu5 Pharmacological 
Evaluation  
Given known lead mGlu5 NAMs 4.44 and 4.45 were required as positive controls 
for pharmacological comparison to novel probe compounds, these compounds were 
synthesized according to the known chemical literature (Iso et al., 2006; Mishra et al., 
2012).  In this regard, condensation of acid chloride 3.72 with bis(trimethylsilyl)acetylene 
(3.73) first provided α-chloroketone derivative 3.74 in 70% yield (Scheme 5.41).  
Subsequent cyclization with thioacetamide (3.75) provided alkyne-protected 
methylthiazole derivative 3.76 (Cosford et al., 2003) in 60% yield.  In turn, this 
trimethylsilyl protected alkyne was subjected to one-pot desilylation and Sonogashira 
coupling with either iodobenzene (3.69) or 3-iodo-phenol (5.68) to provide known lead 
mGlu5 NAMs 4.44 (Iso et al., 2006) and 4.45 (Mishra et al., 2012) in 80% and 50% 
yield, respectively.  Additionally, with the objective of pursuing novel benzylic ether 4.46 
as a potential lead compound (i.e., should this compound display appreciable mGlu5 
binding affinity and retain NAM function), trimethylsilyl-protected alkyne 3.76 was 
subjected to one-pot desilylation and Sonogashira coupling (conditions adapted from Iso 
et al., 2006) with aryl iodide 5.69 to give benzyl ether 4.46 in 70% yield.  With these 
control compounds in hand, synthesis of novel mGlu5 irreversible NAMs as chemical 
probes for mGlu5 structure-function studies were subsequently initiated. 
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Scheme 5.41.  Synthesis of several lead mGlu5 NAMs as control  
compounds for mGlu5 pharmacological studies. 
5.3.2. Synthesis of a Clickable Benzophenone Propargyl Ether mGlu5 NAM 
Photoprobe for mGlu5 Structure-Function Studies 
As previously described in Section 4.8.1, we desired clickable benzophenone 
propargyl ether mGlu5 NAM 4.49 (RVDU-3-130) as a potential photoprobe suitable for 
mGlu5 structure-function studies.  The synthesis of target photoprobe 4.49 (RVDU-3-
130) was envisioned via O-alkylation of known phenol 4.45 (Mishra et al., 2012) with 
alkyl bromide 5.70, which in turn we believed could be accessed via O-alkylation of 
known phenol 5.72 (Tae et al., 2010) with dibromoethane (5.71) (Scheme 5.42).  It is 
known that phenol 5.72 can be obtained by monopropargylation of bis-phenol 5.74 (Tae 
et al., 2010). 
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Scheme 5.42.  Proposed retrosynthesis of a clickable benzophenone propargyl ether  
mGlu5 NAM photoprobe. 
With this retrosynthesis in mind, commercially available bis-phenol 5.74 was first 
mono-alkylated with propargyl bromide (5.73) to provide benzophenone derivative 5.72 
(Tae et al., 2010) in 40% yield (Scheme 5.43).  Subsequent alkylation with 
dibromoethane (5.71) then provided alkyl bromide 5.70 in 28% yield.  Next, alkyl 
bromide 5.70 was treated with phenol 4.45 (from Scheme 5.41) under basic conditions to 
provide target probe 4.49 (RVDU-3-130) in 70% yield. Given clickable benzophenone 
propargyl ether mGlu5 NAM 4.49 (RVDU-3-130) displays improved mGlu5 binding 
affinity (Ki = 11 ± 0.8 nM) versus lead compounds 4.45 (Ki = 59 ± 0.9 nM) and 4.46 (Ki 
= 48 ± 0.8 nM), and retained mGlu5 NAM functional potency, this photoprobe is 
currently being evaluated in mGlu5 tandem photoaffinity labeling-bioorthogonal 
conjugation experiments in Dr. Karen Gregory’s laboratory at Monash University (see 
Section A.3 in Appendix) 
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Scheme 5.43.  Synthesis of a clickable benzophenone propargyl ether mGlu5 NAM photoprobe 
suitable for mGlu5 structure-function studies. 
5.3.3. Synthesis of a Clickable MPEP-Binding Site Diazido mGlu5 NAM 
Photoprobe for mGlu5 Structure-Function Studies 
As previously discussed in Section 4.8.2, a MPEP-binding site diazido mGlu5 
NAM thiazole (4.50) was desired as a clickable photoprobe for mGlu5 structure-function 
studies.  We envisioned the synthesis of this target compound via O-alkylation of known 
phenol 4.45 (Mishra et al., 2012) with known diazido mesylate 5.79 (Hosoya et al., 2005) 
(Scheme 5.44). 
 
 
Scheme 5.44.  Proposed retrosynthesis of a MPEP-binding site diazido mGlu5 NAM as a clickable 
photoprobe for mGlu5 structure-function studies. 
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With this synthetic strategy in mind, commercially available dimethyl 5-
aminoisophthalate (5.80) was first reduced with excess lithium aluminum hydride to 
provide diol 5.81 in 55% yield (Scheme 5.45).  Aniline 5.81 was then subjected to 
diazotization and azide displacement to provide aryl azide 5.82 in 70% yield, which upon 
treatment with bis(2,4-dichlorophenyl chlorophosphate) and sodium azide provided 
known diazido alcohol 5.83 (Neelarapu et al., 2011) in 56% yield.  In turn, the remaining 
primary alcohol of 5.83 was converted into a mesylate leaving group (5.79; Hosoya et al., 
2005) then displaced with phenol 4.45 (from Scheme 5.41) under basic conditions to 
provide target clickable photoprobe 4.50 in 50% yield. 
 
Scheme 5.45.  Synthesis of a clickable MPEP-binding site diazido mGlu5 NAM photoprobe for 
mGlu5 structure-function studies. 
5.3.4. Synthesis of an Azido-Iodo Thiazole mGlu5 MPEP-Binding Site NAM 
Photoprobe for mGlu5 Structure-Function Studies 
As previously described in Section 4.8.3, an azido-iodo thiazole mGlu5 MPEP-
binding site NAM photoprobe (4.52) was envisioned and desired for mGlu5 structure 
function studies.  In order to access this target photoprobe, we envisioned 4-((3-fluoro-5-
nitrophenyl)ethynyl)thiazol-2-amine (5.84) could be subjected to a sequence of 
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diazotization followed by iodide displacement, nitro reduction, then diazotization 
followed by azide displacement (Scheme 5.46). In turn, 4-((3-fluoro-5-
nitrophenyl)ethynyl)thiazol-2-amine (5.84) was envisioned by Sonogashira coupling 
known TMS-protected alkyne 5.85 (Simeon et al., 2011) with commercially available 1-
fluoro-3-iodo-5-nitrobenzene (5.86).  
 
Scheme 5.46.  Proposed retrosynthesis of an azido-iodo thiazole mGlu5 MPEP-binding site NAM 
photoprobe for mGlu5 structure function studies. 
With this retrosynthetic strategy in mind, α-chloro ketone 3.74 (Cosford et al., 
2003) was first cyclized with thiourea (5.87) to provide amino thiazole 5.85 (Simeon et 
al., 2011) in 70% yield (Scheme 5.47).  Subsequent one-pot desilylation and Sonogashira 
coupling (conditions adapted from Simeon et al., 2011) with commercially available aryl 
iodide 5.86 provided impure disubstituted alkyne 5.84 in 25% yield after silica gel 
chromatography.  Next, impure thiazoloaniline 5.84 was directly converted to heteroaryl 
iodide 5.88 in 70% yield using diazotization and iodide displacement conditions from 
Simeon et al., 2011.  Subsequent reduction of the nitro group within intermediate 5.88 
using tin (II) chloride under strong acidic conditions resulted in the deiodinated analog of 
intermediate 5.89.  Alternatively, the nitro group of intermediate 5.88 was reduced with 
solid iron under weak acidic conditions (adapted from Gamble et al., 2007) to provide 
aniline 5.89 in 20% yield.  Finally, aniline 5.89 was subjected to diazotization and 
displacement with sodium azide to provide target azido-based photoprobe 4.52 in 15% 
yield. 
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Scheme 5.47.  Synthesis of an azido-iodo thiazole mGlu5 MPEP-binding site NAM photoprobe for 
mGlu5 structure function studies. 
5.3.5. Synthesis of a Clickable Azido-Propargyl Ether mGlu5 MPEP-Binding Site 
NAM Photoprobe for mGlu5 Structure-Function Studies 
As previously described in Section 4.8.4, a mGlu5 MPEP-binding site NAM 
(4.54) containing an aryl azide photoreactive group and a propargyl ether click chemistry 
handle was envisioned as a photoprobe for mGlu5 structure function studies.  The 
synthesis of this target photoprobe was envisioned by subjecting 2-((3-methoxy-5-
nitrophenyl)ethynyl)-6-methylpyridine (5.90) to a sequence of demethylation, 
propargylation, nitro reduction, then diazotization followed by azide displacement 
(Scheme 5.48).  In turn, 2-((3-methoxy-5-nitrophenyl)ethynyl)-6-methylpyridine (5.90) 
was envisioned by Sonogashira coupling TMS-protected alkyne 3.68 (Alagille et al., 
2005) with 1-iodo-3-methoxy-5-nitrobenzene (5.91) (Jorgensen et al., 2011). 
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Scheme 5.48.  Proposed retrosynthesis of a clickable azido-propargyl ether mGlu5 MPEP-binding site 
NAM photoprobe for mGlu5 structure function studies. 
With this synthetic strategy in mind, 2-bromo-6-methyl pyridine (3.64) was first 
reacted with trimethylsilyl acetylene (3.67) under Sonogashira coupling conditions to 
provide known TMS-protected alkyne 3.68 (Alagille et al., 2005) in 70% yield (Scheme 
5.49).  
 
Scheme 5.49.  Synthesis of a clickable azido-propargyl ether mGlu5 MPEP-binding site NAM 
photoprobe for mGlu5 structure function studies. 
In parallel, 3,5-dinitro-iodobenzene (5.94) was reacted with sodium methoxide in 
MeOH according to Jorgensen et al., 2011 to provide 1-iodo-3-methoxy-5-nitrobenzene 
5.91 in 77% yield.  Next, protected terminal alkyne 3.68 was subjected to one-pot 
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desilylation and Sonogashira coupling (conditions adapted from Iso et al., 2006) with 1-
iodo-3-methoxy-5-nitrobenzene 5.91 to provide disubstituted alkyne 5.90 in 78% yield.  
Deprotection of methoxy ether 5.90 followed by propargylation provided ether 5.92 in 
35% yield.  Finally, the nitro group of intermediate 5.92 was reduced under acidic 
conditions to provide aniline 5.93 in 91% yield, which was then subjected to 
diazotization and displacement with sodium azide to provide target clickable photoprobe 
4.54 in 30% yield. 
5.3.6. Synthesis of a Methanethiosulfonate-Containing mGlu5 MPEP-Binding Site 
NAM Thiol-Reactive Chemical Probe for mGlu5 Engineered Affinity 
Labeling Experiments 
As previously described in Section 4.8.5, a methanethiosulfonate-containing 
mGlu5 MPEP-binding site NAM thiol-reactive chemical probe (4.55) was envisioned and 
desired for mGlu5 engineered affinity labeling experiments.  The synthesis of this 
particular affinity labeling probe was envisioned via S-alkylation of bromide 5.96 with 
sodium methanethiosulfonate (5.95) (Scheme 5.50).  In turn, we believed alkyl bromide 
5.96 could be obtained by O-alkylation of known phenol 4.45 (Mishra et al., 2012) with 
dibromethane (5.71).  
 
Scheme 5.50.  Proposed retrosynthesis of a methanethiosulfonate-containing mGlu5 MPEP-binding 
site NAM thiol-reactive chemical probe for mGlu5 engineered affinity labeling experiments. 
Given this retrosynthesis, previously obtained phenol 4.45 (from Scheme 5.41) 
was alkylated with 1,2-dibromoethane (5.71) to provide alkyl bromide 5.96 in 32% yield 
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(Scheme 5.51).  Subsequent displacement of this alkyl bromide with sodium 
methanethiosulfonate (5.95) provided target thiol-reactive affinity labeling probe 4.55 in 
85% yield.  Given methanethiosulfonate-containing mGlu5 MPEP-binding site NAM 
thiol-reactive chemical probe 4.55 retained appropriate mGlu5 binding affinity (Ki = 13 ± 
0.8 nM, ~2-fold lower than parent compound 4.44) and NAM functional potency, this 
probe has been subjected to prelimary docking experiments  in a mGlu5 homology model 
developed by Dr. Jens Meiler’s group (Vanderbilt University) to suggest rational cysteine 
mutations for proposed mGlu5 engineered affinity labeling experiments (see Section A.4 
in Appendix).   
 
Scheme 5.51.  Synthesis of a methanethiosulfonate-containing mGlu5 MPEP-binding site NAM thiol-
reactive chemical probe for mGlu5 engineered affinity labeling experiments. 
5.3.7. Synthesis of a Maleimide-Based mGlu5 MPEP-Binding Site NAM Thiol-
Reactive Chemical Probe for mGlu5 Engineered Affinity Labeling 
Experiments 
As previously described in Section 4.8.6, we envisioned and desired a maleimide-
based mGlu5 MPEP-binding site NAM thiol-reactive chemical probe (4.56) for mGlu5 
engineered affinity labeling experiments.  The synthesis of this affinity labeling probe 
was anticipated via condensation of 3-((2-methylthiazol-4-yl)ethynyl)aniline (5.98)  with 
maleic anhydride (5.97) (Scheme 5.52).  In turn, we believed 3-((2-methylthiazol-4-
yl)ethynyl)aniline (5.98) could be obtained by Sonogashira coupling of known TMS-
protected alkyne 3.76 (Cosford et al., 2003) with bromo aniline 5.99. 
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Scheme 5.52.  Proposed retrosynthesis of a maleimide-based mGlu5 MPEP-binding site thiol-reactive 
chemical probe for mGlu5 engineered affinity labeling experiments. 
Initial one-pot desilylation of TMS-protected alkyne 3.76 (from Scheme 5.41) and 
Sonogashira coupling (conditions adapted from Iso et al., 2006) with bromo aniline 5.99 
failed to provide disubstitued alkyne 5.98 (Scheme 5.53). As a result, one-pot desilylation 
of TMS-protected alkyne 3.76 and Sonogashira coupling with 3-iodo-nitrobenzene 
(5.100) provided disubstitued alkyne 5.101 (Alagille et al., 2004) in 70% yield.  
Subsequent reduction of the nitro group in intermediate 5.101 with solid iron under acidic 
conditions gave aniline 5.98 in 91% yield.  Finally, treatment of aniline 5.98 with maleic 
anhydride (5.97) and condensation with acetic anhydride provided target maleimide-
based probe 4.56 in 70% yield. 
 
 
Scheme 5.53.  Synthesis of a maleimide-based mGlu5 MPEP-binding site thiol-reactive chemical 
probe for mGlu5 engineered affinity labeling experiments. 
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5.4. Summary of Significance, Innovation, and Research Accomplishments 
Associated With This Dissertation Work 
Despite decades of committed research, no agents are clinically available to 
combat psychostimulant abuse and addiction.  This prodigious void can be linked in part 
to sparse information on the 3-D structure and function of the DAT (DAT), which 
pharmacological and behavioral studies indicate is the brain receptor chiefly responsible 
for the reinforcing / reward properties associated with amphetamines and cocaine.  
Specifically, there is a fundamental gap in understanding the mechanism of inhibitors and 
the structural elements and conformational states associated with the DAT. 
One of the long-term goals of the Lapinsky research group is to develop chemical 
entities towards understanding how abused and therapeutic compounds interact with the 
DAT at the amino acid level.  In particular, the initial objective of this dissertation work 
was to develop non-tropane irreversible ligands for mapping drug-binding pockets within 
the DAT.  The hypothesis was that non-tropane irreversible ligands could serve as 
complimentary probes to existing tropane-based (e.g., cocaine, benztropine) irreversible 
ligands for high-resolution elucidation of DAT 3-D structure.  Guided by the literature, 
identification of the structural elements of MP- and GBR-12909-based irreversible 
ligands essential for successful labeling of the DAT was pursued.  In particular, the 
specific hypothesis for this part of dissertation work tested whether these non-tropane-
based inhibitor scaffolds could be structurally modified to covalently label the DAT via a 
photoaffinity labeling experiment.  Specifically, MP and GBR-12909 were modified to 
contain a tag (i.e., I125, a terminal alkyne, or an aliphatic azide) and a photoreactive 
functional group (i.e., an aryl azide or a benzophenone).  The synthesized analogs were 
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then pharmacologically evaluated at the DAT by the Surratt laboratory in order to 
identify candidate probes for irreversible DAT labeling experiments performed by the 
Vaughan lab.  In particular, an innovative, systematic design approach towards MP-based 
DAT irreversible ligands was explored in order to address noted shortcomings associated 
with previously established tropane-based DAT irreversible ligands.  This portion of 
research is significant because the binding sites and conformational preferences for MP 
and GBR-12909 as non-tropane therapeutically relevant compounds are unknown relative 
to tropane-based DAT ligands.  Furthermore, a battery of developed probes based on 
these chemical scaffolds is expected to advance the field towards rational structure-based 
drug design for a myriad of DAT-implicated disorders besides drug addiction (e.g., 
Parkinson’s disease, schizophrenia, ADHD, depression).  In this regard and as previously 
described in Section 5.1, synthesis of racemic threo-p-azido-N-benzyl-4-iodo-MP ((±)-
4.26) and (R,R)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) represent the first successful 
examples of DAT photoaffinity ligands based on MP.  Moreover, racemic threo-p-azido-
N-benzyl-4-iodo-MP ((±)-4.26) represents the first successful example of a DAT 
photoaffinity ligand wherein the photoreactive azide and iodine tag are on different parts 
of the chemical scaffold (Lapinsky et al., 2011). 
In terms of practical organic synthesis troubleshooting and as previously 
described in Section 5.1.1.2.2, a novel, efficient large-scale synthesis of racemic threo-4-
iodo-MP ((±)-3.31) was developed in order to synthesize a series of racemic threo-N-
azidobenzyl-4-iodo-MP photoaffinity ligands ((±)-4.24 to (±)-4.26) as potential 
candidates for DAT structure-function studies.  This optimized synthesis of racemic 
threo-4-iodo-MP (Scheme 5.7) utilizes 6 steps and produces the target compound in 26% 
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overall yield (Lapinsky et al., 2011).  This represents a significant improvement in terms 
of number of synthetic steps and overall product yield when compared to the previously 
known synthetic route for racemic threo-4-iodo-MP (Pan et al., 1996; 10 steps, 9% 
overall yield, Schemes 5.2 and 5.3).  Additionally and as previously described in Section 
5.1.2, synthesis of racemic threo-4-iodo-ritalinol ((±)-5.25) was needed towards racemic 
threo-p-azido-N-benzyl-4-iodo-ritalinol ((±)-4.33) as a potential photoprobe for DAT 
structure-function studies.  However, the synthesis of racemic threo-4-iodo-ritalinol ((±)-
5.25) was problematic wherein ester reduction of racemic threo-4-iodo-MP ((±)-3.31) 
using LiAlH4 routinely resulted in formation of the dehalogenated side product, racemic 
threo-ritalinol ((±)-5.27).  In order to overcome this problem, borane reduction of 
racemic threo-4-iodo-ritalinic acid ((±)-3.30) was employed in order to successfully 
access racemic threo-4-iodo-ritalinol ((±)-5.25) without formation of any dehalogenated 
side product, racemic threo-ritalinol ((±)-5.27).  Finally, as previously described in 
Section 5.2.2.2.2, an efficient, large-scale synthesis of aldehyde 5.57 was needed in order 
to synthesize diazido-based GBR-12909 photoprobe 4.43 for DAT structure-function 
studies.  An initial route featuring hydroboration-oxidation of a terminal alkene (Scheme 
5.39, red color) was not optimal due to low yield of the target aldehyde.  In turn, a unique 
Heck coupling was employed (Scheme 5.39, blue color) in order to produce target 
aldehyde 5.57 with improved yield and fewer steps when compared to the hydroboration-
oxidation route (Scheme 5.39, blue color, 2 steps, 40% overall yield versus Scheme 5.39, 
red color, 3 steps, 7% over all yield). 
To date, it should be noted that the development of DAT photoprobes has been 
limited and traditionally involves the use of radioisotope tags.  However, such tags have 
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limited utility and are no longer necessary for sensitive detection.  Instead, photoprobe 
development is rapidly and routinely moving to compounds bearing “clickable handles” 
(e.g., aliphatic azides, terminal alkynes).  These handles allow click chemistry 
derivatization of a probe after covalent photoligation to a protein of interest.  In theory, 
“clicked” DAT-photoprobe complexes can be purified, proteolyzed, and used in mass 
spectrometric (MS) studies in order to sensitively identify specific sites of crosslinking.  
This powerful and innovative tandem photoaffinity labeling-bioorthogonal conjugation 
chemical proteomics approach using MS to identify distinct covalent crosslinks is 
expected to directly map the binding sites of promising anti-addiction compounds within 
the DAT (or mGlu5 (vide infra)).  In particular, the click chemistry approach is 
advantageous in that it allows secondary attachment of a wide variety of tags (e.g., biotin 
for easy enrichment, isolation, and detection, or fluorophores for sensitive detection and 
imaging applications).  Most importantly, it should be noted that previous attempts to 
determine adduction sites of radioisotope-based phenyltropane photoprobes in the DAT 
have relied on labor intensive peptide mapping strategies or construction of mutant 
proteins, constraints which limit the utility and resolution of analysis.  The ability to 
attach biotin as a purification and detection handle to the probe via click chemistry after 
photoligation is expected to permit microlevel analysis of probe-labeled protein 
fragments when coupled to sequential LC-MS/MS.  In this regard and as previously 
described in Section 5.2, benzophenone-alkyne GBR-12909 analog 4.40 and diazido 
GBR-12909 analog 4.43 represent the first clickable photoaffinity ligands synthesized for 
potential DAT structure-function studies, thus representing an important contribution to 
the growing arsenal of irreversible chemical probes useful for determining the binding 
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site(s) and pose(s) of anti-addiction compounds upon coupling photoaffinity labeling with 
molecular modeling studies. 
Analogous to DAT inhibitors, numerous studies also indicate allosteric 
modulation of mGlu5 as a promising pharmacological approach for treating drug abuse.  
In particular, mGlu5 NAMs are currently being pursued as drug abuse therapeutics given 
their ability to reduce conditioned reward, self-administration, and reinstatement of drug 
seeking.  However, numerous challenges are associated with the discovery and 
optimization of mGlu5 allosteric modulators as potential therapeutics including biased 
pharmacology, difficult SAR, and molecular switches. Collectively these challenges are 
linked to a lack of understanding around the specific molecular determinants that govern 
mGlu5 allosteric modulator affinity, selectivity, and cooperativity (i.e., the magnitude and 
direction of their effect).  Towards addressing this knowledge gap, 3-D molecular models 
of mGlu5’s 7-TM-spanning domain have been generated based on crystal structures from 
related 7TM-spanning domain receptors.  In turn these models are capable of predicting 
critical residues that control the pharmacological profile of these modulators, yet lack 
appropriate atomic level resolution for definitive conclusions to be drawn.  Thus, there 
remains a critical need to further refine and experimentally validate these molecular 
models in order to aid rational drug design efforts. 
 The overall objective of the second portion of this dissertation work was to 
develop mGlu5 NAM irreversible ligands as chemical probes to map their corresponding 
binding sites and poses within mGlu5.  The hypothesis for this portion of the work was 
that chemically distinct mGlu5 NAMs could be derivatized with a functional group 
capable of forming a covalent bond to mGlu5 and, if necessary, a tag functional group.  
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These irreversible mGlu5 NAM chemical probes would then be expected to allow the 
Gregory group to couple mGlu5 affinity or photoaffinity labeling experiments with 
computational modeling studies performed by the Meiler group in order to directly map 
the ligand-binding poses and sites of NAMs within mGlu5.  The rationale behind this 
research is that it will become possible to accurately predict the pharmacological profile 
of existing and novel mGlu5 allosteric modulators, as well as their metabolites.  In 
particular, a deeper understanding of the specific molecular interactions that underlie 
mGlu5 allosteric modulation is expected to facilitate vertical advancement of the field 
from ligand- to rational structure-based drug design, as well as improve virtual / in silico 
screening approaches to identify novel mGlu5 allosteric modulator chemotypes.  
The specific aim of the second portion of this dissertation was to test the 
hypothesis that mGlu5 NAMs could be structurally modified without significant loss in 
pharmacological activity to contain a functional group capable of forming a covalent 
bond to mGlu5 and, if necessary, a tag functional group.  In particular, the creation of 
irreversible chemical probes based on mGlu5 NAMs is expected to aid in mapping the 
binding sites and poses of these compounds within mGlu5 via affinity or photoaffinity 
labeling performed by the Gregory group.  Subsequently, several probes were rationally 
designed, chemically synthesized, and pharmacologically evaluated by the Gregory group 
in order to identify appropriate candidates for mGlu5 irreversible labeling studies. 
In particular, it should be noted that SAR for mGlu5 allosteric modulators are 
notoriously difficult wherein minimal changes to the structure can result in complete loss 
of activity.  Furthermore, numerous mGlu5 modulator chemotypes display a “molecular 
switch” phenomenon whereby a PAM arises from a NAM scaffold (or vice versa) or 
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mGlu selectivity may be altered.  As a result, molecular switches raise concern over the 
pharmacology of putative metabolites and represent a true nightmare for medicinal 
chemists trying to develop SAR to drive a program towards a clinical candidate with a 
single mode of pharmacology.  Collectively these challenges may be attributed to the 
affinity and / or cooperativity of mGlu5 allosteric modulators dictated via specific 
modulator-mGlu5 interactions within distinct mGlu5 binding sites.  Despite recent 
identification of point mutations that engender a molecular switch in mGlu5 PAM 
pharmacology, understanding of mechanistic and / or conformational mGlu5 structure-
function relationships remains in its infancy.  mGlu5 molecular models provide powerful 
tools for hypothesis generation and prediction of ligand-binding modes; however, 
experimental strategies that further refine and validate such models are sorely needed 
given the current absence of a class C GPCR crystal structure.  Elucidation of the 
molecular determinants for mGlu5 allosteric modulator affinity versus cooperativity 
represents a key knowledge gap that must be resolved if we are to understand the inherent 
complexities of these compounds that hinder their rational development into therapeutics.  
In this regard, the mGlu5 NAM compounds described in Section 5.3 represent the first 
potentially irreversible chemical probes directed at this therapeutically significant protein 
to be used in critical structure-function studies.  In particular, the mGlu5 research 
approach proposed by the Lapinsky and Gregory groups is expected to contribute the 
finest level of structural information available for mGlu5 by coupling affinity or 
photoaffinity labeling with molecular modeling studies, thus shedding light on the direct 
interactions mGlu5 allosteric modulators form with mGlu5.  This contribution is expected 
to vertically advance the field towards accurate prediction of mGlu5 allosteric modulator 
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pharmacology, and, ideally, preempt undesirable molecular switches associated with 
these compounds and their metabolites.   
In conclusion, since the basis of medicinal chemistry is the interactions of ligands 
with a target structure, a key component in pharmacophore research and drug 
development is precise knowledge of ligand-binding sites.  In particular, the research 
being performed by the Lapinsky group in collaboration with numerous research groups 
is expected to refine established DAT and mGlu5 molecular models to improve current 
virtual screening / medicinal chemistry drug discovery efforts.  As a consequence, the 
synthesis and utilization of the irreversible chemical probes described in this dissertation 
is ultimately expected to transition the design and development of DAT inhibitors and 
mGlu5 allosteric modulators from a ligand- to structure-based perspective, with the 
ultimate aim to develop effective medications to treat drug abuse and prevent relapse. 
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5.5. Summary of  Final Compounds Synthesized for This Dissertation Work 
Table 5.3.  Final compounds synthesized for this dissertation work. 
Compound Name Novel/ 
Known 
Scale 
(±)-threo-MP hydrochloride ((±)-1.10) Known Large 
(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31) Known Large 
(±)-threo-o-Azido-N-benzyl-4-iodo-MP ((±)-4.24) Novel Small 
(±)-threo-m-Azido-N-benzyl-4-iodo-MP ((±)-4.25) Novel Small 
(±)-threo-p-Azido-N-benzyl-4-iodo-MP ((±)-4.26) Novel Small 
±)-threo-o-Azido-N-benzyl-3-iodo-MP ((±)-4.27) Novel Small 
(±)-threo-m-Azido-N-benzyl-3-iodo-MP ((±)-4.28) Novel Small 
(±)-threo-p-Azido-N-benzyl-3-iodo-MP ((±)-4.29) Novel Small 
(±)-threo-p-Azido-N-benzyl-4-iodo-ritalinol ((±)-4.33) Novel Small 
(±)-threo-3-Iodo-4-azido-N-benzyl-MP ((±)-4.35) Novel Small 
(R,R)-3-Iodo-4-azido-N-benzyl-MP ((-)-4.35) Novel Small 
(±)-threo-3-Iodo-4-azido-N-benzyl-ritalinol ((±)-4.36) Novel Small 
(R,R)-3-Iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) Novel Small 
(R,R)-3-Iodo-4-azido-N-benzyl-ritalinol oxalate (5.39) Novel Small 
(±)-threo-3-Iodo-4-azido-N-benzyl- 
3,4-dichloro-MP ((±)-4.37) 
Novel Small 
(±)-threo-3-Iodo-4-azido-N-benzyl- 
3,4-dichloro-ritalinol ((±)-4.38) 
Novel Small 
GBR-12909 (1.12) Known Large 
(4-(3-(4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-
yl)propyl)phenyl)(4-ethynyl phenyl) methanone (4.40) 
Novel Small 
1-(3-(3-Azido-5-(azidomethyl)phenyl)propyl)-4-(2-(bis(4-
fluorophenyl)methoxy) ethyl) piperazine (4.43) 
Novel Small 
2-methyl-4-(phenylethynyl)thiazole (4.44) Known Small 
3-((2-methylthiazol-4-yl)ethynyl)phenol (4.45) Known Large 
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Compound Name Novel/ 
Known 
Scale 
4-((3-(Benzyloxy)phenyl)ethynyl)-2-methylthiazole (4.46) Novel Small 
(4-(2-(3-((2-Methylthiazol-4-
yl)ethynyl)phenoxy)ethoxy)phenyl)(4-(prop-2-yn-1-
yloxy)phenyl)methanone (4.49) 
Novel Small 
4-((3-((3-Azido-5-(azidomethyl)benzyl)oxy)phenyl)ethynyl)-2-
methylthiazole (4.50) 
Novel Small 
4-((3-Azido-5-fluorophenyl)ethynyl)-2-iodothiazole (4.52) Novel Small 
2-((3-Azido-5-(prop-2-yn-1-yloxy)phenyl)ethynyl)-6-
methylpyridine (4.54) 
Novel Small 
S-(2-(3-((2-Methylthiazol-4-yl)ethynyl)phenoxy)ethyl) 
methanesulfonothioate (4.55) 
Novel Small 
1-(3-((2-Methylthiazol-4-yl)ethynyl)phenyl)-1H-pyrrole-2,5-
dione (4.56) 
Novel Small 
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CHAPTER SIX  
Experimental 
Reaction conditions and yields were not optimized.  All reactions were performed using 
flame-dried glassware under an inert atmosphere of argon unless otherwise noted.  All 
solvents and chemicals were purchased from Aldrich Chemical Co. or Fisher Scientific 
and used without further purification unless otherwise noted.  Flash column 
chromatography was performed according to the method of Still et al., 1978 using Fisher 
S826-25 silica gel sorbent (70–230 mesh) and eluting solvent mixtures as specified.  
Thin-layer chromatography (TLC) was performed using TLC Silica Gel 60 F254 plates 
obtained from EMD Chemicals, Inc. and compounds were visualized under UV light 
and/or I2 stain.  Proportions of solvents used for TLC are by volume.  
1H and 13C NMR 
spectra were recorded on either a Bruker 400 or 500 MHz spectrometer.  Chemical shifts 
for 1H and 13C NMR spectra are reported as parts per million (δ ppm) relative to 
tetramethylsilane (0.00 ppm) as an internal standard.  Coupling constants are measured in 
hertz (Hz).  HRMS samples were analyzed at Old Dominion University (Norfolk, VA) by 
positive ion electrospray on a Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II 
ion source.  Combustion analyses of selected solid compounds were performed by 
Atlantic Microlab, Inc. (Norcross, GA) and are in agreement within 0.4% of calculated 
values.  Melting point determinations were conducted using a Thomas-Hoover melting 
point apparatus and are uncorrected.  Infrared spectra were recorded using a Perkin–
Elmer Spectrum RZ I FT-IR spectrometer.  Optical rotation was recorded using AutoPol 
IV, Automatic Polarimeter. On the basis of NMR and combustion data, all compounds 
were ≥ 95% pure. 
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1-(4-Iodophenylglyoxylyl)piperidine (5.7) 
A solution of ethyl 2-(4-iodophenyl)-2-oxoacetate (5.6, Kiesewetter, 1993) (230 mg, 0.75 
mmol) in EtOH (3 mL) was added to a stirred mixture of piperidine (3.8) (0.22 mL, 2.25 
mmol) in EtOH (3 mL).  The reaction mixture was stirred at 70 ˚C for 3 hrs, cooled to 
room temperature, diluted with H2O then 1M aq. HCl, and extracted with EtOAc.  The 
organic layer was dried (MgSO4), filtered, concentrated, and chromatographed 
(EtOAc:hexanes, 1:9) to provide 220 mg of keto amide 5.7 as a colorless oil (63%).  Rf = 
0.23 (EtOAc:hexanes, 1:9).  1H NMR (CDCl3, 400 MHz): δ 7.82 (d, 2H, J = 8.2 Hz), 7.59 
(d, 2H, J = 8.2 Hz), 3.63 (t, 2H, J = 5.6 Hz), 3.21 (t, 2H, J = 5.5 Hz), 1.63-1.59 (m, 4H), 
1.50-1.45 (m, 2H).  13C NMR (CDCl3, 100 MHz): δ 191.0, 164.8, 138.3, 132.5, 130.7, 
103.2, 47.0, 42.2, 26.2, 25.4, 24.3.  HRMS calcd for C13H14INO2Na
+ 365.9961, found 
365.9962. 
1-(4-Iodophenylglyoxylyl)piperidine (5.7)  (Alternative Method) 
A solution of 4-nitrophenylglyoxylate (5.9) (2.23 g, 10 mmol) in EtOH (12 mL) was 
treated with piperidine (3.8) (3 mL, 30 mmol).  The mixture was stirred at 70 ˚C 
overnight then cooled to room temperature, diluted with 1M aq. HCl, and extracted with 
EtOAc.  The combined organic extracts were washed with H2O and brine, then dried 
(MgSO4), filtered, and concentrated to provide 2.49 g of 1-(4-nitrophenyl)-2-(piperidin-1-
yl)ethane-1,2-dione (5.10) as a yellow solid (95%).  1H NMR data proved identical to that 
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previously reported (Song et al., 2007).  1-(4-nitrophenyl)-2-(piperidin-1-yl)ethane-1,2-
dione (5.10) (2.49 g, 9.5 mmol) was added to MeOH (25 mL) at 0 ˚C followed by 
concentrated HCl (7 mL) and SnCl2 (5.87 g, 30.97 mmol).  The mixture was allowed to 
stir at room temperature overnight then quenched with H2O (50 mL).  The pH was then 
adjusted to 11 with 1 M aq. NaOH and then the mixture was extracted with EtOAc.  The 
organic layer was washed with brine, dried (MgSO4), filtered, concentrated, and 
chromatographed (CHCl3:MeOH, 9.5:0.5) to give 1.54 g of 1-(4-aminophenyl)-2-
(piperidin-1-yl)ethane-1,2-dione (5.11) as a colorless oil (70%).  1H NMR data proved 
identical to that previously reported (Song et al., 2007).  1-(4-aminophenyl)-2-(piperidin-
1-yl)ethane-1,2-dione (5.11) (1.54 g, 6.62 mmol) was added to a solution of p-TsOH 
(3.42 g, 19.89 mmol) in acetonitrile at 0 ˚C.  NaNO2 (1.37 g, 19.89 mmol) was carefully 
added to this solution and the mixture was stirred for 15 min.  Finally, KI (3.3 g, 19.89 
mmol) was added and the reaction mixture was allowed to stir at room temperature for 12 
hrs.  The reaction mixture was then diluted with water, extracted with EtOAc, washed 
with brine, dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 
1:9) to give 1.77 g of iodide 5.7 as a colorless oil (78%).  Rf = 0.23 (EtOAc:hexanes, 1:9). 
1H NMR (CDCl3, 400 MHz): δ 7.82 (d, 2H, J = 8.2 Hz), 7.59 (d, 2H, J = 8.2 Hz), 3.63 (t, 
2H, J = 5.6 Hz), 3.21 (t, 2H, J = 5.5 Hz), 1.63-1.59 (m, 4H), 1.50-1.45 (m, 2H).  13C 
NMR (CDCl3, 100 MHz): δ 191.0, 164.8, 138.3, 132.5, 130.7, 103.2, 47.0, 42.2, 26.2, 
25.4, 24.3.  HRMS calcd for C13H14INO2Na
+ 365.9961, found 365.9962. 
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1-(4-Iodophenylglyoxylyl)piperidine p-toluenesulfonylhydrazone (5.8) 
A solution of ketone 5.7 (930 mg, 2.71 mmol) in EtOH (10 mL) was added to a stirred 
mixture of p-toluenesulfonyl hydrazide (550 mg, 2.93 mmol) in ethanol (10 mL) 
containing H2SO4 (4 mg, 2 µL, 0.04 mmol).  The reaction was refluxed at 85 ˚C 
overnight then cooled to room temperature.  The white solid that formed was filtered, 
washed with cold MeOH and cold hexanes, then dried under reduced pressure to give 1.1 
g of tosylhydrazone (5.8) as a white solid (85%).  Rf = 0.45 (EtOAc:hexanes, 4:6).  
1H 
NMR (CDCl3, 400 MHz): δ 8.40 (s, 1H), 7.83 (d, 2H, J = 8.3 Hz), 7.71 (d, 2H, J = 8.7 
Hz), 7.31 (d, 2H, J = 8.6 Hz), 7.26 (d, 2H, J = 8.1 Hz), 3.70-3.66 (m, 2H), 3.17 (t, 2H, J = 
5.6 Hz), 2.38 (s, 3H), 1.66-1.64 (m, 4H), 1.50-1.40 (m, 2H).  13C NMR (CDCl3, 100 
MHz): δ 161.5, 149.5, 144.2, 137.9, 135.0, 131.7, 129.6, 127.9, 127.7, 97.2, 47.3, 42.3, 
26.3, 25.5, 24.1, 21.6.  HRMS calcd for C20H22IN3O3SNa
+ 534.0319, found 534.0318.  
Anal. Calcd for: C20H22IN3O3S: C, 46.97; H 4.34; N, 8.22; I, 24.82; S, 6.27.  Found: C, 
46.92; H 4.31; N, 8.23; I, 24.63; S, 6.42.  MPt: 137-138 ˚C. 
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 (±)-7-(4-Iodophenyl)-1-azabicyclo[4.2.0]octan-8-one ((±)-5.4) 
Hydrazone 5.8 (1 g, 2 mmol) was added to a stirred mixture of 50% aq. NaOH (170 µL, 
2.08 mmol) and Aliquat 336 (8 mg, 9 µL, 0.02 mmol) in toluene (20 mL).  The reaction 
was refluxed at 130  ˚C overnight then cooled to room temperature, diluted with H2O, and 
extracted with toluene.  The organic layer was dried (MgSO4), filtered, concentrated, and 
chromatographed (EtOAc:hexanes, 2:8) to afford bicyclic lactam (±)-5.4 as a yellow 
solid.  Recrystallization from Et2O provided 390 mg of bicyclic lactam (±)-5.4 (60%).  Rf 
= 0.20 (EtOAc:hexanes, 2:8).  1H NMR (CDCl3, 500 MHz): δ 7.64 (d, 2H, J = 8.3 Hz), 
7.03 (d, 2H, J = 8.4 Hz), 3.92 (d, 1H, J = 4.3 Hz), 3.91-3.88 (m, 1H), 3.34-3.30 (m, 1H), 
2.82-2.76 (m, 1H), 2.18-2.14 (m, 1H), 1.94-1.91 (m, 1H), 1.71-1.67 (m, 1H), 1.45-1.38 
(m, 3H).  13C NMR (CDCl3, 100 MHz): δ 165.5, 137.7, 135.3, 129.3, 92.6, 62.8, 56.5, 
39.0, 30.4, 24.4, 22.1.  HRMS calcd for C13H14INONa
+ 350.0012, found 350.0009.  Anal. 
Calcd for: C13H14INO: C, 47.73; H 4.31; N, 4.28; I, 38.79.  Found: C, 47.84; H, 4.29; N, 
4.23; I, 38.57.  MPt: 127-128 ˚C. 
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(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31) 
 (±)-threo-β-Lactam  (±)-5.4 (90 mg, 0.28 mmol) was refluxed in 1.25 M HCl in MeOH 
(10 mL) at 85 ˚C for 7 hrs then concentrated under reduced pressure to afford 107 mg of 
methyl ester (±)-3.31 as a yellow solid (99%).  1H NMR proved identical to that 
previously reported (Pan et al., 1996).  This threo-iodo-MP was determined to be ≥95% 
diastereomerically pure by 1H NMR upon comparison to the known data for 
enantiomerically pure threo- and erythro-MP and its para-substituted derivatives (Thai et 
al., 1998).  1H NMR (CD3OD, 400 MHz): δ 7.76 (d, 2H, J = 7.9 Hz), 7.11 (d, 2H, J = 8.0 
Hz), 3.95 (d, 1H, J = 9.6 Hz), 3.83 (t, 1H, J = 9.9 Hz), 3.73 (s, 3H), 3.45 (d, 1H, J = 12.4 
Hz), 3.10 (t, 1H, J = 11.8 Hz), 1.89-1.71 (m, 3H), 1.53-1.40 (m, 3H).  13C NMR (CD3OD, 
100 MHz): δ 172.8, 139.6, 134.9, 131.7, 95.0, 58.9, 54.7, 53.6, 46.7, 27.6, 23.3, 22.8.  
HRMS calcd for C14H18INO2Na
+ 382.0274, found 382.0275.  MPt: 188-189 ˚C. 
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(±)-threo-o-Azido-N-benzyl-4-iodo-MP ((±)-4.24) 
(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31) (80 mg, 0.2 mmol) was added to a 
suspension of K2CO3 (110 mg, 0.81 mmol) in DMF (5 mL).  The mixture was stirred at 
room temperature for 10 minutes then o-azido-N-benzyl bromide (5.1; Mornet et al., 
1984) (42 mg, 0.2 mmol) was added.  The reaction was allowed to stir at room 
temperature in the dark for 30 hrs.  Et2O (20 mL) was then added and the mixture was 
decanted followed by rinsing with Et2O (2 × 20 mL).  The combined organic layers were 
washed with H2O, dried (MgSO4), filtered, concentrated, and chromatographed (100% 
hexanes) to give 48 mg of tertiary amine (±)-4.24 as a colorless oil (50%).  Rf = 0.28 
(100% hexanes).  1H NMR (CDCl3, 400 MHz): δ 7.63 (d, 2H, J = 8.4 Hz), 7.38 (d, 1H, 
J = 7.6 Hz), 7.29–7.25 (m, 1H), 7.14–7.09 (m, 4H), 4.09 (d, 1H, J = 11.5 Hz), 3.92 (d, 
1H, J = 14.4 Hz), 3.68 (d, 1H, J = 14.4 Hz), 3.59 (s, 3H), 3.43–3.38 (m, 1H), 2.99–2.93 
(m, 1H), 2.58–2.52 (m, 1H), 1.62–1.46 (m, 4H), 1.38–1.33 (m, 1H), 1.06–1.03 (m, 1H).  
13C NMR (CDCl3, 100 MHz): δ 173.4, 138.0, 137.7, 136.6, 131.5, 130.7, 130.3, 127.9, 
124.6, 117.8, 93.0, 62.4, 52.6, 51.9, 50.7, 45.5, 21.3, 20.7, 19.9.  HRMS calcd for 
C21H23IN4O2H
+ 491.0938, found 491.0930.  IR: azide, 2116 cm−1. 
 
 
(±)-threo-m-Azido-N-benzyl-4-iodo-MP ((±)-4.25) 
(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31) (150 mg, 0.38 mmol) was added to a 
suspension of K2CO3 (130 mg, 0.9 mmol) in DMF (5 mL).  The mixture was stirred at 
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room temperature for 10 minutes then m-nitro-N-benzyl bromide (5.22) (82 mg, 
0.38 mmol) was added.  The reaction was allowed to stir at room temperature in the dark 
for 30 hrs.  Et2O (20 mL) was then added and the mixture was decanted followed by 
rinsing with Et2O (2 × 20 mL).  The combined organic layers were washed with H2O, 
dried (MgSO4), filtered, concentrated, and chromatographed (CHCl3:hexanes, 1:1) to 
give 130 mg of (±)-threo-m-nitro-N-benzyl-4-iodo-MP as a yellow oil (69%).  Rf = 0.21 
(CHCl3:hexanes, 1:1).  
1H NMR (CDCl3, 400 MHz): δ 8.18 (s, 1H), 8.10 (d, 1H, 
J = 8.1 Hz), 7.65–7.60 (m, 3H), 7.47 (t, 1H, J = 7.9 Hz), 7.16 (d, 2H, J = 8.4 Hz), 4.13 (d, 
1H, J = 11.6 Hz), 4.05 (d, 1H, J = 14.3 Hz), 3.86 (d, 1H, J = 14.3 Hz), 3.72 (s, 3H), 3.48–
3.44 (m, 1H), 3.03–2.96 (m, 1H), 2.54–2.51(m, 1H), 1.60–1.50 (m, 4H), 1.37–1.34 (m, 
1H), 1.10–1.06 (m, 1H).  13C NMR (CDCl3, 100 MHz): δ 173.6, 148.4, 142.7, 137.8, 
136.4, 134.5, 130.7, 128.9, 123.3, 122.0, 93.2, 62.7, 56.0, 52.4, 52.1, 44.9, 21.2, 20.5, 
19.5.  HRMS calcd for C21H23IN2O4Na
+ 517.0594, found 517.0594.  (±)-threo-m-Nitro-
N-benzyl-4-iodo-MP (100 mg, 0.2 mmol) was added to MeOH (5 mL) at 0 ˚C followed 
by concentrated HCl (1 mL) and SnCl2 (150 mg, 0.78 mmol).  The mixture was allowed 
to stir at room temperature overnight then quenched with H2O (5 mL). The pH was then 
adjusted to 11 with 1 M aq. NaOH and the mixture was extracted with EtOAc.  The 
organic layer was washed with brine, dried (MgSO4), filtered, concentrated, and 
chromatographed (CHCl3:MeOH, 9:1) to give 90 mg of (±)-threo-m-amino-N-benzyl-4-
iodo-MP as a colorless oil (81%).  Rf = 0.29 (CHCl3:MeOH, 9:1).  
1H NMR (CDCl3, 
400 MHz): δ 7.63 (d, 2H, J = 8.4 Hz), 7.15 (d, 2H, J = 8.4 Hz), 7.09 (t, 1H, J = 7.7 Hz), 
6.68–6.65 (m, 2H), 6.56 (d, 1H, J = 7.8 Hz), 4.10 (d, 1H, J = 11.4 Hz), 3.82 (d, 1H, 
J = 13.5 Hz), 3.69 (d, 1H, J = 13.4 Hz), 3.66 (s, 3H), 3.48–3.40 (m, 1H), 2.97–2.91 (m, 
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1H), 2.57–2.52 (m, 1H), 1.54–1.42 (m, 4H), 1.32–1.29 (m, 1H), 1.05–1.02 (m, 1H).  13C 
NMR (CDCl3, 100 MHz): δ 173.6, 146.3, 141.4, 137.7, 136.8, 130.8, 128.9, 118.9, 115.4, 
113.7, 93.0, 62.5, 56.4, 52.7, 51.9, 45.1, 21.3, 20.9, 19.6.  HRMS calcd for 
C21H25IN2O2Na
+ 487.0852, found 487.0859.  A solution of (±)-threo-m-amino-N-benzyl-
4-iodo-MP (62 mg, 0.13 mmol) in concentrated HCl (0.5 mL) and H2O (5 mL) at 0 ˚C 
was treated with NaNO2 (10 mg, 0.15 mmol).  The mixture was stirred in the dark for 
10 minutes at 0 ˚C then carefully treated with NaN3 (18 mg, 0.27 mmol).  The reaction 
was allowed to stir in the dark for 2 hrs at 0 ˚C then diluted with H2O and CHCl3.  The 
organic layer was separated, washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (100% CHCl3) to give 65 mg of azide (±)-4.25 as a yellow oil 
(85%).  Rf = 0.30 (100% CHCl3).  
1H NMR (CDCl3, 400 MHz): δ 7.63 (d, 2H, 
J = 8.4 Hz), 7.29–7.25 (m, 1H), 7.14 (d, 2H, J = 8.4 Hz), 7.05–7.01 (m, 2H), 6.89 (d, 1H, 
J = 7.9 Hz), 4.11 (d, 1H, J = 11.5 Hz), 3.91 (d, 1H, J = 13.8 Hz), 3.76 (d, 1H, 
J = 13.8 Hz), 3.68 (s, 3H), 3.45–3.41 (m, 1H), 2.99–2.93 (m, 1H), 2.55–2.50 (m, 1H), 
1.64–1.48 (m, 4H), 1.33–1.25 (m, 1H), 1.06–1.03 (m, 1H).  13C NMR (CDCl3, 
100 MHz): δ 173.3, 142.4, 139.9, 137.7, 136.6, 130.7, 129.3, 125.1, 119.0, 117.6, 93.1, 
62.5, 56.3, 52.5, 52.0, 44.9, 21.1, 20.6, 19.5.  HRMS calcd for C21H23IN4O2H
+ 491.0938, 
found 491.0940.  IR: azide, 2109 cm−1. 
 
(±)-threo-p-Azido-N-benzyl-4-iodo-MP ((±)-4.26) 
 160 
(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31) (110 mg, 0.27 mmol) was added to a 
suspension of K2CO3 (150 mg, 1.08 mmol) in DMF (6 mL).  The resulting suspension 
was stirred at room temperature for 10 minutes then p-azido-N-benzyl bromide (5.3; 
Mornet et al., 1984) (60 mg, 0.29 mmol) was added and the mixture was allowed to stir 
at room temperature in the dark for 30 hrs.  Et2O (20 mL) was then added and the mixture 
was decanted followed by rinsing with Et2O (2 × 20 mL).  The combined organic layers 
were washed with H2O, dried (MgSO4), filtered, concentrated, and chromatographed 
(EtOAc:hexanes, 5:95) to give 90 mg of tertiary amine (±)-4.26 as a yellow solid (67%).  
Rf = 0.26 (EtOAc:hexanes, 5:95).  
1H NMR (CDCl3, 400 MHz): δ 7.64 (d, 2H, 
J = 8.3 Hz), 7.27 (d, 2H, J = 8.3 Hz), 7.14 (d, 2H, J = 8.4 Hz), 6.97 (d, 2H, J = 8.4 Hz), 
4.11 (d, 1H, J = 11.5 Hz), 3.89 (d, 1H, J = 13.6 Hz), 3.74 (d, 1H, J = 13.6 Hz), 3.65 (s, 
3H), 3.45–3.41 (m, 1H), 2.97–2.91 (m, 1H), 2.55–2.50 (m, 1H), 1.58–1.47 (m, 4H), 1.33–
1.25 (m, 1H), 1.06–1.02 (m, 1H).  13C NMR (CDCl3, 100 MHz): δ 173.5, 138.4, 137.7, 
137.1, 136.6, 130.7, 129.9, 118.7, 93.1, 62.3, 55.9, 52.6, 51.9, 44.8, 21.1, 20.7, 19.5.  
HRMS calcd for C21H23IN4O2H
+ 491.0938, found 491.0930.  Anal. Calcd for: 
C21H23IN4O2: C, 51.44; H 4.73; N, 11.43; I, 25.88.  Found: C, 51.72; H 4.67; N, 11.48; I, 
25.62.  MPt: 108–110 ˚C.  IR: azide, 2109 cm−1. 
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(±)-threo-o-Azido-N-benzyl-3-iodo-MP ((±)-4.27) 
(±)-threo-3-Iodo-MP hydrochloride ((±)-4.18, Lapinsky et al., 2011) (100 mg, 
0.27 mmol) was added to a suspension of K2CO3 (150 mg, 1.08 mmol) in DMF (5 mL).  
The mixture was stirred at room temperature for 10 min then o-azido-N-benzyl bromide 
(5.1; Mornet et al., 1984) (58 mg, 0.27 mmol) was added.  The reaction was allowed to 
stir at room temperature in the dark for 30 hrs.  Et2O (20 mL) was then added and the 
mixture was decanted followed by rinsing with Et2O (2 × 20 mL).  The combined organic 
layers were washed with H2O, dried (MgSO4), filtered, concentrated, and 
chromatographed (CH2Cl2:hexanes, 1:1) to give 67 mg of tertiary amine (±)-4.27 as a 
yellow oil (51%).  Rf = 0.23 (CH2Cl2:hexanes, 7:3).  
1H NMR (CDCl3, 400 MHz): δ 7.74 
(t, 1H, J = 1.7 Hz), 7.59 (d, 1H, J = 7.9 Hz), 7.39 (t, 2H, J = 8.3 Hz), 7.32–7.27 (m, 1H), 
7.14–7.09 (m, 2H), 7.03 (t, 1H, J = 7.8 Hz), 4.07 (d, 1H, J = 11.5 Hz), 3.93 (d, 1H, 
J = 14.5 Hz), 3.67 (d, 1H, J = 14.5 Hz), 3.60 (s, 3H), 3.44–3.40 (m, 1H), 2.99–2.92 (m, 
1H), 2.57–2.51 (m, 1H), 1.58–1.52 (m, 4H), 1.39–1.33 (m, 1H), 1.07–1.03 (m, 1H).  13C 
NMR (CDCl3, 100 MHz): δ 173.3, 139.3, 137.9, 137.6, 136.5, 131.5, 130.3, 128.0, 127.9, 
124.6, 117.8, 94.5, 62.5, 52.6, 51.9, 50.7, 45.4, 21.3, 20.7, 19.8.  HRMS calcd for 
C21H23IN4O2H
+ 491.0938, found 491.0932.  IR: azide, 2115 cm−1. 
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 (±)-threo-m-Azido-N-benzyl-3-iodo-MP ((±)-4.28) 
(±)-threo-3-Iodo-MP hydrochloride ((±)-4.18, Lapinsky et al., 2011) (300 mg, 
0.76 mmol) was added to a suspension of K2CO3 (250 mg, 1.8 mmol) in DMF (5 mL).  
The mixture was stirred at room temperature for 10 minutes then m-nitro-N-benzyl 
bromide (5.22) (160 mg, 0.76 mmol) was added.  The reaction was allowed to stir at 
room temperature in the dark for 30 hrs.  Et2O (20 mL) was then added and the mixture 
was decanted followed by rinsing with Et2O (2 × 20 mL).  The combined organic layers 
were washed with H2O, dried (MgSO4), filtered, concentrated, and chromatographed 
(CHCl3:hexanes, 1:1) to give 260 mg of (±)-threo-m-nitro-N-benzyl-3-iodo-MP as a 
yellow oil (70%).  Rf = 0.31 (CHCl3:hexanes, 1:1).  
1H NMR (CDCl3, 400 MHz): δ 8.18 
(s, 1H), 8.10 (d, 1H, J = 8.1 Hz), 7.76 (s, 1H), 7.60 (d, 2H, J = 7.9 Hz), 7.47 (t, 1H, 
J = 7.9 Hz), 7.37 (d, 1H, J = 7.8 Hz), 7.06 (t, 1H, J = 7.8 Hz), 4.10 (d, 1H, J = 11.6 Hz), 
4.05 (d, 1H, J = 14.3 Hz), 3.86 (d, 1H, J = 14.3 Hz), 3.72 (s, 3H), 3.48–3.45 (m, 1H), 
3.01–2.96 (m, 1H), 2.54–2.50 (m, 1H), 1.61–1.52 (m, 4H), 1.38–1.34 (m, 1H), 1.10–1.07 
(m, 1H).  13C NMR (CDCl3, 100 MHz): δ 173.4, 148.3, 142.6, 138.9, 137.4, 136.7, 134.4, 
130.4, 128.9, 127.9, 123.2, 122.0, 94.6, 62.8, 56.0, 52.4, 52.1, 44.7, 21.2, 20.5, 19.4.  
HRMS calcd for C21H23IN2O4H
+ 495.0775, found 495.0780.  (±)-threo-m-Nitro-N-
benzyl-3-iodo-MP (260 mg, 0.53 mmol) was added to MeOH (5 mL) at 0 ˚C then treated 
with concentrated HCl (2 mL) and SnCl2 (390 mg, 2.05 mmol).  The mixture was 
allowed to stir at room temperature overnight then quenched with H2O (5 mL).  The pH 
was adjusted to 11 with 1 M aq. NaOH and then the mixture was extracted with EtOAc.  
The organic layers were washed with brine, dried (MgSO4), filtered, concentrated, and 
chromatographed (CHCl3:MeOH, 95:5) to give 200 mg of (±)-threo-m-amino-N-benzyl-
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3-iodo-MP as a colorless oil (81%).  Rf = 0.27 (CHCl3:MeOH, 95:5).  
1H NMR (CDCl3, 
400 MHz): δ 7.75 (s, 1H), 7.59 (d, 1H, J = 8.5 Hz), 7.37 (d, 1H, J = 7.8 Hz), 7.09–7.02 
(m, 2H), 6.68–6.65 (m, 2H), 6.56 (d, 1H, J = 7.9 Hz), 4.08 (d, 1H, J = 11.4 Hz), 3.82 (d, 
1H, J = 13.6 Hz), 3.69 (d, 1H, J = 13.7 Hz), 3.66 (s, 3H), 3.48–3.42 (m, 1H), 2.97–2.90 
(m, 1H), 2.57–2.52 (m, 1H), 1.56–1.46 (m, 4H), 1.33–1.28 (m, 1H), 1.06–1.02 (m, 1H).  
13C NMR (CDCl3, 100 MHz): δ 173.4, 146.3, 141.3, 139.2, 137.5, 136.4, 130.2, 128.8, 
127.9, 118.7, 115.2, 113.5, 94.5, 62.5, 56.3, 52.6, 51.0, 44.8, 21.2, 20.8, 19.5.  HRMS 
calcd for C21H25IN2O2H
+ 465.1033, found 465.1026.  A solution of (±)-threo-m-amino-
N-benzyl-3-iodo-MP (180 mg, 0.39 mmol) in 2 N HCl (6 mL) at 0 ˚C was treated with 
NaNO2 (30 mg, 0.43 mmol).  The mixture was stirred in the dark for 10 minutes at 0 ˚C, 
carefully treated with NaN3 (50 mg, 0.78 mmol), stirred in the dark at 0 ˚C for 2 h, then 
diluted with H2O and CHCl3.  The organic layer was separated, washed with brine, dried 
(MgSO4), filtered, concentrated, and chromatographed (100% CHCl3) to give 160 mg of 
azide (±)-4.28 as a yellow oil (95%).  Rf = 0.35 (100% CHCl3).  
1H NMR (CDCl3, 
400 MHz): δ 7.75 (s, 1H), 7.59 (d, 1H, J = 8.4 Hz), 7.37 (d, 1H, J = 7.9 Hz), 7.29–7.25 
(m, 1H), 7.06–7.01 (m, 3H), 6.89 (d, 1H, J = 7.9 Hz), 4.08 (d, 1H, J = 11.5 Hz), 3.93 (d, 
1H, J = 13.8 Hz), 3.76 (d, 1H, J = 13.8 Hz), 3.68 (s, 3H), 3.46–3.41 (m, 1H), 2.98–2.92 
(m, 1H), 2.55–2.50 (m, 1H), 1.64–1.48 (m, 4H), 1.35–1.31 (m, 1H), 1.07–1.03 (m, 1H).  
13C NMR (CDCl3, 100 MHz): δ 173.3, 142.4, 139.9, 139.1, 137.5, 136.6, 130.3, 129.3, 
127.9, 125.0, 118.9, 117.5, 94.5, 62.5, 56.2, 52.5, 52.0, 44.7, 21.1, 20.6, 19.4.  HRMS 
calcd for C21H23IN4O2Na
+ 513.0757, found 513.0763.  IR: azide, 2113 cm−1. 
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(±)-threo-p-Azido-N-benzyl-3-iodo-MP ((±)-4.29) 
(±)-threo-3-Iodo-MP hydrochloride ((±)-4.18, Lapinsky et al., 2011) (140 mg, 
0.35 mmol) was added to a suspension of K2CO3 (190 mg, 1.43 mmol) in DMF (7 mL).  
The mixture was stirred at room temperature for 10 minutes then p-azido-N-benzyl 
bromide (5.3; Mornet et al., 1984) (80 mg, 0.39 mmol) was added.  The reaction was 
allowed to stir at room temperature in the dark for 30 hrs.  Et2O (20 mL) was then added 
and the mixture was decanted followed by rinsing with Et2O (2 × 20 mL).  The combined 
organic layers were washed with H2O, dried (MgSO4), filtered, concentrated, and 
chromatographed (EtOAc:hexanes, 5:95) to give 110 mg of tertiary amine (±)-4.29 as a 
yellow gum (65%).  Rf = 0.23 (EtOAc:hexanes, 5:95).  
1H NMR (CDCl3, 400 MHz): δ 
7.74 (s, 1H), 7.60 (d, 1H, J = 7.9 Hz), 7.36 (d, 1H, J = 7.8 Hz), 7.26 (d, 2H, J = 8.6 Hz), 
7.05 (t, 1H, J = 7.8 Hz), 6.97 (d, 2H, J = 8.4 Hz), 4.08 (d, 1H, J = 11.5 Hz), 3.89 (d, 1H, 
J = 13.6 Hz), 3.74 (d, 1H, J = 13.6 Hz), 3.66 (s, 3H), 3.46–3.42 (m, 1H), 2.97–2.90 (m, 
1H), 2.53–2.49 (m, 1H), 1.58–1.48 (m, 5H), 1.07–1.03 (m, 1H).  13C NMR (CDCl3, 
100 MHz): δ 173.4, 139.2, 138.4, 137.0, 136.6, 130.3, 129.9, 128.0, 118.7, 94.5, 62.5, 
55.9, 52.5, 51.9, 44.6, 21.1, 20.6, 19.4.  HRMS calcd for C21H23IN4O2H
+ 491.0938, found 
491.0945.  IR: azide, 2111 cm−1. 
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(±)-threo-p-Azido-N-benzyl-4-(tri-n-butylstannyl)-MP ((±)-5.23) 
A mixture of (±)-threo-p-azido-N-benzyl-4-iodo-MP ((±)-4.26) (105 mg, 0.21 mmol), 
Pd(PPh3)2Br2 (10 mg, 0.02 mmol), and bis(tri-n-butyltin) (0.15 mL, 0.39 mmol) in 
toluene (10 mL) was heated at 105 ˚C for 6 hrs.  The mixture was then cooled to room 
temperature, diluted with saturated aq. K2CO3 solution, and then extracted with EtOAc.  
The organic phase was washed with brine, dried (MgSO4), filtered, concentrated, and 
chromatographed (EtOAc:hexanes, 1:9) to give 49 mg of organostannane (±)-5.23 as a 
colorless oil (41%).  Rf = 0.35 (EtOAc/hexanes, 1:9).  
1H NMR (CDCl3, 400 MHz): δ 
7.39 (d, 2H, J = 7.9 Hz), 7.32 (d, 2H, J = 7.9 Hz), 7.28 (d, 2H, J = 8.4 Hz), 6.97 (d, 2H, 
J = 8.4 Hz), 4.11 (d, 1H, J = 11.5 Hz), 3.90 (d, 1H, J = 13.6 Hz), 3.76 (d, 1H, 
J = 13.6 Hz), 3.65 (s, 3H), 3.49–3.45 (m, 1H), 2.99–2.94 (m, 1H), 2.54–2.51 (m, 1H), 
1.56–1.49 (m, 9H), 1.34–1.29 (m, 9H), 1.03 (t, 6H, J = 8.0 Hz), 0.88 (t, 9H, J = 7.3 Hz).  
13C NMR (CDCl3, 100 MHz): δ 174.1, 141.0, 138.3, 137.3, 136.7, 136.4, 129.9, 128.2, 
118.7, 62.5, 55.8, 53.1, 51.8, 44.8, 29.0, 27.4, 21.1, 20.8, 19.5, 13.7, 9.5.  HRMS calcd 
for C33H50N4O2SnH
+ 655.3029, found 655.3033.  IR: azide, 2110 cm−1. 
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 (±)-threo-p-Azido-N-benzyl-4-iodo-ritalinol ((±)-4.33) 
A mixture of (±)-threo-4-iodo-β-lactam (±)-5.4 (200 mg, 0.62 mmol) and 6N HCl (5 mL) 
was stirred at room temperature for 12 hrs.  The reaction mixture was then concentrated 
under reduced pressure to afford 235 mg of (±)-threo-4-iodo-ritalinic acid ((±)-3.30) as a 
white solid (99%).  1H NMR data was comparable to that previously described (Pan et 
al., 1996).  (±)-threo-4-iodo-ritalinic acid ((±)-3.30) (180 mg, 0.52 mmol) was added to 
BH3•THF (1.4 mL, 2.68 mmol) in THF (5 mL) at 0 ˚C, and then the mixture was allowed 
to stir at room temperature overnight.  The reaction mixture was treated with MeOH and 
concentrated under reduced pressure.  The crude mixture was then dissolved in Et2O and 
washed with 1M aq. NaOH to afford 70 mg of (±)-threo-4-iodo-ritalinol ((±)-5.25) as oil 
(43%), which was used further without any purification.  Rf = 0.2 (CHCl3:MeOH, 1:1).  
1H NMR (CD3OD, 400MHz): δ 7.62 (d, 2H, J = 8.3 Hz), 6.99 (d, 2H, J = 8.3 Hz), 3.89-
3.85 (m, 1H), 3.80-3.76 (m, 1H), 3.03 (d, 1H, J = 12.3 Hz), 2.85 (td, 1H, J = 10.9, 2.2 
Hz), 2.70-2.60 (m, 2H), 1.69-1.65 (m, 1H), 1.56-1.52 (m, 1H), 1.40 (s, 1H), 1.36-1.26 (m, 
3H), 1.01-0.91 (m, 1H).  A mixture of (±)-threo-4-iodo-ritalinol ((±)-5.25) (70 mg, 0.2 
mmol), p-azido-N-benzyl bromide (5.3; Mornet et al., 1984) (40 mg, 0.2 mmol) and 
K2CO3 (50 mg, 0.4 mmol) in DMF (3 mL) was stirred at room temperature under argon 
for 3 hrs.  The mixture was then diluted with H2O and extracted with Et2O (2 × 10 mL).  
The combined organic layers were washed with brine, dried (MgSO4), filtered, 
concentrated, and chromatographed (EtOAc:hexanes, 2:8) to give 40 mg of tertiary amine 
(±)-4.33 as an oil (50%).  Rf = 0.24 (EtOAc:hexanes, 2:8).  
1H NMR (CDCl3, 400 MHz): 
δ 7.59 (d, 2H, J = 8.3 Hz), 7.35 (d, 2H, J = 8.4 Hz), 7.04 (d, 2H, J = 8.4 Hz,), 6.79 (d, 2H, 
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J = 8.3 Hz), 6.65 (br s, 1H), 3.94 (s, 2H), 3.72 (t, 1H, J = 10.1 Hz), 3.63 (dd, 1H, J = 10.8 
Hz, 3.5 Hz), 3.40 (td, 1H, J = 10.0, 3.4 Hz), 3.22 (td, 1H, J = 11.6, 3.0 Hz), 3.10 (d, 1H, J 
= 11.6 Hz), 2.72 (d, 1H, J = 14.4 Hz), 1.73-1.49 (m, 4H), 1.35 (d, 1H, J = 13.6 Hz), 0.93 
(d, 1H, J = 13.2 Hz).  13C NMR (CDCl3, 100 MHz): δ 140.4, 139.3, 137.8, 135.1, 130.5, 
129.8, 119.3, 91.9, 69.7, 62.7, 56.6, 45.5, 44.6, 20.6, 19.9, 18.6.  HRMS calcd for 
C20H23IN4ONa
+ 485.0808, found 485.0807. 
 
 
 
(±)-threo-3-Iodo-4-azido-N-benzyl-MP ((±)-4.35) 
A mixture of (±)-threo-MP ((±)-1.10, provided by retired Professor Howard M. Deutsch 
(Georgia Tech)) (140 mg, 0.51 mmol), 3-iodo-4-azido benzyl chloride (5.32, Murray et 
al., 2005) (220 mg, 0.76 mmol), and K2CO3 (170 mg, 1.21 mmol) in DMF (5 mL) was 
stirred at room temperature for 36 hrs.  The mixture was then diluted with H2O and 
extracted with EtOAc (2 × 20 mL).  The combined organic layers were washed with 
brine, dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 
5:95) to give 69 mg of tertiary amine (±)-4.35 as a yellow solid (28%).  Rf = 0.20 
(EtOAc:hexanes, 5:95).  1H NMR (CDCl3, 400 MHz): δ 7.74 (d, 1H, J = 1.8 Hz), 7.40-
7.38 (m, 2H), 7.33-7.25 (m, 4H), 7.06 (d, 1H, J = 8.1 Hz,), 4.14 (d, 1H, J = 11.6 Hz), 
3.87 (d, 1H, J = 13.9 Hz), 3.73-3.70 (m, 1H), 3.69 (s, 3H), 3.49-3.45 (m, 1H), 3.01-2.95 
(m, 1H), 2.54-2.48 (m, 1H), 1.64-1.47 (m, 4H), 1.35-1.25 (m, 1H), 1.08-1.04 (m, 1H).  
13C NMR (CDCl3, 100 MHz): δ 174.0, 140.0, 139.9, 139.2, 136.8, 129.6, 128.7, 128.6, 
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127.5, 117.9, 87.6, 62.7, 55.3, 53.0, 52.0, 44.8, 21.1, 20.6, 19.4.  HRMS calcd for 
C21H23IN4O2H
+ 491.0938, found 491.0938.  Anal calcd for C21H23IN4O2: C, 51.44; H, 
4.73; N, 11.43; I, 25.88.  Found: C, 51.48; H, 4.73; N, 11.17; I, 25.65.  MPt: 147-148 ˚C. 
 
 
(R,R)-3-Iodo-4-azido-N-benzyl-MP ((-)-4.35) 
A mixture of enantiopure (R,R)-MP hydrochloride ((+)-1.10, Deutsch et al., 1996, 
provided by retired Professor Howard M. Deutsch (Georgia Tech)) (90 mg, 0.33 mmol), 
3-iodo-4-azido benzyl chloride (5.32, Murray et al., 2005) (150 mg, 0.5 mmol), and 
K2CO3 (110 mg, 0.8 mmol) in DMF (3 mL) was stirred at room temperature for 48 hrs.  
The mixture was then diluted with H2O and extracted with EtOAc (2 × 20 mL).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (DCM:hexanes, 7:3) to give 30 mg of tertiary amine (-)-4.35  as an 
oil (19%).  Rf = 0.10 (DCM:hexanes, 7:3).  
1H NMR (CDCl3, 400 MHz): δ 7.74 (d, 1H, J 
= 1.8 Hz), 7.40-7.38 (m, 2H), 7.33-7.25 (m, 4H), 7.06 (d, 1H, J = 8.1 Hz), 4.14 (d, 1H, J 
= 11.6 Hz,), 3.87 (d, 1H, J = 13.9 Hz), 3.73-3.72 (m, 1H), 3.70 (s, 3H), 3.49-3.44 (m, 
1H), 3.01-2.94 (m, 1H), 2.54-2.49 (m, 1H), 1.59-1.46 (m, 4H), 1.35-1.32 (m, 1H), 1.08-
1.04 (m, 1H).  13C NMR (CDCl3, 100 MHz): δ 174.0, 140.0, 139.9, 139.2, 136.7, 129.6, 
128.7, 128.6, 127.5, 117.9, 87.6, 62.7, 55.3, 53.0, 52.0, 44.8, 21.1, 20.6, 19.4.  HRMS 
calcd for C21H23IN4O2Na
+ 513.0757, found 513.0765.  IR: azide, 2115 cm-1.  [α]D21.8 = -
34.25˚, c = 0.94 (CHCl3). 
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(±)-threo-3-Iodo-4-azido-N-benzyl-ritalinol ((±)-4.36) 
A mixture of (±)-threo-ritalinol ((±)-5.27, Kim et al., 2007) (120 mg, 0.58 mmol), 3-
iodo-4-azido benzyl chloride (5.32, Murray et al., 2005) (260 mg, 0.87 mmol), and 
K2CO3 (160 mg, 1.17 mmol) in DMF (6 mL) was stirred at room temperature for 12 hrs.  
The mixture was then diluted with H2O and extracted with Et2O (2 × 20 mL).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (EtOAc:hexanes, 2:8) to give 50 mg of tertiary amine (±)-4.36 as a 
yellow oil (19%).  Rf = 0.24 (EtOAc:hexanes, 2:8).  
1H NMR (CDCl3, 500 MHz): δ 7.74 
(d, 1H, J = 2 Hz), 7.46 (d, 1H, J = 8.1 Hz), 7.29-7.26 (m, 2H), 7.22-1.19 (m, 1H), 7.15 (d, 
1H, J = 8.2 Hz), 7.05 (d, 2H, J = 7.1 Hz), 6.36 (br s, 1H), 3.92 (s, 2H), 3.84 (t, 1H, J = 
10.1 Hz), 3.71 (dd, 1H, J = 10.9 Hz, 3.6 Hz), 3.46 (td, 1H, J = 9.9 Hz, 3.4 Hz), 3.27 (t, 
1H, J = 12.0 Hz), 3.14 (d, 1H, J = 11.1 Hz), 2.71 (d, 1H, J = 14.6 Hz), 1.70-1.58 (m, 3H), 
1.49-1.47 (m, 1H), 1.37 (d, 1H, J = 12.3 Hz), 0.98-0.96 (m, 1H).  13C NMR (CDCl3, 100 
MHz): δ 140.8, 140.5, 140.3, 137.1, 130.1, 128.7, 127.8, 126.7, 118.5, 87.6, 69.8, 63.1, 
55.7, 45.4, 45.0, 20.5, 19.9, 18.9.  HRMS calcd for C20H23IN4OH
+ 463.0989, found 
463.0989.  
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(R,R)-Ritalinol (5.27) 
(R,R)-MP hydrochloride ((+)-1.10, provided by retired Professor Howard M. Deutsch 
(Georgia Tech)) (1 g, 3.71 mmol) was treated with 1M aq. NaOH to provide 800 mg of 
the free base form of 5.38  (72 %).  To a solution of 5.38 (800 mg, 3.43 mmol) in Et2O (7 
mL) was added 1.0 M lithium aluminum hydride in Et2O (2.2 mL, 2.2 mmol) at 0 ˚C.  
The mixture was stirred from 0 ˚C to room temperature for 3 hrs.  The reaction mixture 
was then diluted with H2O slowly and extracted with Et2O (2 X 10 mL).  The combined 
organic layers were washed with brine, dried (MgSO4), filtered, and concentrated to give 
650 mg of (R,R)-alcohol 5.27 (93%).  1H NMR data proved identical to that previously 
reported (Prashad et al., 1999b). 
 
 
 
(R,R)-3-Iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) 
A mixture of (R,R)-ritalinol (5.27) (270 mg, 1.31 mmol), 3-iodo-4-azido benzyl chloride 
(5.32, Murray et al., 2005) (310 mg, 1.04 mmol), and K2CO3 (724 mg, 5.24 mmol) in 
DMF (6 mL) was stirred at room temperature for 12 hrs.  The mixture was then diluted 
with H2O and extracted with Et2O (2 × 20 mL).  The combined organic layers were 
washed with brine, dried (MgSO4), filtered, concentrated, and chromatographed 
(EtOAc:hexanes, 2:8) to give 150 mg of tertiary amine (-)-4.36 as an oil (46 %).  Rf = 
0.24 (EtOAc:hexanes, 2:8).  1H NMR (CDCl3, 400 MHz): δ 7.73 (d, 1H, J = 1.9 Hz), 7.46 
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(dd, 1H, J = 8.2, 1.9 Hz), 7.29-7.26 (m, 2H), 7.22-7.19 (m, 1H), 7.15 (d, 1H, J = 8.2 Hz), 
7.05 (d, 2H, J = 8.3 Hz), 6.46 (br s, 1H), 3.92 (s, 2H), 3.84 (t, 1H, J = 10.0 Hz), 3.70 (dd, 
1H, J = 10.8 Hz, 3.6 Hz), 3.46 (td, 1H, J = 10.0, 3.4 Hz), 3.27 (t, 1H, J = 12.0 Hz,), 3.14 
(d, 1H, J = 10.9 Hz,), 2.71 (d, 1H, J = 14.9 Hz,), 1.71-1.55 (m, 3H), 1.49-1.47 (m, 1H), 
1.37 (d, 1H, J = 12.8 Hz), 0.98-0.96 (m, 1H).  13C NMR (CDCl3, 100 MHz): δ 140.9, 
140.6, 140.4, 137.2, 130.2, 128.8, 127.9, 126.9, 118.7, 87.7, 69.9, 63.2, 55.9, 45.5, 45.2, 
20.7, 20.0, 18.9.  HRMS calcd for C20H23IN4OH
+ 463.0989, found 463.0999.  IR azide 
2114.9 cm-1.  [α]D 21.7 = -58.63˚, c = 5.168 (MeOH). 
 
 
 
(R,R)-3-Iodo-4-azido-N-benzyl-ritalinol oxalate (5.39)  
A mixture of (R,R)-3-iodo-4-azido-N-benzyl-ritalinol (-)-4.36 (150 mg, 0.32 mmol) and 
oxalic acid (30 mg, 0.32 mmol) in EtOAc (4 mL) was refluxed for 1 hr.  The mixture was 
then cooled to room temperature and concentrated to provide a white foam/solid, which 
was washed with Et2O to provide 60 mg of oxalate salt 5.39 (34%).  
1H NMR (CD3OD, 
400 MHz): δ 8.06 (d, 1H, J = 1.8 Hz), 7.66 (dd, 1H, J = 8.3, 1.8 Hz), 7.36-7.29 (m, 4H), 
7.20 (d, 2H, J = 7.0 Hz,), 4.65 (d, 1H, J = 13.1 Hz), 4.53 (d, 1H, J = 13.2 Hz,), 4.00 (t, 
1H, J = 10.5 Hz), 3.87-3.83 (m, 2H), 3.63 (td, 1H, J = 10.4, 3.5 Hz), 3.43-3.40 (m, 1H), 
3.17-3.11 (m, 1H), 1.85-1.70 (m, 4H), 1.53-1.42 (m, 2H).  Anal Calcd for C22H25IN405: 
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C, 47.84; H, 4.56; N, 10.14; I, 22.97.  Found: C, 48.17; H, 4. 62; N, 9.92; I, 22.59.  IR: 
azide, 2070 cm-1.  MPt: 90-92 ˚C. 
 
 
(R,R)-3-(tri-n-Butylstannyl)-4-azido-N-benzyl-ritalinol ((-)-5.40) 
A mixture of (R,R)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) (93 mg, 0.2 mmol), 
Pd(PPh3)2Br2 (10 mg, 0.02 mmol), bis(tributytin) (140 µL, 0.36 mmol) in toluene (10 
mL) was heated at 105 ˚C for 6 hrs.  The mixture was then cooled to room temperature, 
diluted with saturated aq. K2CO3 solution, then extracted with EtOAc (2 × 20 mL).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (EtOAc:hexanes, 2:8) to give 50 mg of organostannane (-)-5.40 as 
a colorless oil (40%).  Rf = 0.25 (EtOAc:hexanes, 2:8).  
1H NMR (CDCl3, 400 MHz): δ 
7.40 (dd, 1H, J = 8.1, 2.0 Hz), 7.34 (d, 1H, J = 2.0 Hz), 7.27-7.15 (m, 4H), 7.22-7.02 (d, 
2H, J = 6.9 Hz), 6.71 (br s, 1H), 3.94 (d, 2H, J = 3.8 Hz), 3.77 (t, 1H, J = 10.3 Hz), 3.65 
(dd, 1H, J = 10.7, 3.3 Hz), 3. 46 (td, 1H, J = 10.3, 3.3 Hz), 3.28 (t, 1H, J = 11.5 Hz), 3.17 
(d, 1H, J = 11.4 Hz), 2.74 (d, 1H, J = 14.6 Hz,), 1.56-1.51 (m, 8H), 1.35-1.30 (m, 8H), 
1.13-1.09 (m, 6H), 0.87 (t, 11H, J = 7.3 Hz).  13C NMR (CDCl3, 100 MHz): δ 145.1, 
141.0, 138.3, 134.6, 134.4, 130.6, 128.7, 127.8, 126.7, 117.3, 70.0, 62.7, 56.7, 45.5, 45.0, 
29.1, 27.3, 20.5, 20.0, 19.0, 13.7, 10.1.  HRMS calcd for C32H50N4OSnH
+ 627.3079, 
found 627.3084.  IR: azide, 2108 cm-1.  [α]D 21.7 = -55.69˚, c = 1.57 (CHCl3). 
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(±)-threo-3-Iodo-4-azido-N-benzyl-3,4-dichloro-MP ((±)-4.37) 
A mixture of (±)-threo-3,4-dichloro-MP hydrochloride ((±)-3.53, Deutsch et al., 1996, 
provided by retired Professor Howard M. Deutsch (Georgia Tech)) (130 mg, 0.38 mmol), 
3-iodo-4-azido benzyl chloride (5.32, Murray et al., 2005) (190 mg, 0.57 mmol), and 
K2CO3 (120 mg, 0.90 mmol) in DMF (8 mL) was stirred at room temperature for 24 hrs.  
The mixture was then diluted with H2O and extracted with Et2O (2 × 20 mL).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (CHCl3:hexanes, 2:8) to provide 50 mg of tertiary amine (±)-4.37) 
as a colorless oil (24%).  Rf = 0.20 (CHCl3:hexanes, 2:8).  
1H NMR (CDCl3, 500 MHz): δ 
7.71-7.70 (m, 1H), 7.51-7.50 (m, 1H), 7.4-7.38 (m, 1H), 7.28-7.22 (m, 2H), 7.06 (d, 1H, J 
= 8.1 Hz), 4.11 (d, 1H, J = 11.6 Hz), 3.85 (d, 1H, J = 13.9 Hz), 3.71 (s, 3H), 3.68-3.65 
(m, 1H), 3.40-3.38 (m, 1H), 2.96-2.91 (m, 1H), 2.52-2.49 (d, 1H, J = 14.2 Hz,), 1.54-1.52 
(m, 4H), 1.32-1.31 (m, 1H), 1.06-1.04 (m, 1H).  13C NMR (CDCl3, 100 MHz): δ 173.2, 
140.1, 140.0, 139.9, 138.8, 136.9, 132.7, 131.7, 130.6, 129.6, 128.0, 117.9, 87.6, 62.7, 
55.4, 52.3, 52.0, 44.7, 21.1, 20.5, 19.4.  HRMS calcd for C21H21ICl2N4O2H
+ 559.0159, 
found 559.0165. 
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(±)-threo-3-Iodo-4-azido-N-benzyl-3,4-dichloro-ritalinol ((±)-4.38) 
A mixture of (±)-threo-3,4-dichloro-ritalinol ((±)-5.42; Kim et al., 2007) (110 mg, 0.41 
mmol), 3-iodo-4-azido benzyl chloride (5.32; Murray et al., 2005) (180 mg, 0.62 mmol), 
and K2CO3 (130 mg, 1.17 mmol) in DMF (8 mL) was stirred at room temperature for 12 
hrs.  The mixture was then diluted with H2O and extracted with Et2O (2 × 20 mL).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (EtOAc:hexanes, 2:8) to provide 50 mg of tertiary amine (±)-4.38 
as a colorless oil (23%).  Rf = 0.20 (EtOAc:hexanes, 2:8).  
1H NMR (CDCl3, 400 MHz): δ 
7.74 (d, 1H, J = 1.8 Hz), 7.41 (dd, 1H, J = 8.2, 1.8 Hz), 7.35 (d, 1H, J = 8.2 Hz), 7.16 (m, 
2H), 6.90 (dd, 1H, J = 8.2, 2.0 Hz), 6.19 (br s, 1H), 3.92 (s, 2H), 3.77 (t, 1H, J = 10.7 
Hz,), 3.68 (dd, 1H, J = 10.8, 3.6 Hz), 3.41 (td, 1H, J = 9.7, 3.6 Hz), 3.22 (td, 1H, J = 11.9, 
3.0Hz), 3.08 (d, 1H, J = 11.2 Hz), 2.70 (d, 1H, J = 14.6 Hz,), 1.71-1.51 (m, 4H), 1.37 (d, 
1H, J = 13.7 Hz), 0.97 (d, 1H, J = 10.8 Hz).  13C NMR (CDCl3, 100 MHz): δ 141.0, 
140.9, 140.3, 136.9, 132.7, 130.8, 130.7, 130.1, 129.7, 127.2, 118.6, 87.7, 69.2, 62.9, 
55.8, 45.5, 44.6, 20.7, 20.0, 18.8.  HRMS calcd for C20H21Cl2N4OH
+ 531.0209, found 
531.0216.  IR: azide, 2118 cm-1. 
 
 
 
 (4-(3-Bromopropyl)phenyl)(4-iodophenyl)methanone (5.45) 
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AlCl3 (870 mg, 6.5 mmol) was slowly added to a stirring mixture of 4-iodo-benzoyl 
chloride (5.46) (1.73 g, 6.5 mmol) in DCM (6 mL) at 0 ˚C for 10 min.  (3-
Bromopropyl)benzene (3.59) (1.0 g, 5.0 mmol) was then added dropwise at 0 ˚C.  The 
reaction mixture was refluxed overnight, cooled to room temperature, diluted with 
CHCl3, and poured into ice cold concentrated HCl (4 mL).  The organic layer was 
separated, washed with 1M aq. NaOH, brine, dried (MgSO4), filtered, concentrated, and 
chromatographed (EtOAc:hexanes, 1:9) to give 1.3 g of ketone 5.45 as a light yellow 
solid (61%).  Rf = 0.20 (EtOAc:hexanes, 1:9).  
1H NMR (CDCl3, 400 MHz): δ 7.85 (d, 
2H, J = 8.5 Hz), 7.72 (d, 2H, J = 8.3 Hz), 7.51 (d, 2H, J = 8.5 Hz), 7.32 (d, 2H, J = 8.1 
Hz), 3.41 (t, 2H, J = 6.5 Hz), 2.87 (t, 2H, J = 7.5 Hz), 2.22 (quin, 2H, J = 8.0 Hz).  13C 
NMR (CDCl3, 100 MHz): δ 195.5, 146.0, 137.5, 137.0, 135.1, 131.4, 130.4, 128.6, 99.9, 
34.0, 33.7, 32.7.  HRMS calcd for C16H14BrIONa
+ 450.9164, found 450.9162.  MPt: 85-
86 ˚C. 
 
 
 
 
(4-(3-(4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)phenyl)(4-
iodophenyl) methanone (5.44) 
A mixture of 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazine (3.58; Van der zee et 
al., 1980) (200 mg, 0.63 mmol), alkyl bromide 5.45 (300 mg, 0.69 mmol), and K2CO3 
(260 mg, 1.89 mmol) in EtOH (5 mL) was refluxed overnight.  The mixture was then 
cooled to room temperature, diluted with H2O, and extracted with CHCl3 (2 × 20 mL).  
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The combined organic layers were washed with brine, dried (MgSO4), filtered, 
concentrated, and chromatographed (CHCl3:MeOH, 98:2) to give 270 mg of N-
dialkylated piperazine 5.44 as an oil (62%).  Rf = 0.10 (CHCl3:MeOH, 98:2).  
1H NMR 
(CDCl3, 400 MHz): δ 7.82 (d, 2H, J = 8.5 Hz), 7.70 (d, 2H, J = 8.2 Hz), 7.49 (d, 2H, J = 
8.5 Hz), 7.30-7.26 (m, 6H), 6.98 (d, 4H, J = 8.7 Hz), 5.3 (s, 1H), 3.57 (t, 2H, J = 6.0 Hz), 
2.73-2.47 (m, 12H), 2.36 (t, 2H, J = 7.8 Hz), 1.84 (quin, 2H, J = 7.7 Hz).  13C NMR 
(CDCl3, 100 MHz): δ 195.5, 163.3, 160.8, 147.7, 137.8, 137.7, 137.4, 137.0, 134.7, 
131.3, 130.2, 128.6, 128.5, 128.4, 115.3, 115.1, 99.8, 82.4, 66.8, 57.8, 57.7, 53.5, 53.1, 
33.6, 28.2.  HRMS calcd for C35H35F2IN2O2Na
+ 703.1603, found 703.1586. 
 
 
 
 
(4-(3-(4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)phenyl)(4-
ethynyl phenyl) methanone (4.40) 
A mixture of iodo-benzophenone 5.44 (150 mg, 0.22 mmol), Pd (3 mg, 0.02 mmol), 10% 
Pd/C (30 mg, 0.09 mmol), PPh3 (30 mg, 0.09 mmol), CuI (14 mg, 0.06 mmol), NEt3 (1.0 
mL, 7.5 mmol) and trimethylsilyl acetylene (3.67) (40 µL, 0.27 mmol) in CH3CN (4 mL) 
was refluxed for 12 hrs.  The mixture was then cooled to room temperature, diluted with 
EtOAc, and filtered over Celite®.  The organic phase/filtrate was washed with H2O, brine, 
dried (MgSO4), filtered, concentrated, and chromatographed (CHCl3:MeOH, 9.5:0.5) to 
give 120 mg of (4-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-
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yl)propyl)phenyl)(4-((trimethylsilyl)ethynyl) phenyl)methanone as a colorless oil (82 %).  
Rf = 0.2 (CHCl3:MeOH, 9.5:0.5).  
1H NMR (CDCl3, 400 MHz): δ 7.75-7.71 (m, 4H), 
7.57 (d, 2H, J = 8.5 Hz), 7.32-7.27 (m, 6H), 7.00 (d, 4H, J = 8.7 Hz), 5.35 (s, 1H), 3.58 
(t, 2H, J = 6.0 Hz), 2.75-2.48 (m, 12H), 2.38 (t, 2H, J = 7.8 Hz), 1.86 (quin, 2H, J = 7.6 
Hz), 0.29 (s, 9H).  13C NMR (CDCl3, 100 MHz): δ 196.1, 163.8, 161.4, 148.0, 138.3, 
138.2, 137.7, 135.5, 132.2, 130.7, 130.2, 129.1, 129.0, 128.8, 127.5, 115.8, 115.6, 104.5, 
98.1, 82.9, 67.3, 58.3, 58.2, 54.1, 53.6, 34.1, 28.7, 0.3.  HRMS calcd for 
C40H44F2N2O2SiNa
+ 673.3032, found 673.3030.  A mixture of (4-(3-(4-(2-(bis(4-
fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)phenyl)(4-((trimethylsilyl)ethynyl) 
phenyl) methanone (260 mg, 0.4 mmol) and TBAF (1.0 M in THF) (2 mL, 2 mmol) in 
THF (5 mL) was stirred at room temperature for 5 hrs.  The mixture was then diluted 
with H2O and extracted with Et2O (2 × 30 mL).  The combined organic layers were 
washed with saturated aq. NH4Cl solution, brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (100% EtOAc) to give 60 mg of terminal alkyne 4.40 as an oil 
(45%).  Rf = 0.10 (100% EtOAc).  
1H NMR (CDCl3, 400 MHz): δ 7.78-7.72 (m, 4H), 
7.60 (d, 2H, J = 8.5 Hz), 7.32-7.27 (m, 6H), 7.03 (d, 4H, J = 8.7 Hz), 5.35 (s, 1H), 3.59-
3.56 (m, 2H), 3.26 (s, 1H), 2.75-2.47 (m, 12H), 2.38 (t, 2H, J = 7.7 Hz), 1.86 (quin, 2H, J 
= 7.6 Hz).  13C NMR (CDCl3, 100 MHz): δ 195.5, 163.4, 160.9, 147.7, 137.9, 137.8, 
137.7, 134.9, 131.9, 130.3, 129.8, 128.6, 128.5, 128.4, 126.0, 115.4, 115.2, 82.8, 82.5, 
80.0, 66.9, 57.8, 57.7, 53.7, 53.2, 33.7, 28.3.  HRMS calcd for C37H36F2N2O2H
+ 
579.2817, found 579.2809. 
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(3-Iodo-5-nitrophenyl)methanol (5.52) 
A solution of BF3•Et2O (2.57 mL, 20.97 mmol) in THF (7 mL) was added dropwise to a 
THF (5 mL) suspension of NaBH4 (190 mg, 5.15 mmol) and 3-iodo-5-nitrobenzoic acid 
(5.51) (1 g, 3.41 mmol).  The reaction mixture was stirred from 0 ˚C to room temperature 
for 3 hrs, diluted with H2O slowly, then extracted with EtOAc (2 x 10 mL).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and 
concentrated to give 700 mg of benzyl alcohol 5.52 as an oil (71%).  1H NMR data was 
identical to that previously reported for this compound (Vaidyanathan et al., 2001). 
 
 
(3-Amino-5-iodophenyl)methanol (5.53) 
(3-Iodo-5-nitrophenyl)methanol (5.52) (700 mg, 2.50 mmol) was added to MeOH (5 mL) 
at 0 ˚C followed by concentrated HCl (1 mL) and SnCl2 (1.5 g, 8.15 mmol).  The mixture 
was allowed to stir at room temperature overnight then quenched with H2O (5 mL). The 
pH was then adjusted to 11 with 1M aq. NaOH and the mixture was extracted with 
EtOAc.  The organic layer was washed with brine, dried (MgSO4), filtered, and 
concentrated to give 550 mg of aniline 5.53 as a yellow oil (90%).  1H NMR data was 
identical to that previously reported for this compound (Vaidyanathan et al., 2001). 
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Ethyl 3-nitro-5-(3-oxopropyl)benzoate (5.57) 
A mixture of ethyl 3-iodo-5-nitrobenzoate (5.55; Giblin et al., 2005b) (2 g, 6.23 mmol), 
allyl alcohol (5.63; 0.43 mL, 6.23 mmol), Pd(OAc)2 (80 mg, 0.37 mmol), LiCl (260 mg, 
6.23 mmol), LiOAc (1.03 g, 15.57 mmol) and tetrabutylammonium chloride (1.73 g, 6.23 
mmol) in DMF (15 mL) was heated at 71 ˚C for 3 hrs.  The mixture was then cooled to 
room temperature, diluted with EtOAc, and filtered over Celite®.  The organic phase was 
washed with H2O, brine, dried (MgSO4), filtered, concentrated, and chromatographed 
(EtOAc:hexanes, 1:9) to give 860 mg of aldehyde 5.57 as a colorless oil (57%).  Rf = 0.2 
(EtOAc:hexanes, 1:9).  1H NMR (CDCl3, 400 MHz): δ 9.86 (t, 1H, J = 0.9 Hz), 8.68 (d, 
1H, J = 1.9 Hz), 8.26 (t, 1H, J = 2.2 Hz), 8.24-8.23 (m, 1H) 4.44 (q, 2H, J = 7.2 Hz), 3.12 
(t, 2H, J = 7.3 Hz), 2.93 (t, 2H, J = 7.3 Hz), 1.43 (t, 3H, J = 7.1 Hz).  13C NMR (CDCl3, 
100 MHz): δ 199.9, 164.5, 148.4, 143.1, 135.3, 132.3, 127.1, 122.5, 61.9, 44.4, 27.5, 
14.3.  HRMS calcd for C12H13NO5Na
+ 274.0685, found 274.0691. 
 
Ethyl 3-nitro-5-(3-oxopropyl)benzoate (5.57) (Alternative Method) 
To a 0 ˚C solution of ethyl 3-allyl-5-nitrobenzoate (5.58; Ek et al., 2002) (500 mg, 2.12 
mmol) in THF (5 mL) was added 9-BBN (1M in THF, 3 mL, 6.36 mmol).  The mixture 
was then stirred at room temperature for 4 hours, cooled to 0 ˚C, then treated with 1M aq. 
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NaOH (5 mL) followed by 30% H2O2 (5 mL).  The resulting mixture was warmed to 
room temperature then stirred for 1 hour.  The reaction was then diluted with H2O and 
extracted with EtOAc (2 x 15 mL).  The combined organic layers were washed with 
brine, dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 4:6) 
to provide 110 mg of primary alcohol 5.62 (40%).  Rf = 0.2 (EtOAc:hexanes, 4:6).  
1H 
NMR (CDCl3, 400 MHz): δ 8.68-8.67 (m, 1H), 8.26-8.25 (m, 1H), 8.23-8.21 (m, 1H) 
4.45 (q, 2H, J = 7.2 Hz), 3.71 (t, 2H, J = 6.2 Hz), 2.91 (t, 2H, J = 8.0 Hz), 2.06 (br s, 1H), 
2.03-1.3 (m, 2H), 1.43 (t, 3H, J = 7.1 Hz).  A mixture of ethyl 3-(3-hydroxypropyl)-5-
nitrobenzoate (5.62) (110 mg, 0.44 mmol) and PCC (110 mg, 0.49 mmol) in DCM (5 
mL) was stirred at room temperature for 4 hrs.  The reaction mixture was diluted with 
Et2O and filtered over Celite
®. The organic phase was then washed with saturated aq. 
NaHCO3 solution, dried (MgSO4), filtered, concentrated, and chromatographed 
(EtOAc:hexanes, 1:9) to give 50 mg of aldehyde 5.57 as a colorless oil (40%). Rf = 0.2 
(EtOAc:hexanes, 1:9).  1H NMR (CDCl3, 400 MHz): δ 9.86 (t, 1H, J = 0.9 Hz), 8.68 (d, 
1H, J = 1.9 Hz), 8.26 (t, 1H, J = 2.2 Hz), 8.24-8.23 (m, 1H) 4.44 (q, 2H, J = 7.2 Hz), 3.12 
(t, 2H, J = 7.3 Hz), 2.93 (t, 2H, J = 7.3 Hz), 1.43 (t, 3H, J = 7.1 Hz).  13C NMR (CDCl3, 
100 MHz): δ 199.9, 164.5, 148.4, 143.1, 135.3, 132.3, 127.1, 122.5, 61.9, 44.4, 27.5, 
14.3.  HRMS calcd for C12H13NO5Na
+ 274.0685, found 274.0691. 
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Ethyl 3-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)-5-
nitrobenzoate (5.56) 
A mixture of 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazine (3.58; Van der zee et 
al., 1980) (150 mg, 0.45 mmol), aldehyde 5.57 (110 mg, 0.45 mmol), and NaBH(OAc)3 
in DCE (7 mL) was stirred at room temperature for 24 hrs.  The reaction mixture was 
diluted with DCM (20 mL) and 1M aq. NaOH (20 mL).  The organic layer was separated, 
dried (MgSO4), filtered, concentrated, and chromatographed (CHCl3:MeOH, 9.5:0.5) to 
give 180 mg of disubstituted piperazine 5.56 as a colorless oil (70%).  Rf = 0.25 
(CHCl3:MeOH, 9.5:0.5).  
1H NMR (CDCl3, 400 MHz): δ 8.68-8.67 (m, 1H), 8.25-8.20 
(m, 2H), 7.30-7.26 (m, 4H), 7.02-6.97 (m, 4H), 5.34 (s, 1H), 4.43 (q, 2H, J = 7.2 Hz), 
3.58 (t, 2H, J = 6.0 Hz), 2.83 (t, 2H, J = 7.2 Hz), 2.66 (t, 2H, J = 6.1 Hz), 2.64-2.40 (m, 
8H), 2.34 (t, 2H, J = 7.6 Hz), 1.86 (quin, 2H, J = 7.1 Hz), 1.42 (t, 3H, J = 7.2 Hz).  13C 
NMR (CDCl3, 100 MHz): δ 164.7, 163.3, 160.9, 148.3, 144.7, 137.9, 137.8, 135.4, 132.0, 
128.6, 128.5, 127.2, 122.1, 115.4, 115.2, 82.5, 66.9, 61.8, 57.8, 57.0, 53.6, 53.1, 33.0, 
27.9, 14.3.  HRMS calcd for C31H35F2N3O5H
+ 568.2617, found 568.2624. 
 
 
 
Ethyl 3-amino-5-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl) 
benzoate (5.64) 
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A mixture of nitro derivative 5.56 (180 mg, 0.32 mmol) and SnCl2•2H2O (298 mg, 1.29 
mmol) in EtOH (6 mL) was refluxed for 2 hrs.  The reaction mixture was then cooled to 
room temperature, diluted with saturated aq. NaHCO3 solution, and extracted with 
EtOAc.  The organic phase was washed with brine, dried (MgSO4), filtered, and 
concentrated to give 130 mg of aniline 5.64 as a yellow oil (74%).  Rf = 0.3 
(CHCl3:MeOH:NEt3, 90:8:2).  
1H NMR (CDCl3, 400 MHz): δ 7.29-7.25 (m, 5H), 7.19-
7.17 (m, 1H), 7.01-6.97 (m, 4H), 6.69-6.66 (m, 1H), 5.33 (s, 1H), 4.33 (q, 2H, J = 7.1 
Hz), 3.78 (br s, 2H), 3.55 (t, 2H, J = 6.0 Hz), 2.66 (t, 2H, J = 6.0 Hz), 2.62-2.39 (m, 
10H), 2.36 (t, 2H, J = 7.3 Hz), 1.79 (quin, 2H, J = 7.7 Hz), 1.35 (t, 3H, J = 7.1 Hz).  13C 
NMR (CDCl3, 100 MHz): δ 166.9, 163.3, 160.9, 146.5, 143.4, 137.9, 137.8, 131.4, 128.6, 
128.5, 119.8, 119.4, 115.3, 115.1, 113.4, 82.5, 66.9, 60.8, 57.8, 53.5, 53.1, 33.4, 28.2, 
14.3.  HRMS calcd for C31H37F2N3O3H
+ 538.2875, found 538.2869. 
 
 
 
(3-Amino-5-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl) 
phenyl) methanol (5.65) 
LiAlH4 (1.0 M in THF) (530 µL, 0.53 mmol) was added slowly to a solution of ester 5.64 
(140 mg, 0.27 mmol) in THF (6 mL) at -10 ˚C then warmed to room temperature for 4 
hrs.  The reaction mixture was cooled to 0 ˚C, sequentially treated with H2O (30 µL), 
15% w/v NaOH (30 µL), and H2O (90 µL) to form a white solid that was filtered and 
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washed with Et2O.  The organic layer/filtrate was dried (MgSO4), filtered, and 
concentrated to give 110 mg of benzyl alcohol 5.65 as an oil (81%).  Rf = 0.6 
(CHCl3:MeOH:NEt3, 80:18:2).  
1H NMR (CDCl3, 400 MHz): δ 7.28-7.24 (m, 4H), 7.01-
6.97 (m, 4H), 6.54 (s, 1H), 6.48 (s, 1H), 6.39 (s, 1H), 5.32 (s, 1H), 4.57 (s, 2H), 3.61 (br 
s, 1H), 3.53 (t, 2H, J = 6.0 Hz), 2.63 (t, 2H, J = 6.0 Hz), 2.60-2.36 (m, 10H), 2.32 (t, 2H, 
J = 7.4 Hz), 1.74 (quin, 2H, J = 7.7 Hz).  13C NMR (CDCl3, 100 MHz): δ 163.4, 160.9, 
146.6, 143.5, 142.5, 137.8, 137.7, 128.6, 128.5, 117.2, 115.4, 115.2, 114.3, 111.3, 82.5, 
66.8, 64.9, 58.06, 57.7, 53.4, 53.0, 33.6, 28.2.  HRMS calcd for C29H35F2N3O2H
+ 
496.2770, found 496.2766. 
 
 
(3-Azido-5-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl) 
phenyl) methanol (5.66) 
NaNO2 (45 mg, 0.65 mmol) was added to a stirring solution of aniline 5.65 (94 mg, 0.19 
mmol) in MeOH (2 mL) and 0.33N aq. HCl (7 mL) at 0 ˚C.  After 10 minutes, NaN3 (37 
mg, 0.57 mmol) was added and then the reaction mixture was stirred at room temperature 
overnight.  The mixture was then diluted with saturated aq. NaHCO3 solution and 
extracted with CHCl3.  The organic layer was washed with brine, dried (MgSO4), filtered, 
and concentrated to give 70 mg of azide 5.66 as an oil (70%).  Rf = 0.4 
(CHCl3:MeOH:NEt3, 90:8:2).  
1H NMR (CDCl3, 400 MHz): δ 7.28-7.24 (m, 4H), 6.98 (t, 
4H, J = 8.6 Hz), 6.91 (s, 1H), 6.85 (s, 1H), 6.72 (s, 1H), 5.32 (s, 1H), 4.58 (s, 2H), 3.54 (t, 
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2H, J = 5.9 Hz), 2.63 (t, 2H, J = 5.9 Hz), 2.60-2.33 (m, 10H), 2.29 (t, 2H, J = 7.9 Hz), 
1.77 (quin, 2H, J = 7.2 Hz).  13C NMR (CDCl3, 100 MHz): δ 163.4, 160.9, 144.2, 143.3, 
140.1, 137.8, 137.7, 128.6, 128.5, 123.3, 117.9, 115.4, 115.2, 114.8, 82.5, 66.8, 64.2, 
57.7, 53.4, 53.0, 33.4, 28.1.  HRMS calcd for C29H33F2N5O2H
+ 522.2675, found 
522.2671.  IR: azide, 2105 cm-1. 
 
 
 
1-(3-(3-Azido-5-(azidomethyl)phenyl)propyl)-4-(2-(bis(4-fluorophenyl)methoxy) 
ethyl) piperazine (4.43) 
Triethylamine (200 µL, 1.39 mmol) was added to a stirring solution of azide 5.66 (364 
mg, 0.70 mmol) in DCM (4 mL) at 0 ˚C.  After 10 minutes, MsCl (80 µL, 1.04 mmol) 
was added and then the reaction mixture was allowed to stir at room temperature for 3 
hrs.  The mixture was then diluted with saturated aq. NaHCO3 solution and extracted with 
DCM.  The organic phase was washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (CHCl3:MeOH, 98:2) to give 130 mg of 3-azido-5-(3-(4-(2-(bis(4-
fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)benzylmethane sulfonate (5.67) as an 
oil (40%).  This intermediate was used immediately for the next reaction since the 
compound was not stable in the freezer overnight.  Rf = 0.1 (CHCl3:MeOH, 98:2).  
1H 
NMR (CDCl3, 400 MHz): δ 7.28-7.25 (m, 4H), 7.00-6.97 (m, 5H), 6.87-6.86 (m, 1H), 
6.81-6.80 (m, 1H), 5.33 (s, 1H), 4.50 (s, 2H), 3.57-3.55 (m, 2H), 3.11 (s, 3H), 2.72-2.34 
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(m, 14H), 1.83-1.80 (m, 2H).  IR: azide, 2108 cm-1.  A mixture of mesylate 5.67 (125 mg, 
0.23 mmol) and NaN3 (70 mg, 0.92 mmol) in DMF (5 mL) was stirred at room 
temperature for 4 hrs.  The reaction mixture was then diluted with H2O and extracted 
with EtOAc.  The organic phase was washed with brine, dried (MgSO4), filtered, 
concentrated, and chromatographed (CHCl3:MeOH, 98:2) to give 41 mg of diazide 4.43 
as an oil (40%).  Rf = 0.2 (CHCl3:MeOH, 98:2).  
1H NMR (CDCl3, 400 MHz): δ 7.29-
7.25 (m, 4H), 7.01-6.97 (m, 4H), 6.91 (s, 1H), 6.82 (s, 1H), 6.79 (s, 1H), 5.33 (s, 1H), 
4.29 (s, 2H), 3.56-3.54 (m, 2H), 2.68-2.32 (m, 14H), 1.82-1.79 (m, 2H).  13C NMR 
(CDCl3, 100 MHz): δ 163.4, 160.9, 144.8, 140.5, 137.8, 137.3, 128.6, 128.5, 124.8, 
118.8, 116.2, 115.4, 115.2, 82.5, 66.8, 57.8, 57.6, 54.3, 53.6, 53.1, 33.3, 28.2.  HRMS 
calcd for C29H32F2N8ONa
+ 569.2559, found 569.2554.  IR: azide, 2105 cm-1. 
 
 
 
(4-(2-Bromoethoxy)phenyl)(4-(prop-2-yn-1-yloxy)phenyl)methanone (5.70) 
A mixture of phenol 5.72 (Tae et al., 2010) (500 mg, 1.98 mmol), dibromoethane (5.71) 
(3.95 g, 21.01 mmol), and K2CO3 (280 mg, 2.02 mmol) in acetone (25 mL) was refluxed 
overnight.  The mixture was then cooled to room temperature, diluted with H2O, and 
extracted with DCM (2 × 30 mL).  The combined organic layers were washed with 1M 
aq. NaOH, brine, dried (MgSO4), filtered, concentrated, and chromatographed 
(EtOAc:hexanes, 2:8) to give 200 mg of alkyl bromide 5.70 as a white solid (28%).  Rf = 
0.20 (EtOAc/hexanes, 2:8).  1H NMR (CDCl3, 500 MHz): δ 7.79 (d, 4H, J = 8.7 Hz), 7.04 
(d, 2H, J = 8.8 Hz), 6.97 (d, 2H, J = 8.7 Hz), 4.77 (d, 2H, J = 2.3 Hz), 4.38 (t, 2H, J = 6.3 
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Hz), 3.67 (t, 2H, J = 6.4 Hz), 2.56 (t, 1H, J = 2.4 Hz).  13C NMR (CDCl3, 100 MHz): δ 
194.2, 161.3, 160.7, 132.3, 132.1, 131.3, 131.1, 114.4, 114.1, 78.0, 76.3, 67.9, 55.9, 29.0.  
HRMS calcd for C18H15BrO3Na
+ 381.0096, found 381.0093.  Anal calcd for C18H15BrO3: 
C, 60.18; H, 4.21; Br, 22.24.  Found: C, 60.37; H, 4.32; Br, 21.96.  MPt: 91-92 ˚C. 
 
 
 
 
(4-(2-(3-((2-Methylthiazol-4-yl)ethynyl)phenoxy)ethoxy)phenyl)(4-(prop-2-yn-1-
yloxy)phenyl)methanone (4.49) 
A mixture of 3-((2-methylthiazol-4-yl)ethynyl)phenol (4.45; Mishra et al., 2012) (100 
mg, 0.46 mmol), alkyl bromide 5.70 (180 mg, 0.51 mmol), and K2CO3 (190 mg, 1.39 
mmol) in DMF (7 mL) was heated at 60 ˚C for 19 hrs.  The mixture was then cooled to 
room temperature, diluted with H2O, and extracted with EtOAc (2 × 20 mL).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (CHCl3:MeOH, 97:3) to give 165 mg of conjugate 4.49 as a yellow 
solid (70%).  Rf = 0.24 (CHCl3:MeOH , 97:3).  
1H NMR (CDCl3, 400 MHz): δ 7.79 (d, 
4H, J = 8.7 Hz,), 7.37 (s, 1H), 7.30-7.24 (m, 1H), 7.19-7.17 (m, 1H), 7.15-7.11 (m, 1H), 
7.05-6.99 (m, 4H), 6.96 (dd, 1H, J = 8.2, 2.5 Hz), 4.77 (d, 2H, J = 2.3 Hz), 4.37 (dd, 4H, 
J = 18.4, 5.3 Hz), 2.73 (s, 3H), 2.57 (t, 1H, J = 2.3 Hz).  13C NMR (CDCl3, 100 MHz): δ 
194.2, 165.8, 161.8, 160.6, 158.2, 136.6, 132.2, 132.1, 131.3, 130.8, 129.5, 124.7, 123.4, 
122.5, 117.0, 116.1, 114.3, 114.1, 88.6, 83.4, 77.9, 76.2, 66.5, 66.3, 55.8, 19.1.  HRMS 
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calcd for C30H23NO4SNa
+ 516.1240, found 516.1234.  Anal. calcd for C30H23NO4S • 
0.4692 H2O: C, 71.77; H, 4.80; N, 2.79; S, 6.39.  Found: C, 71.75; H, 4.66; N, 2.96; S, 
6.42.  MPt: 90-92 ˚C. 
 
 
4-((3-(Benzyloxy)phenyl)ethynyl)-2-methylthiazole (4.46) 
2-Methyl-4-(trimethylsilylethynyl)thiazole 3.76 (Cosford et al., 2003) (176 mg, 0.90 
mmol) and 1-(benzyloxy)-3-iodobenzene (5.69) (310 mg, 0.99 mmol) were added to a 
flask containing degassed DMF (5 mL).  To this mixture, Pd(PPh3)4 (8 mg, 0.05 mmol), 
CuI (25 mg, 0.09 mmol), and NEt3 (200 µL, 1.08 mmol) were added.  The mixture was 
then degassed again and warmed to 85 ˚C.  TBAF (1.0 M in THF) (1 mL, 0.99 mmol) 
was then added dropwise over 15 min.  The reaction mixture was stirred at 85 ˚C for 1.5 
hrs then cooled to room temperature.  The mixture was then filtered through Celite® and 
washed with EtOAc.  The organic phase was washed with 0.1M aq. HCl, H2O, brine, 
dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 1:9) to 
give 140 mg of disubstituted alkyne 4.46 as an oil (70%).  Rf = 0.20 (EtOAc:hexanes, 
1:9).  1H NMR (CDCl3, 400 MHz): δ 7.42-7.30 (m, 6H), 7.25-7.22 (m, 1H), 7.17-7.15 
(m, 2H), 6.98-6.95 (m, 1H), 5.04 (s, 2H), 2.71 (s, 3H).  13C NMR (CDCl3, 100 MHz): δ 
165.6, 158.4, 136.8, 136.6, 129.4, 128.6, 128.0, 127.4, 124.5, 123.4, 122.2, 117.3, 116.2, 
88.6, 83.3, 69.9, 19.2.  HRMS calcd for C19H15NOSNa
+ 328.0766, found 328.07636.  
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4-((3-((3-Azido-5-(azidomethyl)benzyl)oxy)phenyl)ethynyl)-2-methylthiazole (4.50) 
A mixture of 3-((2-methylthiazol-4-yl)ethynyl)phenol (4.45; Mishra et al., 2012)  (88 mg, 
0.41 mmol), diazido mesylate 5.79 (Hosoya et al., 2005) (111 mg, 0.41 mmol), and 
K2CO3 (170 mg, 1.23 mmol) in acetone (6 mL) was stirred at room temperature for 20 
hrs.  The mixture was then diluted with H2O and extracted with EtOAc (2 × 20 mL).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (EtOAc:hexanes, 2:8) to give 80 mg of benzyl ether 4.50 as an oil 
(50%).  Rf = 0.20 (EtOAc:hexanes, 2:8).  
1H NMR (CDCl3, 400 MHz): δ 7.36 (s, 1H), 
7.28-7.24 (m, 1H), 7.19-7.17 (m, 1H), 7.13 (s, 2H), 7.06 (s, 1H), 6.97-6.95 (m, 1H), 6.93 
(s, 1H), 5.03 (s, 2H), 4.36 (s, 2H), 2.73 (s, 3H).  13C NMR (CDCl3, 100 MHz): δ 165.7, 
158.1, 141.07, 139.5, 137.8, 136.7, 129.6, 124.9, 123.6, 123.1, 122.4, 118.0, 117.5, 117.2, 
116.2, 88.5, 83.5, 69.1, 54.1, 19.2.  HRMS calcd for C20H15N7OSNa
+ 424.0951, found 
424.0947. 
 
 
4-((3-Fluoro-5-nitrophenyl)ethynyl)-2-iodothiazole (5.88) 
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A degassed DME (10 mL) solution of 4-((trimethylsilyl)ethynyl)thiazol-2-amine (5.85; 
Simeon et al., 2011) (750 mg, 3.82 mmol) was sequentially treated with 1-fluoro-3-iodo-
5-nitrobenzene (5.86) (1.3 g, 5.7 mmol), CuI (50 mg, 0.24 mmol), Pd(PPh3)4 (148 mg, 
0.14 mmol), and Et3N (1.47 mL, 10.56 mmol).  The reaction mixture was degassed again 
then warmed to 70 ˚C.  TBAF (1M in THF, 5 mL, 5 mmol) was added to the mixture 
slowly for 5 min and then the reaction was heated at 70 ˚C for 3 hrs.  The reaction 
mixture was then cooled to room temperature, filtered over Celite®, and washed with 
EtOAc (30 mL).  The organic layer was washed with H2O, saturated aq. NH4Cl solution, 
brine, dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 2:8) 
to give 650 mg of impure 4-((3-fluoro-5-nitrophenyl)ethynyl)thiazol-2-amine (5.84).  A 
mixture of impure aminothiazole 5.84 (650 mg, 2.47 mmol), CuI (650 mg, 0.7 mmol) and 
n-butyl nitrite (380 µL, 3.43 mmol) in CH3CN (20 mL) was heated at 60 ˚C for 45 min.  
The mixture was then cooled to room temperature, diluted with 0.1M aq. NEt3 (50 mL) 
and extracted with EtOAc (2 × 30 mL).  The combined organic layers were filtered over 
Celite®, washed with brine, dried (MgSO4), filtered, concentrated, and chromatographed 
(EtOAc:hexanes, 0.5:9.5) to give 100 mg of iodide 5.88 as an oil (70 %).  Rf = 0.20 
(EtOAc:hexanes, 0.5:9.5).  1H NMR (CDCl3, 400 MHz): δ 8.21 (s, 1H), 7.95-7.92 (m, 
1H), 7.59 (s, 1H), 7.58-7.55 (m, 1H).  13C NMR (CDCl3, 100 MHz): δ 162.0 (d, J = 252.8 
Hz), 149.0 (d, J = 9.6 Hz), 138.5, 130.2, 125.3 (d, J = 10.2 Hz), 124.4 (d, J = 23.0 Hz), 
122.6 (d, J = 3.6 Hz), 111.8 (d, J = 26.5 Hz), 100.7, 86.6 (d, J = 3.0 Hz), 85.1.  HRMS 
calcd for C11H4FIN2O2SNa
+ 396.8914, found 396.8913. 
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4-((3-Azido-5-fluorophenyl)ethynyl)-2-iodothiazole (4.52) 
Fe (s) (94 mg, 1.7 mmol) was added to a solution of nitro analog 5.88 (127 mg, 2.47 
mmol) in glacial AcOH (2 mL), H2O (1 mL), and EtOH (2 mL).  The mixture was 
sonicated for 1 hr, diluted with EtOAc, and filtered over Celite®.  The organic 
phase/filtrate was washed with 2M aq. NaOH, brine, dried (MgSO4), filtered, 
concentrated, and chromatographed (EtOAc:hexanes, 2:8) to give 30 mg of 3-fluoro-5-
((2-iodothiazol-4-yl)ethynyl)aniline (5.89) as an oil (20%).  Rf = 0.20 (EtOAc:hexanes, 
2:8).  1H NMR (CDCl3, 500 MHz): δ 7.45 (s, 1H), 6.63-6.61 (m, 2H), 6.40-6.37 (m, 1H), 
3.84 (br s, 2H).  NaNO2 (12 mg, 0.174 mmol) in ice cold H2O (1 mL) was slowly added 
to a stirring mixture of 3-fluoro-5-((2-iodothiazol-4-yl)ethynyl)aniline (5.89) (30  mg, 
0.09 mmol) and p-TsOH•H2O (50 mg, 0.26 mmol) in CH3CN (3 mL) at -10 ˚C.  After 5 
min, NaN3 (13 mg, 0.10 mmol) in ice cold H2O (1 mL) was added slowly and the mixture 
was stirred from -10 ˚C to room temperature for 4 hrs.  The mixture was then diluted with 
H2O and cooled to 0 ˚C.  Saturated aq. NaHCO3 solution was then added to adjust the pH 
to 9 and the mixture was extracted with EtOAc.  The organic phase was washed with 
brine, dried (MgSO4), filtered, concentrated, and chromatographed (100% CHCl3) to give 
30 mg of azide 4.52 as an oil (15%).  Rf = 0.20 (100% CHCl3).  
1H NMR (CDCl3, 400 
MHz): δ 7.51 (s, 1H), 7.03-7.01 (m, 2H), 6.75-6.72 (m, 1H).  13C NMR (CDCl3, 100 
MHz): δ 162.9 (d, J = 248.5 Hz), 142.2 (d, J = 11.0 Hz), 139.0, 129.3, 124.9 (d, J = 11.7 
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Hz), 117.9 (d, J = 3.3 Hz), 115.0 (d, J = 23.5 Hz), 107.7 (d, J = 25.4 Hz), 100.4, 88.1 (d, 
J = 3.7 Hz), 83.3.  HRMS calcd for C11H4FIN4SH
+ 370.9258, found 370.9258. 
 
 
 
 
2-((3-Methoxy-5-nitrophenyl)ethynyl)-6-methylpyridine (5.90) 
A degassed DMF (8 mL) solution of 2-methyl-6-((trimethylsilyl)ethynyl)pyridine (3.68; 
Alagille et al., 2005) (500 mg, 2.64 mmol) was sequentially treated with 1-iodo-3-
methoxy-5-nitrobenzene (5.91; Jorgensen et al., 2011) (884 mg, 3.16 mmol), 
PdCl2(PPh3)4 (90 mg, 0.13 mmol), CuI (50 mg, 0.26 mmol), Et3N (1.47 mL, 10.56 
mmol), and DMF (2 mL).  The reaction mixture was degassed again then warmed to 70 
˚C.  TBAF (1M in THF, 2.9 mL, 2.9 mmol) was added to the mixture slowly for 5 min 
and then the reaction was heated at 70 ˚C for 3 hrs.  The reaction mixture was then cooled 
to room temperature, filtered (Celite®), and washed with EtOAc (30 mL).  The organic 
layer was washed with H2O, saturated aq. NH4Cl solution, brine, dried (MgSO4), filtered, 
concentrated, and chromatographed (EtOAc:hexanes, 2.5:7.5) to give 550 mg of 
disubstituted alkyne 5.90 as a yellow solid (78%).  Rf = 0.15 (EtOAc:hexanes, 2.5:7.5).  
1H NMR (CDCl3, 500 MHz): δ 7.98-7.97 (m, 1H), 7.66 (t, 1H, J = 2.2 Hz), 7.59 (d, 1H, J 
= 7.7 Hz), 7.38-7.36 (m, 2H), 7.16 (d, 1H, J = 7.7 Hz), 3.88 (s, 3H), 2.58 (s, 3H).  13C 
NMR (CDCl3, 100 MHz): δ 159.7, 159.0, 148.8, 141.4, 136.4, 124.6, 124.5, 123.2, 123.0, 
118.8, 109.3, 90.6, 85.7, 55.9, 24.4.  HRMS calcd for C15H12N2O3Na
+ 291.0740, found 
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291.0740.  Anal calcd for C15H12N2O3: C, 67.16; H, 4.51; N, 10.44.  Found: C, 66.90; H, 
4.54; N, 10.40.  MPt: 102-103 ˚C. 
 
 
 
2-Methyl-6-((3-nitro-5-(prop-2-yn-1-yloxy)phenyl)ethynyl)pyridine (5.92) 
A 1.0 M BBr3 solution in DCM (3.72 mL, 3.72 mmol) was added dropwise to solution of 
methoxy ether 5.90 (250 mg, 0.93 mmol) in DCM (6 mL) at -78 ˚C and then stirred at 
this temperature for 1hr.  The reaction was mixture was warmed to room temperature and 
subsequently stirred for 5 hrs.  The mixture was then cooled to -78 ˚C, slowly quenched 
with MeOH (60 mL), and then stirred for 20 min.  The mixture was then concentrated, 
partitioned between EtOAc and cold saturated aq. NaHCO3 solution.  The organic layer 
was washed with brine, dried (MgSO4), filtered (Celite
®), and concentrated to give 390 
mg of 3-(6-methylpyridin-2-yl)ethynyl)-5-nitrophenol as a yellow solid. Rf = 0.3 
(EtOAc:hexanes, 1: 1).  The crude phenol was then directly treated with 80% propargyl 
bromide (5.73) in toluene (420 µL, 2.78 mmol), K2CO3 (384 mg, 2.78 mmol), and DMF 
(5 mL) then stirred at room temperature for 9 hrs.  The reaction mixture was then diluted 
with H2O and extracted with EtOAc (2 x 20 mL).  The combined organic layers were 
washed with saturated aq. NH4Cl solution, brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (EtOAc:hexanes, 2.5:7.5) to give 100 mg of propargyl ether 5.92 as 
a yellow oil (35%).  Rf = 0.3 (EtOAc:hexanes, 2.5:7.5).  
1H NMR (CDCl3, 500 MHz): δ 
8.08-8.07 (m, 1H), 7.81 (t, 1H, J = 2.2 Hz), 7.62 (t, 1H, J = 7.7 Hz), 7.50-7.49 (m, 1H), 
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7.40 (d, 1H, J = 7.7 Hz), 7.17 (d, 1H, J = 7.7 Hz), 4.80 (d, 2H, J = 2.4 Hz), 2.62 (t, 1H, J 
= 2.4 Hz), 2.60 (s, 3H).  13C NMR (CDCl3, 100 MHz): δ 159.3, 157.7, 148.9, 141.6, 
136.6, 124.8, 124.7, 124.0, 123.4, 119.9, 110.7, 90.9, 85.8, 77.5, 76.8, 56.5, 24.6.  HRMS 
calcd C17H12N2O3Na
+ 315.0740, found 351.0740. 
 
 
 
 
3-((6-Methylpyridin-2-yl)ethynyl)-5-(prop-2-yn-1-yloxy)aniline (5.93) 
Fe (s) (105 mg, 1.88 mmol) was added to a solution of nitro analog 5.92 (100 mg, 0.34 
mmol) dissolved in glacial AcOH (1 mL, 13.04 mmol), H2O (0.5 mL, 20.75 mmol), and 
EtOH (1 mL, 12.73 mmol).  The reaction mixture was sonicated for 1.5 hrs, diluted with 
EtOAc, and then filtered (Celite®).  The organic layer/filtrate was washed with 1M aq. 
NaOH, brine, dried (MgSO4), filtered (Celite
®), and concentrated to give 80 mg of aniline 
5.93 as a black oil (91%).  Rf = 0.20 (EtOAc:hexanes, 1:1).  
1H NMR (CDCl3, 500 MHz): 
δ 7.54 (t, 1H, J = 7.7 Hz), 7.32 (d, 1H, J = 7.7 Hz), 7.09 (d, 1H, J = 7.8 Hz), 6.61-6.60 
(m, 1H), 6.55-6.54 (m, 1H), 6.30 (t, 1H, J = 2.2 Hz), 4.62 (d, 2H, J = 2.4 Hz), 3.83 (br s, 
2H), 2.57 (s, 3H), 2.54 (t, 1H, J = 2.4 Hz).  13C NMR (CDCl3, 100 MHz): δ 158.8, 158.3, 
147.7, 142.5, 136.4, 124.4, 123.6, 122.6, 112.3, 107.8, 103.3, 88.9, 88.0, 78.4, 75.7, 55.7, 
24.5.  HRMS calcd for C17H14N2ONa
+ 285.0998, found 285.0999. 
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2-((3-Azido-5-(prop-2-yn-1-yloxy)phenyl)ethynyl)-6-methylpyridine (4.54) 
NaNO2 (60 mg, 0.86 mmol) was slowly added to a solution of aniline 5.93 (76 mg, 0.29 
mmol) in 0.5M aq. HCl (7 mL, 3.54 mmol) at 0 ˚C.  After 10 minutes, NaN3 (90 mg, 1.38 
mmol) was added slowly and the mixture was warmed from 0 ˚C to room temperature 
and stirred for 1.5 hrs.  The mixture was diluted with saturated aq. NaHCO3 solution at 0  
˚C to achieve a pH of ~7 and then extracted with EtOAc (2 x 20 mL).  The combined 
organic layers were washed with brine, dried (MgSO4), filtered (Celite
®), concentrated, 
and chromatographed (100% CHCl3) to give 37 mg of azide 4.54 as a brown oil (30%).  
Rf = 0.20 (100% CHCl3).  
1H NMR (CDCl3, 500 MHz): δ 7.57 (t, 1H, J = 7.7 Hz), 7.36 
(d, 1H, J = 7.7 Hz), 7.13 (d, 1H, J = 7.8 Hz), 6.98-6.97 (m, 1H), 6.94-6.93 (m, 1H), 6.63-
6.62 (m, 1H), 4.69 (d, 2H, J = 2.3 Hz), 2.59 (s, 3H), 2.57-2.56 (m,1H).  13C NMR 
(CDCl3, 100 MHz): δ 159.1, 158.3, 142.1, 141.5, 136.4, 124.6, 124.5, 123.0, 115.7, 
114.3, 107.5, 89.5, 87.4, 77.7, 76.3, 56.0, 24.6.  HRMS calcd for C17H12N4ONa
+ 
311.0903, found 311.0903. 
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4-((3-(2-Bromoethoxy)phenyl)ethynyl)-2-methylthiazole (5.96) 
A mixture of 3-((2-methylthiazol-4-yl)ethynyl)phenol (4.45; Mishra et al., 2012) (257 
mg, 1.19 mmol), dibromoethane (5.71) (0.5 mL, 5.80 mmol), and K2CO3 (490 mg, 3.57 
mmol) in DMF (7 mL) was heated at 60 ˚C for 20 hrs.  The mixture was then cooled to 
room temperature, diluted with H2O, and extracted with EtOAc (2 × 20 mL).  The 
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated, 
and chromatographed (EtOAc:hexanes, 2:8) to give 100 mg of alkyl bromide 5.96 as a 
yellow oil (32%).  Rf = 0.20 (EtOAc:hexanes, 2:8).  
1H NMR (CDCl3, 400 MHz): δ 7.37-
7.36 (m, 1H), 7.27-7.22 (m, 1H), 7.18-7.16 (m, 1H), 7.08-7.07 (m, 1H), 6.92-6.89 (m, 
1H), 4.28-4.24 (m, 2H), 3.64-3.60 (m, 2H), 2.73-2.71 (m, 3H).  13C NMR (CDCl3, 100 
MHz): δ 165.6, 157.7, 136.6, 129.5, 124.8, 123.5, 122.3, 117.1, 116.0, 88.4, 83.4, 67.7, 
28.9, 19.2.  HRMS calcd for C14H12BrNOSH
+ 321.9895, found 321.9896.  
 
 
 
S-(2-(3-((2-Methylthiazol-4-yl)ethynyl)phenoxy)ethyl) methanesulfonothioate (4.55) 
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A mixture of alkyl bromide 5.96 (105 mg, 0.32 mmol) and sodium methanethiosulfonate  
(5.95) (62 mg, 0.46 mmol) in DMF (7 mL) was heated at 50 ˚C for 20 hrs.  The mixture 
was then cooled to room temperature, diluted with H2O, and extracted with EtOAc (2 × 
20 mL).  The combined organic layers were washed with brine, dried (MgSO4), filtered, 
concentrated, and chromatographed (100% CHCl3) to give 100 mg of 
methanethiosulfonate 4.55 as a yellow oil (85%).  Rf = 0.15 (100% CHCl3).  
1H NMR 
(CDCl3, 400 MHz): δ 7.38 (s, 1H), 7.27-7.23 (m, 1H), 7.18-7.17 (m, 1H), 7.07-7.06 (m, 
1H), 6.90-6.87 (m, 1H), 4.26 (t, 2H, J = 5.8 Hz), 3.54 (t, 2H, J = 5.8 Hz), 3.40 (s, 3H), 
3.72 (s, 3H).  13C NMR (CDCl3, 100 MHz): δ 165.8, 157.6, 136.5, 129.7, 125.0, 123.7, 
122.6, 117.2, 115.6, 88.3, 83.7, 66.6, 50.8, 35.7, 19.2.  HRMS calcd for C15H15NO3S3Na
+ 
376.0106, found 376.0107.  
 
 
 
3-((2-Methylthiazol-4-yl)ethynyl)aniline (5.98) 
Fe (s) (340 mg, 6.10 mmol) was added to a solution of 2-methyl-4-((3-
nitrophenyl)ethynyl)thiazole (5.101; Alagille et al., 2004) (271 mg, 1.11 mmol) in glacial 
AcOH (2.43 mL, 42.61 mmol), H2O (1.21 mL, 67.75 mmol), and  EtOH (2.41 mL, 41.19 
mmol).  The mixture was sonicated for 1.5 hrs then diluted with EtOAc and filtered over 
Celite®.  The organic phase/filtrate was washed with 2M aq. NaOH, brine, dried 
(MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 3.5:6.5) to give 
214 mg of aniline 5.98 as an oil (91%).  Rf = 0.25 (EtOAc:hexanes, 3.5:6.5).  
1H NMR 
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(CDCl3, 400 MHz): δ 7.32 (s, 1H), 7.07 (t, 1H, J = 7.8 Hz), 6.93 (dt, 1H, J = 7.6, 1.2 Hz), 
6.82 (t, 1H, J = 2.1 Hz), 6.63 (dd, 1H, J = 8.0, 0.9 Hz), 3.73 (br s, 2H), 2.69 (s, 3H).  13C 
NMR (CDCl3, 100 MHz): δ 165.7, 146.5, 136.9, 129.3, 122.9, 122.2, 121.9, 117.8, 115.7, 
89.2, 82.8, 19.2.  HRMS calcd for C12H10N2SH
+ 215.0637, found 215.0637. 
 
 
 
 
1-(3-((2-Methylthiazol-4-yl)ethynyl)phenyl)-1H-pyrrole-2,5-dione (4.56) 
A mixture of aniline 5.98 (124 mg, 0.58 mmol) and maleic anhydride (5.97) (60 mg, 0.58 
mmol) in THF (5 mL) was refluxed for 3 hrs.  The reaction mixture was then cooled to 
room temperature, diluted with Et2O, and concentrated under reduced pressure.  NaOAc 
(25 mg, 0.24 mmol) and acetic anhydride (7 mL) was then added to the previous reaction 
flask and the mixture was heated at 100 ˚C for 40 min.  The mixture was cooled to room 
temperature, diluted with 5% aq. NaHCO3, and then extracted with CHCl3 (2 × 30 mL).  
The combined organic layers were washed with brine, dried (MgSO4), filtered, 
concentrated, and chromatographed (EtOAc:hexanes. 1:1) to give 120 mg of succinimide 
4.56 as a yellow solid (70%).  Rf = 0.40 (EtOAc:hexanes, 1:1).  
1H NMR (CDCl3, 400 
MHz): δ 7.57-7.53 (m, 2H), 7.44 (t, 1H, J = 8.1 Hz), 7.39 (s, 1H), 7.37-7.34 (m, 1H), 6.87 
(s, 2H), 2.74 (s, 3H).  13C NMR (CDCl3, 100 MHz): δ 169.1, 165.8, 136.5, 134.2, 131.4, 
130.9, 129.1, 128.9, 126.0, 123.5, 122.7, 87.6, 84.4, 19.2.  HRMS calcd for 
C16H10N2O2SNa
+ 317.0355, found 317.0354. 
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Appendix 
A.1.  Stannylation, Radioiodination and DAT Covalent Ligation of Racemic threo-
p-Azido-N-Benzyl-4-Iodo-MP  
With respect to identifying candidate probes for photoaffinity labeling 
experiments, ideal compounds are those that are bioactive in the same range as the parent 
compound.  However, compounds with as much as 1000-fold lower activity can still be 
useful (Dorman and Prestwich, 2000).  Given racemic threo-p-azido-N-benzyl-4-iodo-
MP ((±)-4.26) displayed modest DAT binding affinity, and the highest DAT binding 
affinity (Ki = 363 ± 28 nM) in the series of racemic threo-N-azidobenzyl-4-iodo/3-iodo-
MP compounds (4.24-4.29), further development of this compound into a potential DAT 
photoprobe was pursued.  Given that wash-resistant binding experiments involving 
nonradioactive azido compounds frequently give false positives in the assessment of 
covalent attachment (Agoston et al., 1997), synthesis of a radioiodinated (i.e., [125I]) 
version of racemic threo-p-azido-N-benzyl-4-iodo-MP ((±)-4.26) was pursued to 
determine if photoactivation could produce covalent ligation to the DAT.  In this regard, 
racemic p-azido-N-benzyl-4-iodo-MP ((±)-4.26) was subjected to Stille coupling 
(conditions adapted from Shu et al., 1996) with bis(tributyltin) to provide stannyl 
derivative (±)-5.23 in 40% yield (Scheme A.1).  This compound was then converted to 
radioactive iodide derivative [125I]-(±)-4.26 by Dr. John Lever at the University of 
Missouri-Columbia.  Briefly, Dr. Lever treated stannyl derivative (±)-5.23 with [125I]-NaI 
(1.53 mCi) in the presence of Chloramine- T.  This chemistry ended with reversed-phase 
HPLC isolation to provide [125I]-(±)-4.26 in 61% isolated yield, high purity (98%), and 
high specific activity (2099 mCi/umol).  Furthermore, this radioligand exhibited a 
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chromatographic profile identical to that of non-radioactive (±)-4.26.  Also, purified 
[125I]-(±)-4.26 co-eluted with a fully characterized sample of non-radioactive (±)-4.26 
under the same reverse-phase HPLC conditions (Lapinsky et al., 2011).   
 
Scheme A.1.  Stannylation, radioiodination and DAT covalent ligation of racemic threo-p-azido-N-
benzyl-4-iodo-MP 
 
To determine if the DAT was able to be irreversibly labeled ((±)-5.24, Scheme 
A.1) with [125I]-(±)-4.26, Dr. Roxanne Vaughan’s group (University of North Dakota) 
performed photoaffinity labeling with rat striatal membranes and HEK 293 cells 
expressing 6Xhis-DAT incubated with 30 nM [125I]-(±)-4.26 in the absence or presence 
of 10 M or 100 M -CFT ((-)-2--carbomethoxy-3--(4-fluoro-phenyl)tropane, WIN-
35,428, a cocaine analog) or D-(+)-MP (D-MPH) (Scheme A.1).  The membranes and 
cells were then detergent-solubilized and the lystates were immunoprecipitated with DAT 
antibody and analyzed by SDS-PAGE/autoradiography.  Labeled proteins of ~80 kDa 
were obtained from both rat striatal tissue (Figure A.1) and HEK hDAT cells, 
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demonstrating the incorporation of [125I]-(±)-4.26 into the DAT.  Incorporation of the 
ligand was blocked by 75-90% by both -CFT and D-MPH, demonstrating the 
appropriate pharmacological specificity of [125I]-(±)-4.26 attachment to the DAT.  In 
particular, [125I]-(±)-4.26 represents the first successful example of a DAT photoaffinity 
ligand based on a MP scaffold, thus representing an important contribution to the arsenal 
of probes for characterizing DAT function and 3-D structure (Lapinsky et al., 2011). 
 
Figure A.1.  Photoaffinity labeling of the DAT with [125I]-(±)-4.26 performed by the Vaughan group 
(Lapinsky et al., 2011).  Rat striatal membranes were photoaffinity labeled with 30 nM [125I]-(±)-4.26 
in the absence or presence of 10 M or 100 M -CFT or D-MPH.  Membranes were solubilized and 
DATs were immunoprecipitated followed by analysis by SDS-PAGE and autoradiography.  The 
relevant portion of a representative autoradiograph is pictured followed by a histogram that quantitates 
relative band intensities.  Mean ± SE of three independent experiments is shown; ***P<0.001 versus 
control. 
 
A.2. Stannylation, Radioiodination and DAT Covalent Ligation of (-)-3-Iodo-4-
Azido-N-Benzyl-Ritalinol  
Given (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) displayed the highest DAT 
binding affinity (Ki = 218 ± 29 nM) of the enantiopure MP-based photoaffinity ligands 
synthesized during this work, further development of this compound into a potential DAT 
photoprobe was pursued.  Once again, given that wash-resistant binding experiments 
involving nonradioactive azido compounds frequently give false positives in the 
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assessment of covalent attachment (Agoston et al., 1997), synthesis of a radioiodinated 
(i.e., [125I]) version of enantiopure (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) was 
pursued to determine if photoactivation could produce covalent ligation to the DAT.   
 
Scheme A.2.  Stannylation, radioiodination and DAT covalent ligation of (-)-3-iodo-4-azido-N-
benzyl-ritalinol 
 
In this regard, enantiopure (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) was 
subjected to Stille coupling (conditions adapted from Shu et al., 1996) with 
bis(tributyltin) to provide stannyl derivative (-)-5.40 in 40% yield (Scheme A.2).  This 
compound was then converted to radioactive iodide derivative [125I]-4.36 by Dr. John 
Lever at the University of Missouri-Columbia.  Briefly, Dr. Lever treated stannyl 
derivative (-)-5.40 with [125I]-NaI (1.53 mCi) in the presence of Chloramine- T.  This 
chemistry ended with reversed-phase HPLC isolation to provide [125I]-4.36 in 35% 
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isolated yield with a high specific activity (2120 mCi/umol).  This radioligand exhibited a 
chromatographic profile identical to that of non-radioactive (-)-4.36.  Furthermore, 
purified [125I]-4.36 co-eluted with a fully characterized sample of non-radioactive (-)-4.36 
under the same reverse-phase HPLC conditions (Lapinsky et al., unpublished results).  
To determine if the DAT could be irreversibly labeled (5.41, Scheme A.2) with 
[125I]- 4.36, Dr. Roxanne Vaughan’s group (University of North Dakota) performed 
photoaffinity labeling with rat striatal membranes and HEK 293 cells expressing 6Xhis-
DAT incubated with 30 nM [125I]-4.36 in the absence or presence of 10 M -CFT ((-)-2-
-carbomethoxy-3--(4-fluoro-phenyl)tropane, WIN-35,428, a cocaine analog) or D-(+)-
MP (D-MPH) (Scheme A.2).  The membranes and cells were then detergent-solubilized 
and the lystates were immunoprecipitated with DAT antibody and analyzed by SDS-
PAGE/autoradiography.  Labeled proteins of ~80 kDa were obtained from both rat 
striatal tissue (Figure A.2) and HEK hDAT cells, demonstrating the incorporation of 
[125I]-4.36 into the DAT.  Incorporation of the enantiomerically pure photoaffinity ligand 
was blocked by 60-70% by both -CFT and D-MPH, demonstrating the appropriate 
pharmacological specificity for [125I]-4.36 attachment to the DAT.  In summary, [125I]-
4.36 represents the first successful example of an enantiopure DAT photoaffinity ligand 
based on a MP scaffold, thus representing an important contribution to the arsenal of 
chemical probes useful for characterizing DAT function and 3-D structure. 
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Figure A.2.  Photoaffinity labeling of the DAT with [125I]-4.36 performed by the Vaughan group 
(Lapinsky et al., unpublished results).  Rat striatal membranes were photoaffinity labeled with 30 nM 
[125I]-4.36 in the absence or presence of 10 M or 100 M -CFT or D-MPH.  Membranes were 
solubilized and DATs were immunoprecipitated followed by analysis by SDS-PAGE and 
autoradiography.  The relevant portion of a representative autoradiograph is pictured followed by a 
histogram that quantitates relative band intensities.  Mean ± SE of three independent experiments is 
shown; ***P<0.001 versus control. 
 
A.3.  Tandem Photoaffinity Labeling-Bioorthogonal Conjugation of a Clickable 
Thiazole Benzophenone Propargyl Ether mGlu5 NAM  
Given clickable benzophenone propargyl ether mGlu5 NAM 4.49 (RVDU-3-130) 
displays improved mGlu5 binding affinity (Ki = 11 ± 0.8 nM) versus lead compounds 
4.45 (Ki = 59 ± 0.9 nM) and 4.46 (Ki = 48 ± 0.8 nM), and retained mGlu5 NAM 
functional potency, this photoprobe is currently being evaluated in mGlu5 tandem 
photoaffinity labeling-bioorthogonal conjugation experiments in Dr. Karen Gregory’s 
laboratory at Monash University (Scheme A.3). 
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Scheme A.3.  mGlu5 tandem photoaffinity labeling-bioorthogonal conjugation of a clickable thiazole 
benzophenone propargyl ether mGlu5 NAM photoprobe. 
 
  To determine if mGlu5 could be irreversibly labeled (5.75, Scheme A.3) with 
photoprobe 4.49 (RVDU-3-130), Dr. Karen Gregory incubated membrane preparations 
from nontransfected HEK293 cells or HEK-mGlu5 with 1 µM 4.49 (RVDU-3-130), or a 
vehicle control (1% DMSO), for 2 hours with or without UV irradiation for 30 minutes at 
4 ˚C.  After three washes, the cells were then resuspended in assay buffer and an 
inhibition binding assay for MPEP was performed.  These experiments indicate that 
target probe 4.49 (RVDU-3-130) successfully irreversibly labels HEK-mGlu5 not only in 
presence of UV light, but also, unexpectedly, in absence of UV light (Figure A.3). 
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Figure A.3.  Demonstration of irreversible labeling of HEK-mGlu5 in the presence or absence of UV 
light with RVDU-3-130 (4.49), a clickable benzophenone propargyl ether mGlu5 NAM photoprobe. 
 
Subsequently, non-transfected samples were then “clicked” with near-infrared 
fluorescent Cy7.5 azide (Figure A.4 shown as green; 5.78, Figure A.5 for Cy7.5 azide 
structure), while mGlu5 samples were “clicked” with near-infrared fluorescent Cy5.5 
azide (Figure A.4 shown as red; 5.76, Scheme A.3 for Cy5.5 azide structure), then 
separated by SDS-PAGE and visualized using an Odyssey Scanner (LICOR). 
        
 
 
The results of these experiments indicate no incorporation of either azide was evident in 
the absence of RVDU-3-130 (Figure A.4, lanes 1-3).  Furthermore, non-transfected (lane 
4) and mGlu5 samples (lane 5) were combined, wherein yellow bands in lane 6 indicate 
Figure A.5.  Cy7.5 azide Figure A.4.  mGlu5 photoaffinity labeling 
experiments involving RVDU-3-130. 
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non-specific binding of RVDU-3-130 and red bands indicate mGlu5 specific 
incorporation of RVDU-3-130-Cy5.5.  Subsequent immunoblotting experiments 
performed by Dr. Gregory revealed: A) Cy5.5-positive bands at high molecular weight 
that co-localize with anti-Glu5 (consistent with mGlu5 dimers/oligomer), and B) a 
mGlu5-specific band at ~70kDa that does not localize with anti-mGlu5; however, the size 
of this band is consistent with that expected of a N- and C-terminal cleavage product.  In 
subsequent experiments, Dr. Gregory found that incorporation of RVDU-3-130+azide at 
+250kDa and ~70kDa can be blocked by co-incubation with a competitive ligand (4.44) 
at 10 µM (data not shown).  These preliminary efforts demonstrate successful 
photolabeling of mGlu5 and incorporation of a near-infrared fluorescent tag utilizing 
click chemistry, although further optimization is still required.  As of the writing of this 
dissertation, Dr. Gregory is currently working on improving photoaffinity labeling-
biorthogonal conjugation protocols in order to progress towards purification/digestion for 
characterization of mGlu5 3-D structure and function. 
A.4. Preliminary Docking Experiments of a Methanethiosulfonate-Containing 
mGlu5 MPEP-Binding Site NAM Thiol-Reactive Chemical Probe for mGlu5 
Engineered Affinity Labeling Experiments 
Given methanethiosulfonate-containing mGlu5 MPEP-binding site NAM thiol-
reactive chemical probe 4.55 retained appropriate mGlu5 binding affinity (Ki = 13 ± 0.8 
nM, ~2-fold lower than parent compound 4.44) and NAM functional potency, this probe 
has been subjected to prelimary docking experiments (Figure A.6) in a mGlu5 homology 
model developed by Dr. Jens Meiler’s group (Vanderbilt University) to suggest rational 
cysteine mutations for proposed mGlu5 engineered affinity labeling experiments.  These 
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initial efforts indicate that methanethiosulfonate-containing mGlu5 MPEP-binding site 
NAM thiol-reactive chemical probe 4.55 is binding in the same pocket as that of other 
known MPEP-binding site modulators.  In particular, Figure A.6 shows the top three 
lowest energy poses identified.  Based on these studies and as of the writing of this 
dissertation, Dr. Gregory is currently making several rational cysteine mGlu5 mutations 
for engineered affinity labeling experiements involving probe 4.55.  
 
Figure A.6.  The top three lowest energy poses  upon docking of methanethiosulfonate containing 
mGlu5 MPEP-binding site NAM thiol-reactive  
chemical probe 4.55 (green, blue, magenta)  in a mGlu5 homology model. 
 
 
 
